Tobramycin is an aminoglycoside antibiotic. It is produced by a strain of Streptomyces tenebrarius. It was discovered in 1967 and was approved for medical use in 1970. Tobramycin is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. It is also effective against some gram-positive bacteria, such as Staphylococcus aureus. Tobramycin works by binding to the 30S ribosomal subunit of bacteria, inhibiting protein synthesis. It is typically given intravenously or by injection, and is available as a generic drug. Tobramycin is used to treat a variety of serious infections, including pneumonia, urinary tract infections, and bacteremia. It is also used to treat infections in people with cystic fibrosis. Tobramycin is associated with a number of side effects, including nephrotoxicity and ototoxicity. These side effects are more likely to occur with prolonged use or high doses. The research surrounding tobramycin focuses on its efficacy against various bacterial strains, its potential use in combination with other antibiotics, and the development of novel formulations to reduce its toxicities. '
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 36294 |
| CHEMBL ID | 1747 |
| CHEBI ID | 28864 |
| SCHEMBL ID | 2838 |
| MeSH ID | M0021611 |
| Synonym |
|---|
| BIDD:GT0503 |
| AB00052438-12 |
| tobramitsetin |
| lilly 47663 |
| tenemycin |
| nebramycin |
| nebramycin vi |
| tobramaxin |
| nsc-180514 |
| tobramycetin |
| tenebrimycin |
| nebramycin 6 |
| smr000058793 |
| MLS000069544 |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4))-2-deoxy-d-streptamine |
| nebramycin factir 6 |
| (1s,2s,3r,4s,6r)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-d-glucopyranoside |
| CHEBI:28864 , |
| (1s,2s,3r,4s,6r)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-d-glucopyranoside |
| tobracin (tn) |
| D00063 |
| TOB , |
| bethkis (tn) |
| tobi (tn) |
| tobramycin (jp17/usp) |
| tobrex (tn) |
| SPECTRUM_001072 |
| SPECTRUM5_001038 |
| BSPBIO_000587 |
| cas-32986-56-4 |
| NCGC00016814-01 |
| NCGC00178852-01 |
| NCGC00178852-02 |
| tobramicin |
| (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol |
| tobrex |
| nebcin (sulfate) |
| d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-[2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribohexopyranosyl-(1->4)]-2-deoxy- |
| BPBIO1_000647 |
| PRESTWICK3_000544 |
| TOY , |
| AB00513858 |
| C00397 |
| 3'-deoxykanamycin b |
| nebramycin factor 6 |
| 32986-56-4 |
| tobramycin |
| DB00684 |
| BSPBIO_002036 |
| KBIOGR_001104 |
| KBIOSS_001552 |
| KBIO2_006688 |
| KBIO3_001536 |
| KBIO2_001552 |
| KBIO2_004120 |
| SPECTRUM2_000078 |
| SPECTRUM3_000588 |
| SPECTRUM4_000752 |
| SPBIO_000295 |
| SPECTRUM1500579 |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1-6))-2-deoxy-l-streptamine |
| nsc 180514 |
| streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-tyrideoxy-alpha-d-ribohexopyranosyl-(1-6))-2-deoxy-, d- |
| d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1-4))-2-deoxy- |
| gotabiotic |
| nebicin |
| tobramicina [inn-spanish] |
| streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-6))-2-deoxy-, d- |
| hsdb 3259 |
| deoxykanamycin b |
| tobrased |
| tobramycinum [inn-latin] |
| 4-(2,6-diamino-2,3,6-trideoxy-alpha-d-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-d-glycopyranosyl)-2-deoxystreptamine |
| 1-epitobramycin |
| aktob |
| tobramycine [inn-french] |
| c18h37n5o9 |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4))-2-deoxy-d-streptamine |
| tobralex |
| tobacin |
| tobi |
| einecs 251-322-5 |
| brn 1357507 |
| HMS2092M17 |
| HMS2090B16 |
| T2503 |
| o-[3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->6)]-o-[2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1->4)]-2-deoxy-d-streptamine |
| (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol |
| obramycin |
| CHEMBL1747 |
| HMS2096N09 |
| nsc757352 |
| nsc-757352 |
| pharmakon1600-01500579 |
| tox21_110626 |
| dtxsid8023680 , |
| dtxcid903680 |
| tobramycinum |
| tobramicina |
| tobramycine |
| CCG-39936 |
| bethkis |
| kitabis pak |
| unii-vz8rrz51vk |
| tobi podhaler |
| tobramycin [usan:usp:inn:ban:jan] |
| vz8rrz51vk , |
| bdbm50366778 |
| sprc-ab01 |
| S2514 |
| AKOS016339662 |
| tobradex component tobramycin |
| tobramycin [ep monograph] |
| tobramycin [hsdb] |
| tobramycin [who-dd] |
| tobramycin component of tobradex |
| tobradex st component tobramycin |
| tobramycin component of tobrasone |
| tobramycin [mart.] |
| d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-(2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1->4))-2-deoxy- |
| tobramycin [vandf] |
| tobramycin component of zylet |
| tobramycin [usp-rs] |
| tobrasone component tobramycin |
| tobramycin [usp monograph] |
| vantobra |
| tobramycin [mi] |
| o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1.alpha.6))-2-deoxy-l-streptamine |
| zylet component tobramycin |
| tobramycin component of tobradex st |
| tobramycin [orange book] |
| tobramycin [jan] |
| tobramycin [inn] |
| tobramycin [usan] |
| HY-B0441 |
| SCHEMBL2838 |
| KS-1405 |
| tobramycin base |
| tobramycin, antibiotic for culture media use only |
| Q-201837 |
| o-3-amino-3-deoxy-?-d-glucopyranosyl-(1-6)-o-[2,6-diamino-2,3,6-trideoxy-?-d-ribohexopyranosyl-(1-4)]-2-deoxy-d-streptamine |
| d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-[2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1->4)]-2-deoxy- |
| AB00052438_13 |
| AB00052438_14 |
| (2s,3r,4s,5s,6r)-4-amino-2-{[(1s,2s,3r,4s,6r)-4,6-diamino-3-{[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol |
| SR-01000721898-2 |
| sr-01000721898 |
| torbamycin |
| sr-05000001726 |
| SR-05000001726-2 |
| (2s,3r,4s,5s,6r)-4-amino-2-(((1s,2s,3r,4s,6r)-4,6-diamino-3-(((2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2h-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,5-diol |
| SR-05000001726-1 |
| SBI-0051915.P003 |
| HMS3713N09 |
| (2s,3r,4s,5s,6r)-4-amino-2-((1s,2s,3r,4s,6r)-4,6-diamino-3-((2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2h-pyran-2-yloxy)-2-hydroxycyclohexyloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,5-diol |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-[2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4)]-2-deoxy-d-streptamine |
| HB4564 |
| tobramycin,(s) |
| Q1758380 |
| BRD-K05619559-001-12-7 |
| nebramycin factor 6;deoxykanamycin b |
| gtpl10930 |
| kitabis |
| tobradex (tobramycin + dexamethasone) |
| tobramycin deuterated |
| d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1?6)-o-[2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1?4)]-2-deoxy- |
| EN300-7480857 |
| tobramycinum (latin) |
| tobramycin (usan:usp:inn:ban:jan) |
| tobramycin inhalation solution |
| tobramycin (mart.) |
| s01aa12 |
| tobramycin (usp monograph) |
| tobramycin (usp-rs) |
| tobramicina (inn-spanish) |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1alpha6))-2-deoxy-l-streptamine |
| j01gb01 |
| tobramycin ophthalmic solution |
| tobramycininhalation solution pak |
| tobramycin (ep monograph) |
| tobramycine (inn-french) |
| tobramycinum (inn-latin) |
| tobramycin inhalation |
| at02 - tobramycin |
Tobramycin is a powerful and effective aminoglycoside, approved for complicated infections and reinfections. It is indicated mainly against Gram-negative bacteria. In biofilm infections, its efficacy severely decreases due to limited permeability across the biofilm matrix.
Tobramycin has been shown to be safe and effective when given intravenously in combination antibiotic therapy for infected patients with acute leukemia or other profound pancytopenic states.
Both tobramycin and colistin cause acute renal tubular injury with a significant rise in urinary NAG excretion. TobramYcin seemed to enhance the resolution of inflammation by a more rapid decline in C-reactive protein levels.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Both tobramycin and colistin cause acute renal tubular injury with a significant rise in urinary NAG excretion. " | ( Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. Bosomworth, M; Clifton, I; Conway, SP; Etherington, C; Peckham, DG, 2007) | 0.85 |
| "Tobramycin seemed to enhance the resolution of inflammation by a more rapid decline in C-reactive protein levels." | ( Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women. Alestig, K; Eilard, T; Ek, E; Hebelka, M; Johansson, E; Olinder-Nielsen, AM; Sandberg, T, 1997) | 1.02 |
| "Tobramycin has the lower MICs than the other aminoglycosides to Pseudomonas aeruginosa." | ( [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis]. Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P, 1998) | 1.29 |
Tobramycin (0.3%) treatment was applied four times daily for 1 month postoperatively. Treatment of a 72 h biofilm preferentially killed subpopulations on the periphery of the mushroom stalk. The treatment also inhibited MUC5AC mRNA expression after lipopolysaccharide stimulation.
Inhaled tobramycin is generally consider to be safe from otologic complications. The aminoglycosides displayed marked differences in the threshold dose required to produce toxic reactions.
Tobramycin plasma AUC and Cmax were lower after administration of T100 than after TNS. No significant differences in clearance, volume of distribution or half-life were found due to age within a singl group.
| Excerpt | Reference | Relevance |
|---|---|---|
| " The serum half-life thereafter correlated inversely to postnatal age during the first seven days after birth." | ( Pharmacokinetics of tobramycin in the newborn. Fujita, K; Maruyama, S; Takimoto, M; Yoshioka, H, 1979) | 0.58 |
| " Pharmacokinetic studies revealed lower renal concentrations of netilmicin after repetitive administration." | ( [Netilmicin and tobramycin: comparative evaluation of pharmacokinetics, nephrotoxicity, and therapeutic efficacy in animal studies (author's transl)]. Abraham, M; Freiesleben, H; Marre, R; Sack, K, 1979) | 0.61 |
| " The first-phase half-life correlated well with renal function, but the second averaged 146 h and was poorly related to creatinine clearance." | ( Accumulation pharmacokinetics of tobramycin. Cumbo, TJ; Jusko, WJ; Lasezkay, G; Plaut, ME; Schentag, JJ, 1978) | 0.54 |
| "Tobramycin is a new aminoglycoside antibiotic with a broad antibacterial spectrum in vitro, and pharmacokinetic properties similar to those for gentamicin." | ( Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1976) | 3.14 |
| " The half-life average 82 min in normal subjects (endogenous creatinine clearance, greater than 80 ml/1." | ( Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. Dugal, R; Péchère, JC, 1976) | 0.51 |
| " The biological half-life of tobramycin doubled." | ( Pharmacokinetics of tobramycin in rats with reduced renal parenchyma and in experimental shock. Hatala, M; Konícková, Z; Liska, M; Morávek, J; Prát, V; Schück, O, 1976) | 0.87 |
| " There were no pharmacokinetic differences of therapeutic significance between the three drugs." | ( [Pharmacokinetics and clinical observations of sisomicin, a newly developed aminoglycoside derivative (author's transl)]. Kemmerich, B; Koeppe, P; Langmaack, H; Lode, H, 1975) | 0.25 |
| "Alterations in specific pharmacokinetic variables for tobramycin were observed as a result of ECMO." | ( Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep. Gilman, JT; Kearns, GL; Möller, JC; Raszynski, A; Reed, MD; Sussmane, JB; Wolfsdorf, J, 1992) | 0.79 |
| "These data suggest that ECMO circuitry does not sequester tobramycin and that the prolonged elimination half-life observed during ECMO therapy is not due to a change in drug clearance but is due to an ECMO-induced increase in tobramycin volume of distribution." | ( Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep. Gilman, JT; Kearns, GL; Möller, JC; Raszynski, A; Reed, MD; Sussmane, JB; Wolfsdorf, J, 1992) | 0.78 |
| "Comparative studies on some selected pharmacokinetic parameters for kanamycin in sheep, goats, rabbits, chickens and pigeons, and for apramycin in sheep, rabbits, chickens and pigeons were carried out after intravenous administration of the two drugs at a dose of 10 mg/kg." | ( Interspecies differences in the pharmacokinetics of kanamycin and apramycin. Lashev, LD; Marinkov, TN; Pashov, DA, 1992) | 0.28 |
| "The pharmacokinetic parameters of gentamicin and tobramycin were evaluated and compared for 260 patients with pleural effusions and 1,049 patients without pleural effusions by chest radiograph." | ( Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Bertino, JS; Etzel, JV; Nafziger, AN, 1992) | 0.79 |
| " Feto-maternal tobramycin concentrations (F/M ratios) were systematically determined at birth and allowed to make a small scale pharmacokinetic study." | ( [Determination of the ratio of serum concentrations of tobramycin between fetus and mother at birth. A model of small scale pharmacokinetics]. Bourget, P; Delouis, C; Demirdjian, S; Fernandez, H; Frydman, R, 1991) | 0.88 |
| " The decrease in clearance (21%), at 28 weeks and more of gestation leads to an increase in half-life and the mean residence time (MRT) in the second group (33 and 29% respectively)." | ( Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen. Bourget, P; Delouis, C; Fernandez, H; Taburet, AM, 1991) | 0.6 |
| " The pharmacokinetic parameters were determined by a two-compartment open model." | ( Altered tobramycin pharmacokinetics during chemoprophylaxis in bladder surgery. Bressolle, F; Costa, P; Gouby, A; Joubert, P; Laracine, M; Rebière, T, 1991) | 0.72 |
| "6%), at 28 weeks and more gestation leads to an increase in the half-life and the MRT observed in the second group (increment of 49% and 41% respectively), whereas the volume of distribution remained unchanged in the two groups." | ( [The administration of tobramycin in the 2nd and 3rd trimester of pregnancy: contribution to a pharmacokinetic study for the adaptation of posology]. Bourget, P; Delouis, C; Demirdjian, S; Fernandez, H, 1991) | 0.59 |
| "In a prospective, randomized study, 75 adults receiving aminoglycosides were followed by a clinical pharmacokinetic service and 70 followed as controls." | ( Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Bittner, MJ; Destache, CJ; Hermann, KG; Meyer, SK, 1990) | 0.28 |
| " Using individualized pharmacokinetic determinations, the regimens were revised as necessary to provide optimal blood levels." | ( Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. Crotchett, J; Fischer, RP; Miller-Crotchett, P; Reed, RL; Wu, AH, 1989) | 0.28 |
| "The results of tobramycin concentration monitoring in 33 patients with nonspecific pulmonary infections showed a marked individual variability of the antibiotic blood levels and model-independent pharmacokinetic parameters: total clearance, steady-state volume of distribution and mean residence time whose values were distributed log-normally." | ( [Pharmacokinetic monitoring during aminoglycoside treatment: the optimal method for individualizing the dosage of tobramycin]. Alekseeva, ME; Firsov, AA; Fomina, IP; Lukomskiĭ, GI; Manuĭlov, KK, 1989) | 0.84 |
| " A one-compartment pharmacokinetic infusion model was used to calculate k and Vd; AGCL = (k) (Vd)." | ( Comparison of aminoglycoside clearance and calculated serum creatinine clearances. Deeter, RG; Krauss, EA; Nahaczewski, AE; Penn, F, 1989) | 0.28 |
| "So as to estimate the appropriate dose of antibacterial drugs in obese children, prediction of the volume of distribution in these children was attempted based on physiological pharmacokinetic concepts which had been constructed from results in normal-weight children." | ( Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Benet, LZ; Ichimura, F; Koshida, R; Nakashima, E; Taniguchi, N; Tsuji, A, 1989) | 0.52 |
| " Population pharmacokinetic parameters of tobramycin were determined in a heterogenous group of 97 patients using serum samples drawn for the routine monitoring of tobramycin concentrations, following multiple dosing regimens." | ( Population pharmacokinetics of tobramycin. Aarons, L; Follath, F; Vozeh, S; Weiss, P; Wenk, M, 1989) | 0.83 |
| " Serial pharmacokinetic dosing has been proposed as a method to achieve these goals." | ( Serial pharmacokinetic dosing of aminoglycosides: a community hospital experience. Hoffa, DE, 1989) | 0.28 |
| " Although adequate maintenance dosing requires individualization based on pharmacokinetic analyses, large aminoglycoside doses can be used safely in patients with blunt trauma if appropriate monitoring is employed." | ( Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Fink, MP; Murphy, SG; Stein, KL; Townsend, PL, 1989) | 0.28 |
| " The advantages and disadvantages of arbitrary, predictive, and pharmacokinetic methods of dosing determination are summarized." | ( Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. Bailie, GR; Mathews, A, 1987) | 0.27 |
| " With use of numerous multiple-dosing regimens in an animal model, this study is the first to successfully minimize the interdependence between pharmacokinetic parameters and thereby determine, by stepwise multivariate regression analysis, that the time that serum levels exceeded the minimum inhibitory concentration (MIC) was the most significant parameter determining efficacy for beta-lactams and erythromycin against various pathogens, whereas the log area under the curve was the major parameter for aminoglycosides." | ( Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Craig, WA; Ebert, S; Gudmundsson, S; Leggett, J; Turnidge, J; Vogelman, B, 1988) | 0.27 |
| "The objective of this study was to assess the impact of intravenous infusion systems on the pharmacokinetic parameters of tobramycin in newborn infants." | ( Influence of infusion systems on pharmacokinetic parameters of tobramycin in newborn infants. Nahata, MC, 1988) | 0.72 |
| " Activated charcoal did not have a statistically significant effect on any pharmacokinetic parameter." | ( Effect of oral activated charcoal on tobramycin clearance. Davis, RL; Koup, JR; Opheim, KE; Roon, RA; Smith, AN, 1988) | 0.55 |
| "The influence of four intermittent intravenous infusion methods on the determination of tobramycin pharmacokinetic values and predicted doses was evaluated in 11 healthy adult volunteers." | ( Effect of four intravenous infusion methods on tobramycin pharmacokinetics. McKenna, WR; Pleasants, RA; Powell, JR; Sawyer, WT; Williams, DM, 1988) | 0.75 |
| "2 minutes, with a harmonic mean serum half-life of 68." | ( Pharmacokinetics of tobramycin in cats. Hatch, RC; Jernigan, AD; Wilson, RC, 1988) | 0.6 |
| " The use of pharmacokinetic consultants may be of benefit in administering safely optimal aminoglycoside therapy." | ( Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods. Ausman, RK; Bubrick, J; Franson, TR; Quebbeman, EJ; Rosenberger, SL; Thomson, R; Whipple, J, 1988) | 0.27 |
| "This study proposes the use of individual pharmacokinetic parameters to predict effective dosages of aminoglycosides for patients with serious infections." | ( Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Denaro, CP; Ravenscroft, PJ, 1987) | 0.27 |
| " These results demonstrate that a high peak concentration relative to the MIC for the infecting organism is a major determinant of the clinical response to aminoglycoside therapy." | ( Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Lietman, PS; Moore, RD; Smith, CR, 1987) | 0.27 |
| " No significant alteration in pharmacokinetic behavior was noted for cefoperazone or tobramycin alone or in combination." | ( Pharmacokinetics of cefoperazone and tobramycin alone and in combination. Flaherty, JF; Gambertoglio, JG; Guglielmo, BJ; LaFollette, G; Woods, TM, 1987) | 0.77 |
| " Concentrations in serum and urine were measured by radioimmunoassay, and concentrations in serum and urinary excretion rates were simultaneously fitted to a two-compartment pharmacokinetic model." | ( Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers. Adelman, MH; Evans, EJ; Schentag, JJ; Winslade, NE, 1987) | 0.53 |
| "Studies performed in patients with cystic fibrosis (CF) have suggested altered pharmacokinetic parameters for aminoglycosides." | ( Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis. Folli, HL; Harralson, AF; Kelly, PC; Kildoo, CW; Nussbaum, E, ) | 0.44 |
| "The pharmacokinetic disposition of aminoglycosides in critically ill patients with sepsis was studied." | ( Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Awang, R; Cerra, FB; Fuhs, DW; Mann, HJ; Ndemo, FA, 1987) | 0.27 |
| "This study determined the extent and impact of tobramycin pharmacokinetic variability in cystic fibrosis patients." | ( Variability of tobramycin pharmacokinetics in cystic fibrosis. Commissaris, RL; Hsu, MC; Massoud, N; Munzenberger, PJ, 1987) | 0.88 |
| " The program we have evaluated, OPT, calculates the most likely set of pharmacokinetic parameter estimates for individual patients by applying Bayes' theorem and the principle of Maximum Likelihood Estimation." | ( Evaluation of a microcomputer program (OPT) for parameter optimisation in clinical pharmacokinetics: gentamicin and tobramycin. Derkx, FH; Michel, MF; Wagenvoort, JH; Zantvoort, FA, 1987) | 0.48 |
| " The total body clearance of MTX was reduced, while the elimination half-life and the drug distribution to the peripheral body compartments were unchanged." | ( Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Brasch, H; Iven, H, 1986) | 0.51 |
| " The pharmacokinetic profile of ceftazidime during a steady-state dosing interval was ascertained in 21 patients." | ( Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Drusano, GL; Forrest, A; Joshi, J; Leslie, J; Ruxer, R; Schimpff, S; Standiford, H; Wade, J, 1985) | 0.5 |
| " This review addresses the clinical pharmacokinetic aspects of drug therapy in patients undergoing peritoneal dialysis and considers: the efficiency of the peritoneal membrane as a dialysing membrane; the effects of peritoneal dialysis on the pharmacokinetics of drugs; the pharmacokinetic models and estimation methods for peritoneal dialysis clearance and the effects of peritoneal dialysis on drug elimination; the influence of the pharmacokinetic parameters of drugs on drug dialysability; and the application of pharmacokinetic principles to the adjustment of drug dosage regimens in peritoneal dialysis patients." | ( Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations. Cornish, WR; Hardy, BG; Manuel, MA; Paton, TW, ) | 0.13 |
| " A single pharmacokinetic study was performed over one dosing interval after steady-state conditions were achieved." | ( Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vigano, A; Wels, PB; Winslade, NE, ) | 0.13 |
| " In the calculation of pharmacokinetic parameters, a two-compartment open model was used." | ( Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval. Degener, JE; Driessen, O; Dzoljic-Danilovic, G; Hermans, J; Horrevorts, AM; Kerrebijn, KF; Michel, MF, 1985) | 0.59 |
| " A significant variability of the pharmacokinetic parameters of tobramycin and sisomicin under conditions of the changing function of the kidney transplant was shown." | ( [Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney]. Belorusov, OS; Bogomolova, NS; Firsov, AA; Navashin, SM; Treskina, OS, 1983) | 0.79 |
| " The mean half-life and mean serum concentration at 1 h for each drug was determined." | ( Reproducibility study of the pharmacokinetics of amikacin, gentamicin and tobramycin; a three-way crossover study. Acar, J; Adam, D; Cadorniga, R; Dyas, A; Hallynck, T; Pijck, J; Soep, HH; Wenk, M; Wise, R, 1983) | 0.5 |
| " No statistically significant changes in the concentration of drug in serum, the half-life (t1/2), the elimination rate constant (Ke), the volume of distribution (Vd), or the area under the serum concentration-time curve (AUC0-oo) occurred when tobramycin was used concurrently with piperacillin." | ( Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function. Flascha, S; Lau, A; Lee, M; Prasad, R; Sharifi, R, 1983) | 0.75 |
| " Serum tobramycin levels were obtained when the subjects were off plasma exchange to calculate individualized tobramycin pharmacokinetic parameters." | ( A pharmacokinetic evaluation of the effect of plasma exchange on tobramycin disposition. Kennedy, MS; Ouellette, SM; Visconti, JA, 1983) | 0.96 |
| "A microcomputer program has been developed to provide assistance to tobramycin clinical pharmacokinetic consult services." | ( A microcomputer program for tobramycin consult services, based on the two-compartment pharmacokinetic model. Adelman, MH; Schentag, JJ, ) | 0.66 |
| " No significant differences in clearance, volume of distribution or half-life were found due to age within a single drug group (amikacin, gentamicin, or tobramycin) or among the 3 drug groups." | ( Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin. Bauer, LA; Blouin, RA, 1983) | 0.68 |
| " Amino-glycoside pharmacokinetic variables were calculated." | ( Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Bauer, LA; Blouin, RA; Piecoro, JJ; Wilson, HD, ) | 0.48 |
| "The rationale for pharmacokinetic monitoring of aminoglycosides is critically reviewed." | ( Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Evans, WE; Yee, GC, ) | 0.13 |
| " All patients received individualized dosing regimens of the drugs based on pharmacokinetic parameters measured after the initial dose." | ( Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens. Compty, C; Heissler, J; Pancorbo, S, ) | 0.42 |
| " Clinical and pharmacokinetic data were obtained on 240 of 267 courses (120 courses each of gentamicin and tobramycin)." | ( Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Cerra, FB; Plaut, ME; Schentag, JJ, 1982) | 0.48 |
| " Detailed pharmacokinetic analysis of the plasma drug concentration-time data up to 36 h after the intravenous dose revealed that the pharmacokinetics of the aminoglycoside antibiotics can be best described as a three-compartment open model." | ( Comparative pharmacokinetics of aminoglycoside antibiotics in guinea pigs. Assael, BM; Cavanna, G; Chung, M; Parravicini, L; Radwanski, E; Symchowicz, S, 1982) | 0.26 |
| " Evidence is presented to confirm that time of peak concentration times (tmax) following oral or intramuscular dosing may be highly variable when doses, dosing intervals, or drug elimination rates are changing." | ( Mathematical considerations in the estimation of peak drug concentrations under uniform and nonuniform dosing conditions. Hull, JH, ) | 0.13 |
| " Of these 267 courses, pharmacokinetic and clinical data were obtained for 240 (120 gentamicin and 120 tobramycin)." | ( Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Cerra, FB; Plaut, ME; Schentag, JJ, 1981) | 0.74 |
| " Correlation coefficients determined from individual plots of the three pharmacokinetic parameters versus age revealed no correlation between any parameter and age." | ( Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Bauer, LA; Blouin, RA, 1981) | 0.59 |
| " Pharmacokinetic analysis was done with a one-compartment open model in the case of intramuscular injection and a two-compartment open model in the case of intravenous infusion." | ( [Pharmacokinetic studies of tobramycin using the continuous intravenous infusion method (author's transl)]. Yamada, H; Yamasaku, F, 1981) | 0.56 |
| " The use of a single pharmacokinetic dosing model for all patients, irrespective of evidence of increased or decreased drug elimination, results in widely differing drug dosages." | ( Aminoglycoside dosage in pediatric patients:considerations regarding pharmacokinetic-based dose adjustment in patients requiring high versus low dose therapy. Leff, RD; Roberts, RJ, 1981) | 0.26 |
| " The correlation between serum creatinine levels and the half-life of the antibiotics was found to be statistically significant." | ( Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure. Emre, S; Eti, S; Nayir, A; Sirin, A; Yeşilbek, T, ) | 0.39 |
| " Secondary endpoints were elimination rate constant (ke), clearance (Cl), and half-life (t1/2)." | ( Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion. Jacobs, LR; MacArthur, RD; Mauro, LS; Mauro, VF; White, DB, 1995) | 0.65 |
| " The tmax values observed following fast CRIS and ivpb were 28 +/- 8 and 32 +/- 4 minutes, respectively, and not significantly different from each other." | ( Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion. Jacobs, LR; MacArthur, RD; Mauro, LS; Mauro, VF; White, DB, 1995) | 0.65 |
| " Compared with ivpb, fast CRIS resulted in a higher Cmax, but the tmax values of fast CRIS and ivpb administration were not statistically different." | ( Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion. Jacobs, LR; MacArthur, RD; Mauro, LS; Mauro, VF; White, DB, 1995) | 0.65 |
| " pneumoniae O3 lipopolysaccharide modifies the glomerular filtration rate and tubular reabsorption without change in the terminal half-life and that drug distribution characteristics from the rapidly-distributing compartment to the peripheral compartment were altered without expansion of the extracellular fluid volume." | ( Influence of a bacterial lipopolysaccharide on the pharmacokinetics of tobramycin in rats. Hasegawa, T; Kato, K; Kato, N; Nabeshima, T; Nadai, M; Wang, L, 1993) | 0.52 |
| " In contrast, tazobactam administered with piperacillin achieved higher plasma concentrations and had a longer half-life than tazobactam administered alone." | ( Pharmacokinetic characteristics of piperacillin/tazobactam. Kinzig, M; Sörgel, F, 1994) | 0.29 |
| " Three different methods, standard two-stage (STS), extended least-squares non-linear regression [MULTI(ELS)] and non-parametric expected maximization (NEPM), were used to estimate the pharmacokinetic (PK) population parameters." | ( Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches. Jiménez, NV; López, R; Ordovás, JP; Poveda, JL; Ronchera, CL, 1994) | 0.29 |
| " The half-life to tobramycin was 189 +/- 21 min and the mean residence time was 254 +/- 26 min." | ( Pharmacokinetics of tobramycin in the camel. Amiri, MH; Baggot, JD; Bashir, AK; Gadir, FA; Hadi, AA; Wasfi, IA, 1994) | 0.95 |
| " The mean residence time (MRT) and terminal half-life (t1/2 beta) of tobramycin were similar in young and aged rats." | ( The effect of endotoxin on tobramycin pharmacokinetics in young and aged rats. Wasfi, IA, 1993) | 0.82 |
| " Steady-state serum concentrations of AG and vancomycin (more than four half-lives) were obtained and kinetic parameters (Ke, Vd) were calculated using first-order pharmacokinetic equations." | ( Correlation of aminoglycoside and vancomycin pharmacokinetic parameters. Cooper, BE; Wragge, TM, 1993) | 0.29 |
| "A novel technique for in vivo intrabronchial pharmacokinetic measurements using microdialysis is described." | ( Pharmacokinetic measurement of drugs in lung epithelial lining fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. Conzentino, P; Cundy, KC; Eickhoff, WM; Eisenberg, EJ, 1993) | 0.29 |
| " There have been no studies published to date comparing once-daily dosing and pharmacokinetic dosing of aminoglycosides." | ( Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Hawa, Z; Koo, J; Rajkumar, V; Tight, R, 1996) | 0.29 |
| "Ninety-six patients were randomly assigned to either the once-daily dosing group (4 mg/kg) or the pharmacokinetic dosing group (initial dose of 2 mg/kg every 12 hours)." | ( Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Hawa, Z; Koo, J; Rajkumar, V; Tight, R, 1996) | 0.29 |
| "Once-daily dosing and pharmacokinetic dosing of aminoglycosides appear to have equal efficacy and toxicity." | ( Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Hawa, Z; Koo, J; Rajkumar, V; Tight, R, 1996) | 0.29 |
| " The adaptive feedback control algorithm for ceftazidime used an initial population model, a maximum a posteriori (MAP)-Bayesian pharmacokinetic parameter value estimator, and an optimal, sparse sampling strategy for ceftazidime that had been derived from data in the literature obtained from volunteers." | ( Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Ballow, CH; Forrest, A; Kashuba, AD, 1996) | 0.29 |
| " In addition, because most pharmacokinetic computer models use an a priori relationship between CrCl and tobramycin elimination rate constant [k(el)], regression analysis of k(el) on CrCl was performed." | ( Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Bakker, W; Heijerman, HG; Jacobs, F; Town, DJ; Vinks, AA, 1996) | 0.78 |
| " Three monotherapy and six combination therapy schedules were tested in an in vitro pharmacokinetic model, using a Pseudomonas aeruginosa resistant to both antibiotics." | ( Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. den Hollander, JG; Horrevorts, AM; Mouton, JW; van Goor, ML; Verbrugh, HA, 1997) | 0.63 |
| " The purpose of this study was to determine the magnitude and variability of aminoglycoside Cmax and the duration of the aminoglycoside-free period after simulated single, daily-dose regimens in patients with burn injuries." | ( Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. Guay, DR; Hoey, LL; Rotschafer, JC; Tschida, SJ; Vance-Bryan, K, ) | 0.13 |
| "This research examined the applicability of using a neural network approach to analyze population pharmacokinetic data." | ( Application of neural networks to population pharmacokinetic data analysis. Chen, H; Chow, HH; Elsberry, V; Roe, DJ; Tolle, KM, 1997) | 0.3 |
| " This algorithm estimates the entire discrete joint probability density of the pharmacokinetic parameters." | ( Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Neef, C; Touw, DJ; Vinks, AA, 1997) | 0.56 |
| "To describe the pharmacokinetic parameters of gentamicin and tobramycin in pediatric bone marrow transplant patients." | ( Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. Hutchinson, RJ; Jacobson, PA; Price, J; West, NJ, 1997) | 0.89 |
| "Pharmacokinetic parameters (apparent volume of distribution [Vd] in L/kg, half-life [t1/2] in h, elimination rate constant [ke] in h-1, clearance [Cl] in mL/min/1." | ( Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. Hutchinson, RJ; Jacobson, PA; Price, J; West, NJ, 1997) | 0.65 |
| " Tobramycin data were analyzed according to a one-compartment open model with use of NONMEM population pharmacokinetic software." | ( Tobramycin population pharmacokinetics in neonates. de Hoog, M; Mouton, JW; Schoemaker, RC; van den Anker, JN, 1997) | 2.65 |
| " A one-compartment in vitro pharmacodynamic model was used to simulate bacteremic infection." | ( Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model. Hoban, DJ; Kabani, A; Karlowsky, JA; Zelenitsky, SA; Zhanel, GG, ) | 0.43 |
| " We conclude that neutropenic patients form a target group for successful pharmacokinetic intervention and cost saving." | ( Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies. Armstrong, VW; Binder, C; Binder, L; Erichsen, N; Hiddemann, W; Menke, CF; Oellerich, M; Schiel, X; Schüttrumpf, S; Unterhalt, M, 1998) | 0.3 |
| "We compared pharmacokinetic parameters derived from three aminoglycoside serum concentration sampling methods and evaluated their effects on recommended aminoglycoside dosing regimens in 60 critically ill surgery patients." | ( Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients. Baghaie, AA; Cerra, FB; Mann, HJ; Wittbrodt, ET, ) | 0.13 |
| " We studied various tobramycin and ceftazidime dosing regimens against four resistant Pseudomonas aeruginosa strains in an in vitro pharmacokinetic model to determine the usability of combination therapy for the treatment of infections due to resistant bacterial strains." | ( Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. den Hollander, JG; Mouton, JW; Verbrugh, HA, 1998) | 0.62 |
| " The function defining the rate of infusion required to perform the simulation of an intravenous bolus was first determined generally and symbolically for linear pharmacokinetic models independently from the number of compartments involved." | ( In vivo simulation of human pharmacokinetics in the rabbit. Baron, D; Bugnon, D; Caillon, J; Drugeon, HB; Feigel, P; Kergueris, MF; Potel, G, 1998) | 0.3 |
| "Various suggestions have been made for empirical pharmacodynamic indices of antibiotic effectiveness, such as areas under the drug concentration-time curve in serum (AUC), AUC > MIC, AUC/MIC, area under the inhibitory curve (AUIC), AUC above MIC, and time above MIC (T > MIC)." | ( Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Barbaut, X; Bleyzac, N; Bouvier d'Yvoire, MY; Corvaisier, S; Jelliffe, RW; Maire, PH, 1998) | 0.3 |
| " The main objective of this pharmacokinetic observational study was to determine the adequacy of a 3 mg/kg loading dose of gentamicin or tobramycin in attaining an initial peak level of 8 micrograms/ml or greater." | ( Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Dorman, T; Lipsett, PA; Swoboda, S; Trentler, B; Zarfeshenfard, F, 1998) | 0.5 |
| "The postantibiotic effect (PAE) exhibited by Pseudomonas aeruginosa after exposure to single doses of tobramycin was investigated under various pharmacokinetic conditions using an established in-vitro kinetic model." | ( Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model. Li, RC; Zhu, ZY, 1998) | 0.73 |
| " Serum peak concentration of tobramycin on day 1 was 13." | ( Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arrouet-Lagande, C; Ategbo, S; Deschildre, A; Druon, D; Husson, MO; Launay, V; Loeuille, GA; Sardet, A; Turck, D; Vic, P, 1998) | 0.84 |
| " Pharmacokinetic parameters (clearance, volume of distribution, elimination rate and half-life) were calculated using a one-compartment Bayesian method." | ( Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation. Dupuis, RE; Sredzienski, ES, 1999) | 1.75 |
| " The purpose of the present study was to compare the predicted pharmacodynamic activity of tobramycin at 10 mg/kg of body weight/day administered every 24 h (q24h), q12h, and q8h." | ( Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Beringer, PM; Jelliffe, RW; Shapiro, BJ; Vinks, AA, 2000) | 0.85 |
| " Pharmacokinetic parameters were calculated using a monoexponential model." | ( Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. Bailie, GR; Frye, R; Hess, LD; Manley, HJ; McGoldrick, MD, 2000) | 0.55 |
| " However, the pharmacokinetic parameters are variable in these patients." | ( Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. Barletta, JF; Erstad, BL; Johnson, SB; Nix, DE; Nix, LC, 2000) | 0.31 |
| " Population pharmacokinetic parameters were estimated on the basis of a one-compartment structural model and the program nonlinear mixed effects modeling." | ( Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. Barletta, JF; Erstad, BL; Johnson, SB; Nix, DE; Nix, LC, 2000) | 0.31 |
| "There is marked variability in aminoglycoside pharmacokinetic parameters in critically ill trauma patients." | ( Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. Barletta, JF; Erstad, BL; Johnson, SB; Nix, DE; Nix, LC, 2000) | 0.31 |
| "To examine the impact of individualized pharmacokinetic monitoring (IPM) on the development of aminoglycoside-associated nephrotoxicity (AAN)." | ( Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Bertino, AS; Destache, CJ; Nafziger, AN; Streetman, DS, 2001) | 0.31 |
| "Individualized pharmacokinetic monitoring significantly decreased the frequency of AAN and its associated economic costs." | ( Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Bertino, AS; Destache, CJ; Nafziger, AN; Streetman, DS, 2001) | 0.31 |
| " No systematic changes in pharmacokinetic parameters were observed." | ( Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment. Amorusi, P; Dowell, JA; Korth-Bradley, J; Milisci, M; Tantillo, K; Tse, S, 2001) | 0.56 |
| " Pharmacokinetic parameters for each antibiotic were determined using population modeling, and variables potentially related to outcomes were evaluated using tree-based modeling, logistic regression, and nonlinear regression methods." | ( Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Ballow, CH; Booker, BM; Forrest, A; Schentag, JJ; Smith, PF, 2001) | 0.56 |
| "To report a case of acinetobacter meningitis treated with a once-daily intravenous dose of tobramycin and to propose a pharmacokinetic model for the drug disposition." | ( Pharmacokinetic model for tobramycin in acinetobacter meningitis. Cercós-Lletí, AC; Chicano-Piá, PV; Romá-Sánchez, E, 2002) | 0.84 |
| " Pharmacokinetic parameters were calculated with plasma and CSF concentration values obtained during the first once-daily dose by using a compartment-effect model which allows fitting of simultaneous plasma and CSF concentrations." | ( Pharmacokinetic model for tobramycin in acinetobacter meningitis. Cercós-Lletí, AC; Chicano-Piá, PV; Romá-Sánchez, E, 2002) | 0.61 |
| " Pharmacokinetic data were best represented by a two-compartment model with biexponential decay and slope estimates comparable to those following parenteral administration." | ( Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Geller, DE; Nardella, PA; Pitlick, WH; Ramsey, BW; Tracewell, WG, 2002) | 0.57 |
| " Pharmacokinetic parameters were calculated by using a two-compartment model with NONMEM." | ( Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Ducharme, MP; Lavigne, J; Marier, JF, 2002) | 0.54 |
| "The authors studied the inaccuracy effect in the determination of C(min) and C(1h) post-infusion serum concentrations of vancomycin, amikacin, and tobramycin on the recommended dose regimen (RDR) using the Abbottbase Pharmacokinetic Systems (PKS) program (Abbott; Abbott Park, IL)." | ( Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the Abbottbase Pharmacokinetic Systems. Hermida, J; Tutor, JC; Zaera, S, 2002) | 0.74 |
| " It appears that the AUIC, by conveying the pharmacokinetic and susceptibility information, could serve as a PK/PD index in bridging the interdependency of PAE and bactericidal activity." | ( The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics. Li, RC; Zhu, ZY, 2002) | 0.31 |
| " Pharmacokinetic parameters were calculated using a two-compartment model with NONMEM." | ( Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. Brazier, JL; Ducharme, MP; Lavigne, J; Marier, JF, 2003) | 0.72 |
| ") elimination half-life (t(1/2beta)) and pulmonary exposure (AUC) of the conventional formulation were 14." | ( Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. Brazier, JL; Ducharme, MP; Lavigne, J; Marier, JF, 2003) | 0.72 |
| "To describe the pharmacokinetic disposition of tobramycin in children undergoing stem cell transplantation (SCT) after intravenous administration either every 24 hours or every 8 hours, and to use this information to create initial dosing guidelines for administration every 24 hours in this patient population." | ( Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Abdolell, M; Allen, U; Doyle, J; Dupuis, LL; Sung, L; Taddio, A; Taylor, T, 2004) | 2.02 |
| "A two compartment pharmacokinetic model best described the aminoglycoside data." | ( Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Holford, N; Kirkpatrick, C; Matthews, I, 2004) | 0.32 |
| "This paper considers the updating of Bayesian posterior densities for pharmacokinetic models associated with patients having changing parameter values." | ( A Bayesian approach to tracking patients having changing pharmacokinetic parameters. Bayard, DS; Jelliffe, RW, 2004) | 0.32 |
| " To circumvent these limitations, we propose an alternative approach to the quantification of pharmacodynamic drug interaction (PDI)." | ( Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Boucher, AN; Lewis, RE; Melnick, DA; Schilling, AN; Tam, VH, 2004) | 0.32 |
| " We investigated various regimens of cefepime alone and in combination against two clinical MRSA isolates (R2481 and R2484) in an established in vitro pharmacodynamic model." | ( Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Huang, V; Rybak, MJ, 2005) | 0.33 |
| " The half-life of the drug varied with the level of the serum creatinine in the first group of patients, and the average volume of distribution was 15 liters." | ( Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis. Hirschman, SZ; Jaffe, G; Meyers, BR, 1974) | 0.58 |
| "Relationships between pharmacodynamic indices (PI), such as the area under the concentration-time curve (AUC)/MIC ratio and time > MIC (T(>MIC)), and efficacy have been described for antimicrobial drugs." | ( Pharmacodynamics of tobramycin in patients with cystic fibrosis. Horrevorts, AM; Jacobs, N; Mouton, JW; Tiddens, H, 2005) | 0.65 |
| "To report aminoglycoside pharmacokinetic observations in a consecutive series of patients receiving intermittent hemodialysis (IHD), including treatment impact of patient-specific dosing regimens." | ( Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Dager, WE; King, JH, 2006) | 0.33 |
| "In this prospective study, all calculated pharmacokinetic parameters used concentrations drawn more than 12 hours after the initial dose and peak concentrations at least 2 hours after the dose." | ( Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Dager, WE; King, JH, 2006) | 0.33 |
| "A large variability in aminoglycoside pharmacokinetic parameters in IHD exists, with aminoglycoside elimination off IHD significantly faster in ARF." | ( Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Dager, WE; King, JH, 2006) | 0.33 |
| " There are limited data on the pharmacokinetic (PK) profile for once-daily tobramycin in patients with CF." | ( Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. Cranswick, N; Massie, J, 2006) | 0.82 |
| " Population pharmacokinetic models stratified to treatment schedule were created, and individual pharmacokinetic parameters were calculated." | ( Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. Knox, AJ; Smyth, A; Touw, DJ, 2007) | 0.63 |
| "The reduced elimination rate in OD may either be caused by circadian pharmacokinetic behaviour of tobramycin or indicates early renal damage caused by high tobramycin doses not detected by biochemical measurements." | ( Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. Knox, AJ; Smyth, A; Touw, DJ, 2007) | 0.84 |
| "Patient characteristics and pharmacokinetic parameters of patients receiving tobramycin three times daily from 1 January 1992 to 31 October 2005 were analysed using univariate analysis and multiple linear regression to determine statistically significant relationships and to derive dosing models." | ( Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. Atenafu, E; Bitnun, A; Dekker, A; Lam, W; Ratjen, F; Seto, W; Solomon, M; Tjon, J; Waters, V; Wong, C; Yau, Y, 2007) | 0.8 |
| " Using a target peak concentration range of 25-35 mg/L, the initial dose for female CF patients at least 14 years of age was calculated to be 7 mg/kg/day given intravenously as a single daily dose." | ( Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. Atenafu, E; Bitnun, A; Dekker, A; Lam, W; Ratjen, F; Seto, W; Solomon, M; Tjon, J; Waters, V; Wong, C; Yau, Y, 2007) | 0.57 |
| "Tobramycin dry powder formulations were evaluated by gamma scintigraphy and pharmacokinetic methods." | ( Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Amighi, K; Blocklet, D; Goole, J; Knoop, C; Pilcer, G; Van Gansbeke, B; Vanderbist, F, 2008) | 2.03 |
| " Pharmacokinetic parameters, calculated on the basis of concentrations determined with the microbiological assay were not statistically different from those obtained when data from HPLC analysis were used, but the microbiological assay was more sensitive in the detection of low plasma and urine values." | ( Pharmacokinetic studies on tobramycin in horses. Bakalov, D; Haritova, A; Hubenov, H; Krastev, S; Lashev, L; Yanev, S, 2007) | 0.64 |
| "* Two recent papers have been published which have attempted to build a full population pharmacokinetic model for tobramycin in children with cystic fibrosis." | ( Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. Hennig, S; Kirkpatrick, CM; Norris, R, 2008) | 0.81 |
| "The primary aim was to estimate the population pharmacokinetic parameters of once-daily intravenous (i." | ( Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. Hennig, S; Kirkpatrick, CM; Norris, R, 2008) | 0.6 |
| " Serum concentrations were analysed over a period of 6 h and pharmacokinetic key variables for each drug were calculated." | ( Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. Aadahl, P; Aasarød, K; Asheim, P; Spigset, O; Uggen, PE; Walstad, RA; Zahlsen, K, 2008) | 0.57 |
| "The pharmacokinetic properties after intraperitoneal administration differed among the three drugs, but the results are encouraging and provide a basis for further investigation in humans." | ( Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. Aadahl, P; Aasarød, K; Asheim, P; Spigset, O; Uggen, PE; Walstad, RA; Zahlsen, K, 2008) | 0.57 |
| " The serum pharmacokinetic values for tobramycin were best represented using a one- or two-compartment open model, depending on the method of administration." | ( Pharmacokinetics of tobramycin in ducks and sex-related differences. Dimitrova, D; Dinev, T; Kanelov, I; Lashev, L; Moutafchieva, R, 2009) | 0.95 |
| " Our objective was to describe the pharmacokinetic parameters of high doses of tobramycin administered at extended intervals in severely burned patients." | ( Pharmacokinetic variability of extended interval tobramycin in burn patients. Bracco, D; Dubois, MJ; Eggimann, P; Landry, C, 2008) | 0.83 |
| " Pharmacokinetic parameters were derived from two points first order kinetics." | ( Pharmacokinetic variability of extended interval tobramycin in burn patients. Bracco, D; Dubois, MJ; Eggimann, P; Landry, C, 2008) | 0.6 |
| "Tobramycin had a normal clearance, but an increased volume of distribution and a prolonged half-life in burned patients." | ( Pharmacokinetic variability of extended interval tobramycin in burn patients. Bracco, D; Dubois, MJ; Eggimann, P; Landry, C, 2008) | 2.04 |
| " pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data." | ( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008) | 0.35 |
| " The clearance (Cl), serum half-life (t(1/2)), and volume of distribution (Vd) of aminoglycosides change during the neonatal life, and the pharmacokinetics of aminoglycosides need to be studied in neonates in order to optimise therapy with these drugs." | ( Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Pacifici, GM, 2009) | 0.35 |
| "Because of the high frequency of multidrug resistant bacteria in our intensive care units (ICUs), we implemented a ventilator-associated pneumonia (VAP) clinical pathway based on unit-specific minimum inhibitory concentration (MIC) distributions and pharmacodynamic modeling in 3 of our ICUs." | ( Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E, 2010) | 0.36 |
| "In our ICUs where multidrug resistant bacteria are common, an approach considering ICU-specific antibiotic MICs coupled with pharmacodynamic dosing strategies resulted in improved outcomes and shorter duration of treatments." | ( Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E, 2010) | 0.36 |
| "For each of the three patients, predicted pharmacokinetic parameters (volume of distribution, first-order elimination rate constant, half-life, and renal drug clearance) based on population data were compared with their actual pharmacokinetic parameters that were calculated based on observed tobramycin serum levels." | ( Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Mercer, JM; Neyens, RR, 2010) | 0.54 |
| " Caution should be exercised when attempting to use predicted pharmacokinetic parameters to dose aminoglycosides in this patient population, and first-dose pharmacokinetics should be considered to optimize the dose and dosing interval early in the course of therapy." | ( Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Mercer, JM; Neyens, RR, 2010) | 0.36 |
| " Pharmacokinetic data were obtained from a set of prospectively collected data (1982 to 2003) of 2,073 (53." | ( Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Bertino, JS; Nafziger, AN; Pai, MP, 2011) | 0.37 |
| " The pharmacokinetic profile in plasma and sputum were determined after single and multiple dose administration on Day 1 and Day 28, respectively." | ( Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Acerbi, D; Annoni, O; Cicirello, H; Govoni, M; Poli, G; Ružička, J; Santoro, D, 2013) | 0.65 |
| "Plasma tobramycin pharmacokinetic profiles were similar for the eFlow and LC Plus nebulisers both on Day 1 and Day 28." | ( Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Acerbi, D; Annoni, O; Cicirello, H; Govoni, M; Poli, G; Ružička, J; Santoro, D, 2013) | 1.1 |
| "Plasma and sputum pharmacokinetic data in CF patients with chronic PA infection support comparable pulmonary delivery and safety of TNS4 administered using different nebulisers, with a significantly shorter nebulisation time for the eFlow." | ( Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Acerbi, D; Annoni, O; Cicirello, H; Govoni, M; Poli, G; Ružička, J; Santoro, D, 2013) | 0.65 |
| " We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing." | ( Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. Bullington, WM; Flume, PA; Heh, JL; Stenbit, AE, 2013) | 0.72 |
| " The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements." | ( Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Hennig, S; Staatz, CE; Standing, JF; Thomson, AH, 2013) | 0.68 |
| "To investigate this issue, a population pharmacokinetic meta-analysis of data from eight centres was undertaken." | ( Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Hennig, S; Staatz, CE; Standing, JF; Thomson, AH, 2013) | 0.68 |
| "Aminoglycoside concentration-time data and relevant clinical characteristics were collated from clinical pharmacokinetic databases established in Glasgow, Scotland and The Hague, The Netherlands." | ( Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. Alghanem, S; Paterson, I; Thomson, AH; Touw, DJ, 2013) | 0.39 |
| "The serum pharmacokinetic profile of intravenous (i." | ( Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Beegle, S; Butterfield, JM; Farkas, J; Lodise, TP; Pai, MP; Rosen, J, 2013) | 0.62 |
| " A retrospective study was conducted in 58 eligible patients who received tobramycin and had at least one set of steady-state levels from which pharmacokinetic parameters could be determined using standard first-order pharmacokinetic equations." | ( Determination of tobramycin pharmacokinetics in burn patients to evaluate the potential utility of once-daily dosing in this population. Daneman, N; Simor, A; Vella, D; Walker, SA; Walker, SE, ) | 0.7 |
| " We sought to evaluate the effectiveness of a local aminoglycoside guideline to achieve pharmacodynamic goals in patients with CF that received ≧3 doses of HEAT from 2005 to 2011." | ( Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis. Cios, D; DeGrado, JR; Greenwood, BC; Kubiak, DW; Szumita, PM, 2014) | 0.64 |
| "In the pharmacokinetic analysis (NONMEM VI) based on data of gentamicin, tobramycin and vancomycin collected in 1,760 patients (age 1 day-18 years, bodyweight 415 g-85 kg), a distinction was made between drug-specific and system-specific information." | ( Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Allegaert, K; Brussee, JM; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Mulla, H; Sherwin, CM; van den Anker, JN, 2014) | 0.88 |
| "Tobramycin plasma AUC and Cmax were lower after administration of T100 than after TNS." | ( Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. Gąszczyk, G; Mazurek, H; Sands, D; Sapiejka, E, 2014) | 2.18 |
| "Aminoglycoside elimination half-life values were highly variable (median 7 hours, range 3 - 26 hours) and did not correlate with total body weight or estimated creatinine clearance derived from the dose of continuous venovenous hemofiltration." | ( Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. Barns, B; Block, C; Burrill, S; Chuk, AC; Fu, J; Katrych, O; Kousar, N; Lahey, T; Rickrode, G; Saeed, F; Saunders-Hao, P, 2015) | 0.67 |
| " Once daily dosing achieved higher Cmax as compared to TDD (29." | ( Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis. Biondo, L; Brigg Turner, R; Elbarbry, F, 2016) | 0.67 |
| "No significant differences were found in pharmacokinetic parameters between the two nebulizers." | ( Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization. Bos, AC; Heijerman, HG; Janssens, HM; Tiddens, HA; Touw, DJ; van Velzen, AJ, 2016) | 0.68 |
| "To assess local tolerability and the pharmacokinetic parameters of inhaled excipient free dry powder tobramycin as free base administered with the Cyclops dry powder inhaler to participants with non-cystic fibrosis bronchiectasis." | ( Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. Akkerman, OW; Alffenaar, JW; de Boer, AH; Frijlink, HW; Hagedoorn, P; Hoppentocht, M; Kerstjens, HA; van der Werf, TS, 2016) | 0.89 |
| "Several population pharmacokinetic models describe the dose-exposure relationship of tobramycin in pediatric patients." | ( Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Bloomfield, C; Hennig, S; Staatz, CE; Unwin, S, 2016) | 0.88 |
| " Population pharmacokinetic analyses were performed using non-linear mixed-effects modelling." | ( Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Bennett, MR; Clancy, JP; Dong, M; Downes, KJ; Fukuda, T; Goldstein, SL; Haffner, C; Vinks, AA, 2017) | 0.73 |
| " The population pharmacokinetic parameter estimates were CL = 8." | ( Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Bennett, MR; Clancy, JP; Dong, M; Downes, KJ; Fukuda, T; Goldstein, SL; Haffner, C; Vinks, AA, 2017) | 0.73 |
| "We describe urinary biomarkers as predictors of tobramycin CL using a population pharmacokinetic modelling approach." | ( Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Bennett, MR; Clancy, JP; Dong, M; Downes, KJ; Fukuda, T; Goldstein, SL; Haffner, C; Vinks, AA, 2017) | 0.98 |
| " The unique structure of the eye requires specially-designed formulations able to favor the pharmacokinetic profile of administered drugs, mainly minimizing the influence of ocular barriers." | ( Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. Burgalassi, S; Cavalli, R; Chetoni, P; Cuffini, AM; Monti, D; Muntoni, E; Spagnolo, R; Tampucci, S; Tullio, V; Zara, GP, 2016) | 0.68 |
| " Unfortunately, burn patients are excluded from ODA due to concerns over altered pharmacokinetics resulting in a shortened half-life and low peak aminoglycoside concentrations." | ( A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Jeschke, M; Lee, C; Seto, W; Simor, A; Walker, SAN; Walker, SE, 2017) | 0.74 |
| "This prospective single dose pharmacokinetic clinical trial was conducted at the Ross Tilley Burn Centre." | ( A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Jeschke, M; Lee, C; Seto, W; Simor, A; Walker, SAN; Walker, SE, 2017) | 0.74 |
| " Tobramycin half-life was similar to healthy, non-burn patients." | ( A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Jeschke, M; Lee, C; Seto, W; Simor, A; Walker, SAN; Walker, SE, 2017) | 1.65 |
| "The selection and dose of antibiotic therapy for biofilm-related infections are based on traditional pharmacokinetic studies using planktonic bacteria." | ( Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. Engel, J; Haagensen, J; Huang, L; Spormann, AM; Verotta, D; Yang, K, 2017) | 0.71 |
| "Several clinical trials have shown the efficacy of continuous infusion beta-lactam (BL) antibiotics in patients with cystic fibrosis (CF); however, little is known about pharmacokinetic changes during the treatment of an acute pulmonary exacerbation (APE)." | ( Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Deka, R; Hong, LT; King, JB; Liou, TG; Stevens, V; Young, DC, 2018) | 0.48 |
| " There are three major barriers to achieving the desired pharmacodynamic effect with these compounds: aerosol delivery, lung deposition and clearance." | ( Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. Garcia-Contreras, L; Hickey, AJ; Kukut Hatipoglu, M, 2018) | 0.48 |
| " Tobramycin population pharmacokinetic (PK) modeling can be used to decipher the best approach to define eGFR for pediatric bridging studies." | ( Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis. Crass, RL; Pai, MP, 2019) | 1.42 |
| " In previous pharmacokinetic studies, lung interstitial space fluid concentrations have never been reported." | ( Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. Barnett, A; Boidin, C; Chaudhary, J; Chew, M; Cohen, J; Dhanani, JA; Diab, S; Fraser, JF; Parker, SL; Roberts, JA; Wallis, SC, 2019) | 0.82 |
| " In this study, we investigate the full pharmacokinetic profile of tobramycin in obese and non-obese individuals with normal renal function." | ( Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Brüggemann, RJM; Knibbe, CAJ; Mouton, JW; Smit, C; van Dongen, HPA; Wasmann, RE; Wiezer, MJ, 2019) | 2.19 |
| " Pharmacokinetic (PK) parameters were derived for each patient from a published model using Monte Carlo simulation." | ( Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. Alghanem, SS; Thomson, AH; Touw, DJ, 2019) | 0.75 |
| "More patients achieved standard Cmax and AUC0-24 targets with 3 mg/cm/day (64% and 62%, respectively) than with 10 mg/kg/day (43% and 48%, respectively)." | ( Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. Alghanem, SS; Thomson, AH; Touw, DJ, 2019) | 0.75 |
| "To evaluate augmented renal clearance (ARC) using aminoglycoside clearance (CLAMINO24h) derived from pharmacokinetic (PK) modelling." | ( Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. Avedissian, SN; Bradley, J; Kim, Y; Le, J; Rhodes, NJ; Valdez, JL, 2020) | 0.56 |
| " The aim of this study is to assess the potential of exhaled breath condensate (EBC) as a matrix for pharmacokinetic analysis of inhaled and intravenous medication." | ( Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis. Birkhoff, WAJ; Cholewinski, T; Cohen, AF; Dröge, MJ; Klarenbeek, NB; Kruizinga, MD; Nelemans, T; van Esdonk, MJ; Zuiker, RGJA, 2020) | 0.8 |
| " Conclusions The methods described here meet validation acceptance criteria and were suitable for application in a pilot pharmacokinetic research study performed in a sheep model." | ( Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. Dhanani, J; Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Wallis, SC, 2020) | 0.8 |
| " Pharmacokinetic and kidney function parameters were compared between the 2 groups." | ( Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis? Heijerman, HGM; Neef, C; Touw, DJ; van der Meer, R; van Maarseveen, EM, 2020) | 0.8 |
| "The pharmacokinetic parameters of intravenously administered tobramycin during admission for acute pulmonary exacerbation do not appear to change significantly after initiating chronic therapy with a CFTR modulator." | ( Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population. Albright, JC; Houck, AP; Pettit, RS, 2020) | 1.05 |
| " The extracted concentration data of tobramycin were used for the construction of the population pharmacokinetic model using a non-linear mixed-effects modelling approach." | ( Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. Cheng, Z; Li, S; Peng, Y; Wang, Y; Xie, F, 2021) | 1.15 |
| "A population pharmacokinetic model was built based on 307 measurements in 140 unique patients and externally validated by an independent study dataset." | ( Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. Cheng, Z; Li, S; Peng, Y; Wang, Y; Xie, F, 2021) | 0.88 |
| " This study aimed to empirically test a pharmacokinetic (PK) model using Bayesian estimation of drug exposure in the deeper body tissues to determine feasibility for prediction of ototoxicity." | ( Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. Blankenship, CA; Dong, M; Hunter, LL; McPhail, G; Rodriguez, AV; Vinks, AA, 2021) | 0.85 |
| "To perform a population pharmacokinetic (PPK) analysis and predict an efficacious dose based on data from a first-in-human Phase I trial." | ( Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose. Chirkova, A; Friberg, LE; Hobbie, SN; Lindberg, J; Palma Villar, R; Rosenborg, S; Zhao, C, 2022) | 0.72 |
| " Emerging drug resistance and changing pharmacokinetic profile in an aging population involve a reevaluation of tobramycin dosing recommendations." | ( New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis. Koloskoff, K; Marsot, A; Matouk, E; Thirion, DJG, 2023) | 1.37 |
| "Tobramycin (TOB) exhibits variable pharmacokinetic properties due to the clinical condition of patients." | ( Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria. Hashiguchi, Y; Jono, H; Matsumoto, N; Oda, K; Saito, H, 2023) | 2.6 |
| "To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at or higher than the clinical breakpoint (MIC ≥ 4 mg/L)." | ( Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR, 2023) | 1.31 |
Tobramycin in combination with clindamycin or lincomycin were used as systemic antibiotics in the treatment of 20 consecutive patients with septic peritonitis or intraabdominal sepsis, 10 of which were in septic shock. The study was to compare once daily (To24) and thricedaily (To8) tobramYcin dosing regimens.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin in bacteriostatic (MIC) and bactericidal (MBC) concentrations were compared using the checkerboard dilution technique against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species." | ( In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains. Daschner, FD; Langmaack, H; Steffens, A, 1979) | 0.5 |
| " To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin." | ( Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients. Bodey, GP; Issell, BF; Keating, MJ; Valdivieso, M, ) | 0.71 |
| " Tobramycin was the most effective aminoglycoside when used in combination with beta-lactam antibiotics." | ( In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens. Bartlett, M; Crane, JK; Griffin, PS; Miller, MA; Yousuf, M, 1979) | 1.17 |
| "To explore more effective therapy for Pseudomonas aeruginosa, 264 recent clinical isolates were tested by agar dilution using gentamicin and tobramycin alone and combined with carbenicillin to seek synergistic effects." | ( Susceptibility of Pseudomonas aeruginosa to tobramycin or gentamicin alone and combined with carbenicillin. Anderson, EL; Farrar, WE; Gramling, PK; Vestal, PR, 1975) | 0.72 |
| "The in vitro activity of nafcillin, oxacillin, and methicillin alone and in combination with gentamicin and tobramycin against 30 strains of enterococci was investigated." | ( Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci. Glotzbecker, C; Watanakunakorn, C, 1977) | 0.68 |
| "Fifteen strains of Enterococcus faecalis, all clinical blood culture isolates from patients with endocarditis, were studied by kill-kinetic experiments using penicillin G, ampicillin and amoxicillin alone and in combination with tobramycin." | ( Bactericidal effect of penicillin, ampicillin, and amoxicillin alone and in combination with tobramycin against Enterococcus faecalis as determined by kill-kinetic studies. Frimodt-Møller, N; Gutschik, E; Westh, H, ) | 0.53 |
| "Efficacy of the ceftazidime monotherapy in 120 febrile children with neoplastic diseases and granulocytopenia was compared with that of tobramycin combined with amoxycillin/ampicillin." | ( [Assessment of the efficacy of treating infections in hematopoietic proliferative diseases: Monotherapy with ceftazidime and tobramycin combined with amoxycillin/ampicillin]. Bubała, H; Janik-Moszant, A; Koehler, M; Kuder, K; Sońta-Jakimczyk, D; Wieczorek, M, ) | 0.54 |
| "The efficacy of ciprofloxacin alone and in combination with azlocillin was compared with that of azlocillin plus tobramycin in a rat model of aortic valve endocarditis due to Pseudomonas aeruginosa." | ( Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa. Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin, C, ) | 0.34 |
| "In vitro susceptibility studies of cefpirome versus cefotaxime, ceftazidime, imipenem, and piperacillin alone and in combination with tobramycin were performed against 153 clinical isolates of Pseudomonas aeruginosa from four medical centers." | ( In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa. Bale, M; Cabezudo, I; Pfaller, M; Wenzel, R, ) | 0.55 |
| " The bactericidal effect obtained with daptomycin in combination with aminoglycosides suggest that further evaluation of these combinations in enterococcal endocarditis could have a clinical interest if this bactericidal effect was confirmed by in vivo studies." | ( [Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus]. Cordin, X; Duez, JM; Kazmierczak, A; Péchinot, A; Siébor, E, 1989) | 0.5 |
| "Seven strains of Streptococcus faecalis, of which two possessed high-level resistance to streptomycin (MIC greater than or equal to 2000 mcg/ml), and two strains of Streptococcus faecium were evaluated with respect to killing-effect and duration of post-antibiotic effect (PAE) of ampicillin and vancomycin in combination with streptomycin, gentamicin, tobramycin and netilmicin." | ( Evaluation of the combination effects of ampicillin or vancomycin combined with streptomycin, gentamicin, tobramycin or netilmicin against enterococci. Fuursted, K, 1989) | 0.66 |
| "The objectives of this study were to investigate the bactericidal activity in serum of cefotaxime alone or in combination with tobramycin against clinical strains and to determine the influence of tobramycin on the pharmacokinetics of cefotaxime." | ( Comparative study of serum bactericidal activity of cefotaxime alone or in combination with tobramycin. Bergeron, MG; Charest, A; Forcier, JF; LeBel, M; Morin, J; Vallée, F, 1986) | 0.7 |
| "5 mg/kg body weight per day), alone or in combination with immunopreparations, ensured the survival rate of the animals equal to 100%." | ( [Dynamics of the contamination of mice during the treatment of burn sepsis due to Pseudomonas aeruginosa using tobramycin alone or combined with active and passive immunization]. Minukhin, VV; Tsyganenko, AIa, 1986) | 0.48 |
| "The in vitro activity of aztreonam combined with tobramycin and with gentamicin was assessed in 78 clinical isolates of Pseudomonas aeruginosa and 11 clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis." | ( In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Bosso, JA; Matsen, JM; Saxon, BA, 1987) | 0.79 |
| "The antibacterial activity of ciprofloxacin, either alone or in combination with azlocillin, imipenem, mezlocillin or tobramycin, was tested against enterococcus and pseudomonas species." | ( [Ciprofloxacin in combination with other antimicrobial substances]. Mellinghoff, D; Shah, PM; Stille, W, 1988) | 0.48 |
| "Emergence of bacterial resistance to antimicrobial agents was studied during a period of 30 months of continuous use of parenteral cefotaxime combined with oral non-absorbable polymyxin E and tobramycin (selective decontamination) in a surgical intensive care unit (ICU)." | ( Cefotaxime combined with selective decontamination in long term intensive care unit patients. Virtual absence of emergence of resistance. Stoutenbeek, CP; van Saene, HK; Zandstra, DF, 1988) | 0.46 |
| " Activity of eremomycin alone or in combination with tobramycin was studied with using 25 clinical strains of staphylococci." | ( [Study of the activity of a new glycopeptide antibiotic eremomycin combined with tobramycin against Staphylococci in vitro]. Iakushkina, IV; Malkova, IV; Prozorova, IN, 1988) | 0.75 |
| "The nephrotoxic potentials of cisplatin and carboplatin, alone and in combination with the aminoglycoside antibiotic tobramycin, were compared in male rats." | ( Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Bregman, CL; Williams, PD, 1986) | 0.71 |
| "Effects of tobramycin (TOB) alone and in combination with latamoxef (LMOX) on the stability of rat kidney lysosomal membranes were investigated." | ( Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (4). Effects of tobramycin alone and in combination with latamoxef on the stability of rat kidney lysosomal membranes. Ito, M; Kojima, R; Suzuki, Y, 1987) | 0.87 |
| "Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas aeruginosa, twenty-six of which were carbenicillin-(CARB) resistant, were tested for susceptibility to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination with tobramycin (TOB) using the microtiter broth diluent method and an inoculum density of 10(6) CFU/ml." | ( Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas. Andriole, VT; Downs, JT; Ryan, JL, ) | 0.54 |
| "189 bacterial strains were investigated for their in vitro sensitivity against ceftazidime (alone and in combination with another antibiotic)." | ( In vitro activity of ceftazidime in combination with other antibiotics. Littschwager, G; Simon, C, ) | 0.13 |
| "A broth dilution checkerboard synergy assay was used to assess the activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, in combination with tobramycin, against 38 strains of Pseudomonas aeruginosa." | ( Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa. Drew, WL; Mintz, L, 1981) | 0.67 |
| "The in vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against 50 Pseudomonas aeruginosa strains was studied by the broth dilution method and the time-kill curve method." | ( In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. Watanakunakorn, C, 1983) | 0.72 |
| "A comparative study was made on tobramycin combined with either carbenicillin (500 mg/kg/day) or one of the new penicillins: azlocillin or piperacillin (both 300 mg/kg/day) in 50 cystic fibrosis patients with chronic Pseudomonas aeruginosa infection." | ( Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Eriksen, KR; Feddersen, C; Flensborg, EW; Høiby, N; Møller, NE; Norn, S; Rosendal, K; Schiøtz, PO; Skov, PS, 1982) | 0.75 |
| "The stability of the aminoglycosides gentamicin, tobramycin, and amikacin stored in combination with carbenicillin, piperacillin, cefotaxime, and moxalactam was evaluated at four temperatures (25, 4, -8, and -70 degrees C) over a 3-week period." | ( Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics. Glew, RH; Pavuk, RA, 1983) | 0.82 |
| "Ninety-four cases of pyelonephritis including 20 who had concurrent bacteremia were treated with cefamandole alone or in combination with either gentamicin or tobramycin." | ( Cefamandole alone and combined with gentamicin or tobramycin in the treatment of acute pyelonephritis. Gentry, LO; Martin, MD; Smythe, J; Wood, BA, 1980) | 0.71 |
| "Tobramycin in combination with clindamycin or lincomycin were used as systemic antibiotics in the treatment of 20 consecutive patients with septic peritonitis or intraabdominal sepsis, 10 of which were in septic shock." | ( High-dose tobramycin combined with clindamycin or lincomycin in the treatment of septic peritonitis and intraabdominal sepsis. Edén, T; Muth, L, 1981) | 2.11 |
| "The antipseudomonal activities of ceftriaxone (CEF) or ceftazidime (CAZ), each combined with tobramycin (TOB) or netilmicin (NET), against 90 clinically significant Pseudomonas aeruginosa isolates were examined both by checkerboard and time-kill assays." | ( In vitro synergism of ceftriaxone combined with aminoglycosides against Pseudomonas aeruginosa. Chow, AW; Gallimore, B; Laverdière, M; Poonia, K; Restieri, C, 1994) | 0.51 |
| "The purpose of this study was to compare once daily (To24) and thrice daily (To8) tobramycin dosing regimens alone and in combination with ceftazidime, ciprofloxacin and imipenem against a clinical and ATCC strain of Pseudomonas aeruginosa." | ( Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model. Hoban, DJ; Kabani, A; Karlowsky, JA; Zelenitsky, SA; Zhanel, GG, ) | 0.66 |
| " The combination beta-lactam-ciprofloxacin-tobramycin was the combination with the most consistently synergistic effect." | ( Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999) | 0.77 |
| "Cefepime, a fourth-generation cephalosporin, is currently one of the primary agents used in combination with an aminoglycoside when treating Pseudomonas aeruginosa infections." | ( Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Nicolau, DP; Nightingale, CH; Onyeji, CO; Tessier, PR, ) | 0.34 |
| " The patients were randomly divided into four groups to receive topical applications of either ciprofloxacin and tobramycin alone, or in combination with dexamethasone." | ( [Efficacy of topical ciprofloxacin and tobramycin in combination with dexamethasone in the treatment of chronic suppurative otitis media]. Demirbağ, E; Gök, U; Karlidağ, T; Kaygusuz, I; Kaygusuz, TO; Keleş, E; Yalçin, S, ) | 0.61 |
| " Human pharmacokinetic regimen simulations were as follows: cefepime, 2 g every 8 h (q8h) (C8) and 12 h (C12), continuous-infusion 2-g loading dose followed by 4 g alone or in combination with gentamicin and tobramycin (1." | ( Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Huang, V; Rybak, MJ, 2005) | 0.52 |
| "This randomized, double-blind, multicenter study compared the efficacy and safety of piperacillin/tazobactam (P/T) and imipenem/cilastatin (IMP), both in combination with an aminoglycoside, in hospitalized patients with acute nosocomial pneumonia (NP)." | ( Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S, 2006) | 0.56 |
| "The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa." | ( Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Adam, HJ; Laing, N; Mayer, M; Zhanel, GG, 2006) | 0.72 |
| "When administered with penicillin G, tobramycin given once daily was as efficacious and safe as tobramycin given three times daily in cancer patients with febrile neutropenia in Norway, provided the regimen was modified according to the clinical response." | ( Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. Bø, K; Grøttum, K; Holte, H; Høiby, EA; Jacobsen, AB; Kvaløy, S; Lauritzsen, GF; Meyer, P; Olsen, H; Sandstad, B; Tangen, JM; Torfoss, D; Weyde, K, 2007) | 2.06 |
| "To evaluate the in vitro efficacy of an ophthalmic drug combination against common corneal pathogens of horses." | ( In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses. Brooks, DE; Schuman Rose, CD; Scotty, NC, 2008) | 0.35 |
| "The drug combination was at least as effective as each medication separately for inhibiting microbial growth of all pathogens tested and was significantly more effective against B-hemolytic Streptococcus spp, Aspergillus spp, and Fusarium spp than the relevant medications separately." | ( In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses. Brooks, DE; Schuman Rose, CD; Scotty, NC, 2008) | 0.35 |
| "Levofloxacin and tobramycin, alone and in combination with cefepime, were investigated for their in vitro activities and post-antibiotic effects (PAEs) on Pseudomonas aeruginosa." | ( Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa. Otuk, G; Ozbek, B, 2009) | 0.96 |
| " The bactericidal activity of CSA-13 in combination with colistin was measured using the time-kill curve method for two strains." | ( In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Bozkurt-Guzel, C; Gerceker, AA; Savage, PB, 2011) | 0.59 |
| "Colistin, tigecycline, levofloxacin, tobramycin, and rifampin alone and in combination with doripenem were investigated for their in vitro activities and postantibiotic effects (PAEs) on Klebsiella pneumoniae." | ( Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit. Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M, 2014) | 0.68 |
| " aeruginosa, fosfomycin in combination with polymyxin B or tobramycin (FOF(S) isolates) or ciprofloxacin (FOF(R) isolates) increased bacterial killing, but did not suppress emergence of fosfomycin resistance." | ( Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. Bergen, PJ; Hirsch, EB; Kirkpatrick, CM; Landersdorfer, CB; McIntosh, MP; Peleg, AY; Walsh, CC, 2016) | 0.91 |
| "Cystic fibrosis (CF) patients often receive prolonged courses of broad spectrum antibiotics, such as piperacillin-tazobactam or cefepime in combination with vancomycin and tobramycin." | ( Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. LeCleir, LK; Pettit, RS, 2017) | 0.86 |
| "AKI occurred in nearly 55% of patients with piperacillin-tazobactam therapy versus 13% of patients with cefepime therapy, which suggests cefepime may be preferred in combination with vancomycin and tobramycin for pediatric CF patients." | ( Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. LeCleir, LK; Pettit, RS, 2017) | 0.86 |
| " The current study investigated the effects of LILFU combined with tobramycin on extended-spectrum beta-lactamases (ESBLs) Escherichia coli biofilms (a multi-drug resistant bacteria)." | ( Effects of low-intensity and low-frequency ultrasound combined with tobramycin on biofilms of extended-spectrum beta-lactamases (ESBLs) Escherichia coli. Du, Y; Hou, Y; Jiang, H; Li, D; Yang, M, 2019) | 0.99 |
| " The in-vitro bactericidal and synergistic activities of ceftazidime/avibactam alone or in combination with other antibiotics were determined by time-kill curve assays." | ( Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Istanbullu Tosun, A; Mataraci Kara, E; Özbek Çelik, B; Yilmaz, M, 2020) | 0.77 |
| "To investigate the clinical effect of sodium hyaluronate eye drops combined with tobramycin, dexamethasone, and pranoprofen eye drops in the treatment of dry eye after phacoemulsification." | ( Effect of sodium hyaluronate eye drops combined with tobramycin, dexamethasone and pranoprofen eye drops in the treatment of dry eye after phacoemulsification. Guan, Y; Lu, H; Nan, N; Su, Y; Yuan, Y, 2022) | 1.2 |
| " Biofilms of these nine strains were treated with different concentrations of micafungin and combined with tobramycin in microtiter plates." | ( Analyzing the Activity of Micafungin Combined with Tobramycin Against Pseudomonas Aeruginosa Biofilm. Li, YH; Wang, TY; Yang, Y; Zhang, SX; Zheng, JX, 2023) | 1.38 |
| " Its combination with tobramycin exhibited synergistic effects, including inhibiting the biofilm formation of PA02, PA05, PA23, PA24, and PA52 isolates above 1/4 × MIC or 1/2 × MIC and eradicating mature biofilms of PA02, PA04, PA23, PA24, and PA52 above 32 × MIC, 2 × MIC, 16 × MIC, 32 × MIC, and 1 × MIC, respectively." | ( Analyzing the Activity of Micafungin Combined with Tobramycin Against Pseudomonas Aeruginosa Biofilm. Li, YH; Wang, TY; Yang, Y; Zhang, SX; Zheng, JX, 2023) | 1.48 |
| "To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at or higher than the clinical breakpoint (MIC ≥ 4 mg/L)." | ( Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR, 2023) | 1.31 |
Tobramycin showed a high rate of absorption from the muscles. In vitro performance of Bramitob((R)) was similar when nebulized with Pari TurboBoy k/LC Plus and Systam 290 LS nebulizers.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Aminoglycoside antibiotics are poorly absorbed from the gastrointestinal tract, do not penetrate well into the cerebrospinal fluid, are minimally bound to plasma proteins, and are rapidly excreted by the normal kidney." | ( Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin. Brewer, NS, 1977) | 0.48 |
| " Pharmacokinetic analysis revealed that in newborn infants the elimination rate was markedly declined, but the absorption rate was nearly the same as that in older children." | ( Pharmacokinetics of tobramycin in the newborn. Fujita, K; Maruyama, S; Takimoto, M; Yoshioka, H, 1979) | 0.58 |
| " Studies of the pharmacokinetics of tobramycin showed a high rate of absorption from the muscles, a high rate of renal excretion, and effective therapeutic concentrations (higher than the minimal inhibitory concentration for the infecting strains) in renal tissue homogenates." | ( Bacteriological, clinical, and pharmacological investigations with tobramycin in patients with serious urinary tract infection. Cstáry, KN; Iván, E, 1976) | 0.77 |
| " Calculation of the intrinsic absorption rate of an intramuscular dose according to the two-compartment open model indicates that absorption increases during the first 40 minutes, then decreases and is virtually complete 90 minutes after administration in all subjects." | ( Distribution and elimination kinetics of intravenously and intramusculary administered tobramycin in man. Dugal, R; Péchère, JC; Roy, B, 1976) | 0.48 |
| " Although the effects of precipitate formation on drug bioavailability and toxicity have not been fully determined, until such information is available, the use of combinations of drugs that remain in solution during administration is recommended." | ( The solubility of antibiotic and corticosteroid combinations. Lee, BL; Matoba, AY; Osato, MS; Robinson, NM, 1992) | 0.28 |
| " Bioavailability after IM and SC administrations was 102." | ( Pharmacokinetics of tobramycin in cats. Hatch, RC; Jernigan, AD; Wilson, RC, 1988) | 0.6 |
| " For tobramycin, however, limited data are available on the aerosol absorption patterns, and no absolute bioavailability data for tobramycin exist." | ( Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. Cooney, GF; Fiel, SB; Lum, BL; Tomaselli, M, 1994) | 1.04 |
| " A study of vitreous clearance following the administration of a single intravitreal injection in rabbit eyes showed bioavailability of the drug at therapeutically effective levels for more than 72 hours." | ( Ocular pharmacokinetics of tobramycin. A comparative radioimmunoassay and microbiological assay. Desai, S, 1993) | 0.58 |
| "Apramycin was administered to chickens orally, intramuscularly and intravenously to determine blood concentration, kinetic behaviour, bioavailability and tissue residues." | ( Kinetic disposition, systemic bioavailability and tissue distribution of apramycin in broiler chickens. Afifi, NA; Ramadan, A, ) | 0.13 |
| "GS4071 is a novel potent inhibitor of influenza neuraminidase (Ki < 1 nM) with low (< 5%) oral bioavailability in animals." | ( Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Bidgood, A; Cundy, KC; Eisenberg, EJ, 1997) | 0.3 |
| " The bioavailability of an antibacterial agent depends on the target bacterial species, the site of infection and the integrity of the haemato-aqueous barrier." | ( Comparative review of topical ophthalmic antibacterial preparations. Adenis, JP; Robert, PY, 2001) | 0.31 |
| " When compared with an equal dose of TOB administered by standard commercial eyedrops, TOB-SLN produced a significantly higher TOB bioavailability in the aqueous humour." | ( Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Burgalassi, S; Cavalli, R; Chetoni, P; Gasco, MR; Saettone, MF, 2002) | 0.56 |
| "To describe the pharmacokinetics and bioavailability of inhaled tobramycin (TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC Plus; Pari Respiratory; Richmond, VA) and a compressor (Pulmo-Aide, model 5650D; DeVilbiss Health Care; Somerset, PA) in cystic fibrosis (CF) patients during the pivotal phase III trials." | ( Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Geller, DE; Nardella, PA; Pitlick, WH; Ramsey, BW; Tracewell, WG, 2002) | 0.8 |
| " The population estimate of the apparent clearance was used to estimate the bioavailability fraction." | ( Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Geller, DE; Nardella, PA; Pitlick, WH; Ramsey, BW; Tracewell, WG, 2002) | 0.57 |
| " The estimated systemic bioavailability after aerosol administration was 11." | ( Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Geller, DE; Nardella, PA; Pitlick, WH; Ramsey, BW; Tracewell, WG, 2002) | 0.57 |
| " The bioavailability of ofloxacin was 6 times that of ciprofloxacin." | ( [Aqueous humor penetration of topically applied ofloxacin, ciprofloxacin and tobramycin]. Wu, XD; Yang, YH; Yao, K; Zhang, Z, 2003) | 0.55 |
| " The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options." | ( PTC124 targets genetic disorders caused by nonsense mutations. Almstead, NG; Babiak, J; Barton, ER; Branstrom, AA; Campbell, JA; Chen, G; Colacino, JM; Conn, MM; Corson, D; Feng, H; Friesen, WJ; He, F; Hedrick, J; Hirawat, S; Hwang, S; Jacobson, A; Jones, S; Ju, WD; Karp, G; Kawana, M; Khan, A; Miller, LL; Mollin, A; Moon, YC; Northcutt, VJ; Patel, M; Paushkin, S; Peltz, SW; Ren, H; Risher, N; Spatrick, P; Sweeney, HL; Takasugi, J; Tomizawa, Y; Trifillis, P; Trotta, CR; Turpoff, AA; Weetall, M; Welch, EM; Wilde, RG; Yeh, S; Zhuo, J, 2007) | 0.34 |
| "In vitro performance of Bramitob((R)) was similar when nebulized with Pari TurboBoy k/LC Plus and Systam 290 LS nebulizers and comparable to that of TobiThe systemic bioavailability of tobramycin was similar after administration of either Bramitob or Tobi; however, in sputum samples the tobramycin peak concentration was slightly greater after administration of Bramitob than after Tobi." | ( Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Acerbi, D; Corrado, ME; Eichler, HG; Eichler, I; Pennini, R; Poli, G; Soliani Raschini, A, 2007) | 0.79 |
| " In an open single-dose, three-treatment, three-period, cross-over study, nine cystic fibrosis patients received both the two test products and the reference product Tobi (nebulizer solution) in order to assess lung deposition and systemic comparative bioavailability of the two investigational inhaled products versus the marketed inhaled comparator product." | ( Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Amighi, K; Blocklet, D; Goole, J; Knoop, C; Pilcer, G; Van Gansbeke, B; Vanderbist, F, 2008) | 0.59 |
| " When experiments aimed at increasing the oral bioavailability of hydrophilic compounds are performed, timing of fasting should be extremely accurate." | ( Fasting increases tobramycin oral absorption in mice. De Leo, L; Decorti, G; Di Toro, N; Malusà, N; Not, T; Ventura, A, 2010) | 0.69 |
| "The aim of this study was to synthesize charged amphoteric molecules, which after complexation with poorly bioavailable drugs would have the potential to improve their oral uptake." | ( Development and characterization of anionic liposaccharides for enhanced oral drug delivery. Abdelrahim, AS; Simerska, P; Toth, I, 2012) | 0.38 |
| "0 h), with a mean bioavailability of 81." | ( Pharmacokinetics of tobramycin following intravenous, intramuscular, and intra-articular administration in healthy horses. Barlow, BM; Davis, JL; Jennings, S; Newman, JC; Prange, T, 2013) | 0.71 |
| " this study seeks to determine the effect that surface area and volume have on the elution characteristics and bioavailability of tobramycin and vancomycin when mixed in polymethylmethacralate (PMMA) bone cement in various combinations." | ( Mechanical properties and elution characteristics of polymethylmethacrylate bone cement impregnated with antibiotics for various surface area and volume constructs. Chong, AC; Duey, RE; McQueen, DA; Song, Z; Steinberger, TA; Womack, JL; Wooley, PH, 2012) | 0.58 |
| " Bioavailability (F) was assessed by equating clearance (CL) with creatinine clearance (Cockcroft CLCr)." | ( Tobramycin exposure from active calcium sulfate bone graft substitute. Buclin, T; Csajka, C; Gautier, E; Livio, F; Wahl, P, 2014) | 1.85 |
| "A new compound granular premix of amoxicillin (20% w/w dry mass)/apramycin (5% w/w dry mass) was developed, and its pharmacokinetics and relative bioavailability were determined in pigs following oral administration following a cross-over study design." | ( Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. Dai, C; Tang, S; Velkov, T; Xiao, X; Yang, X; Zhao, T, 2017) | 0.46 |
| " Relative bioavailability in patients between 6 months and 7 years increased with age by a linear relationship, and was modeled as a ratio to that of patients over 7 years." | ( Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. Anumolu, SS; Koehne-Voss, S; Wang, X; Yu, J, 2017) | 0.74 |
| "Conventional topical delivery in hyperacute bacterial conjunctivitis and endophthalmitis is associated with low drug bioavailability due to rapid precorneal clearance." | ( Improvement in Ocular Bioavailability and Prolonged Delivery of Tobramycin Sulfate Following Topical Ophthalmic Administration of Drug-Loaded Mucoadhesive Microparticles Incorporated in Thermosensitive In Situ Gel. Khan, S; Singhavi, DJ; Warade, S, 2018) | 0.72 |
| " In situ gel containing drug-loaded microparticles were evaluated for gelation temperature, rheological behavior, mucoadhesive strength, in vitro drug release, in vitro permeation, ocular irritation, and bioavailability in aqueous humor of rabbits." | ( Improvement in Ocular Bioavailability and Prolonged Delivery of Tobramycin Sulfate Following Topical Ophthalmic Administration of Drug-Loaded Mucoadhesive Microparticles Incorporated in Thermosensitive In Situ Gel. Khan, S; Singhavi, DJ; Warade, S, 2018) | 0.72 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| "Devices such as contact lenses and collagen shields have been used to improve the antibiotic bioavailability of eye drops formulations in the treatment of ulcerative keratitis." | ( PVA/anionic collagen membranes as drug carriers of ciprofloxacin hydrochloride with sustained antibacterial activity and potential use in the treatment of ulcerative keratitis. Chaud, MV; da Conceição Amaro Martins, V; Daza, JHU; Lopes Baratella da Cunha Camargo, I; Maria de Guzzi Plepis, A; Righetto, GM, 2020) | 0.56 |
Twenty-three patients with acute peritonitis, intraabdominal abscess, wound infections (including infection of serious burns), sepsis accompanying renal transplantation, or urinary tract infection associated with cancer were treated with various dosage regimens. The efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella bronchopneumonia was compared.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This variation in penetration reflected individual differences in each dosage group and the increase in percent penetration that was observed during therapy." | ( Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis. Mandaleris, CD; Sande, MA; Strausbaugh, LJ, 1977) | 0.26 |
| " Also, it was shown that bronchial secretions frequently do achieve therapeutic concentrations of tobramycin at this dosage level and route of administration." | ( The concentration of tobramycin in bronchial secretions. Alexander, MR; Berglund, EM; Chinn, WM; Fox, A; Kasik, JE, 1979) | 0.8 |
| " Drug dosage was altered to keep serum levels 1 h after administration between 5 and 10 mug/ml (gentamicin or tobramycin) or 20 and 40 mug/ml (amikacin)." | ( Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Lietman, PS; Lipsky, JJ; Smith, CR, 1979) | 0.47 |
| " Pharmacists, in consultation with the infectious diseases service, made recommendations for alternative antibiotic therapy or dosage regimens, provided drug education to prescribing physicians and nurses, and aided in monitoring efficacy and toxicity of therapy." | ( Aminoglycoside use monitored by clinical pharmaceutical services. Barriere, SL; Conte, JE, 1979) | 0.26 |
| " The influence of dosage and renal function on serum levels and their relevance to ototoxicity are discussed." | ( Suggestions for monitoring patients during treatment with aminoglycoside antibiotics. Lerner, SA; Matz, GJ, ) | 0.13 |
| " There were 10 animals in each dosage group." | ( [Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model (author's transl)]. Brummett, RE, 1978) | 0.26 |
| " A linear relation between concentrations in the perilymph and dosage of gentamicin was ascertained." | ( [Pharmacokinetical, histological, and histochemical investigation on the ototoxicity of gentamicin, tobramycin, and amikacin (author's transl)]. Federspil, P; Schätzle, W; Tiesler, E, 1977) | 0.47 |
| " In spite of approximately identical serum concentration curves and in vitro activity, especially the low dosage of netilmicin led to more favourable therapeutic results than equal doses of tobramycin." | ( [Netilmicin and tobramycin: comparative evaluation of pharmacokinetics, nephrotoxicity, and therapeutic efficacy in animal studies (author's transl)]. Abraham, M; Freiesleben, H; Marre, R; Sack, K, 1979) | 0.8 |
| " Differences in methods and dosage of administration depending upon age, status of renal function, and route of administration are discussed." | ( The pharmacology of newer aminoglycosides, with a consideration of the application to clinical situations. Neu, HC, 1977) | 0.26 |
| " Dosage schedules for administering tobramycin to patients with renal function impairment are presented, together with some observations on its intravenous injection by bolus." | ( Tobramycin in the treatment of severe and complicated urinary tract infections. Bailey, RR; Peddie, B, 1977) | 1.97 |
| " An identical dosage of tobramycin was associated with only minimal morphological changes and normal concentrations of serum creatinine and blood urea nitrogen." | ( Comparative nephrotoxicity of gentamicin and tobramycin in rats. Bennet, WM; Gilbert, DN; Houghton, DC; Plamp, C; Porter, G; Starr, P, 1978) | 0.82 |
| " Dose-response data demonstrating linear recovery are included for all four aminoglycosides as well as a comparison of the GLC method with the microbiological method for the assay of gentamicin and amikacin." | ( Gas-liquid chromatographic method for the assay of aminoglycoside antibiotics in serum. Gorbach, SL; Mayhew, JW, 1978) | 0.26 |
| " Appropriate antimicrobial agents administered within the critical time period and in the recommended dosage to achieve adequate serum concentrations effectively reduce the incidence of postoperative wound and other systemic infections." | ( Cephalothin-tobramycin as a preventive antibiotic combination. Crenshaw, CA; Derrick, HC; Glanges, E; Terrell, CJ; Turner, RJ; Webber, CE, 1978) | 0.64 |
| " Such knowledge of serum levels of tobramycin assists the clinician in regulating drug dosage to obtain an optimum therapeutic effect, and yet avoids toxic serum levels." | ( Radioimmunoassay for serum tobramycin levels using 125I-labeled tobramycin. Atkins, RC; Casley, DJ; Johnston, CI; Murphy, GF, 1978) | 0.83 |
| " Gentamicin, sisomicin and amikacin are useful against Serratia infections; but in each case, a higher dosage is needed." | ( Comparative evaluation of five aminoglycosides for treatment. Köhler, M; Naumann, P; Reintjens, E; Rosin, H, 1976) | 0.26 |
| " Depending upon the dosage of the administered drug, Amikacin (150 mg per kg body weight daily, corresponding to 10 times an average recommended human dose) caused pronounced outer hair cell damage even 1 day after the treatment was stopped." | ( Comparative surface studies of ototoxic effects of various aminoglycoside antibiotics on the organ of Corti in the guinea pig. A scanning electron microscopic study. Theopold, HM, ) | 0.13 |
| " A dosage regimen in patients with impaired renal function is proposed." | ( The use of tombramycin in the management of severe infections. Clinical and pharmacological data. Baron, D; Courtieu, A; Drugeon, H; Nicolas, F, 1976) | 0.26 |
| " These relations may be used for dosage adjustment in patients with renal impairment." | ( Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. Dugal, R; Péchère, JC, 1976) | 0.51 |
| " Neither drug accumulated in the serum when the dosage regimen was maintained for three to 19 days." | ( Administration of tobramycin and gentamicin by the intravenous route every 6 hr in patients with normal renal function. Gross, PA; Setia, U, 1976) | 0.59 |
| "0 mug/ml with a standard dosage regimen of approximately 5 mg/kg per day." | ( Tobramycin in pediatric use. McAllister, TA; Raine, PA; Tait, SC; Young, DG, 1976) | 1.7 |
| "Twenty-three patients with acute peritonitis, intraabdominal abscess, wound infections (including infection of serious burns), sepsis accompanying renal transplantation, or urinary tract infection associated with cancer were treated with various dosage regimens of tobramycin, and their clinical responses were analysed." | ( Clinical use of tobramycin in patients with surgical infections due to gram-negative bacilli. Ishiyama, S; Iwai, S; Iwamoto, H; Murata, I; Nakayama, I; Ohashi, M, 1976) | 0.78 |
| " A linear relation between concentrations in the perilymph and the dosage of gentamicin was ascertained." | ( Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. Federspil, P; Schätzle, W; Tiesler, E, 1976) | 0.51 |
| " A dosage interval of 6 hr with a total dosage of 6 mg/kg per day is recommended." | ( Rapid intravenous injection of tobramycin: suggested dosage schedule and concentrations in serum. Andrews, J; Falk, RH; Gillett, AP; Melikian, V; Wise, R, 1976) | 0.54 |
| " The prophylactic effect upon ototoxicity of the administration of dimercaptopropanol or of dividing up the daily dosage was examined." | ( [Ototoxicity of the aminoglycoside antibiotics (author's transl)]. Federspil, P, 1976) | 0.26 |
| " Loss of hair cells occurred when dosage of 1,200 mg/kg was reached." | ( Ototoxicity of tobramycin sulfate. Fischer, ND; Pecorak, JB; Postma, DS; Prazma, J, 1976) | 0.61 |
| "Indications, side effects, dosage and several pharmacokinetic properties of gentamicin, tobramycin, sisomicin, kanamycin, amikacin, and streptomycin are delt with in the first part." | ( [Aminoglycoside antibiotics from clinical viewpoint]. Lüthy, R, 1975) | 0.48 |
| " Superimposition of these regression lines permitted calculation of daily maintenance dosage ranges for tobramycin in patients with all degrees of impairment of renal function as determined by either creatinine clearances or serum creatinine concentrations." | ( Tobramycin in renal impairment. Bechtol, LD; Black, HR, ) | 1.79 |
| " The recommended dosage is 2 mg/kg every 12 hours (4 mg/kg/day) intramuscularly or as a two-hour intravenous infusion to neonates, with the possible exception of full-term infants over seven days of age who may require administration every eight hours." | ( Commentary: An appraisal of tobramycin usage in pediatrics. McCracken, GH; Nelson, JD, 1976) | 0.55 |
| " The dosing regimen caused in dams moderate proximal tubular alterations and increased concentrations in serum creatinine." | ( Tobramycin-induced changes in renal histology of fetal and newborn Sprague-Dawley rats. Guastadisegni, C; Macrì, C; Mantovani, A; Maranghi, F; Ricciardi, C; Stazi, AV, 1992) | 1.73 |
| " To achieve and maintain preselected target tobramycin serum concentrations during ECMO, the usual dosage interval should remain unchanged, but the dose should be increased to compensate for the alteration in the drug's volume of distribution." | ( Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep. Gilman, JT; Kearns, GL; Möller, JC; Raszynski, A; Reed, MD; Sussmane, JB; Wolfsdorf, J, 1992) | 0.8 |
| "The object of this investigation was the development of an implantable sustained-release dosage form, for the treatment of bone infections." | ( An implantable dosage form for the treatment of bone infections. Dash, AK; Suryanarayanan, R, 1992) | 0.28 |
| "To investigate the impact of the introduction of a consultative service on the use, efficiency of dosing and clinical toxicology of the aminoglycoside antibiotics, gentamicin and tobramycin, in a general hospital." | ( Prospective audit of an aminoglycoside consultative service in a general hospital. Ioannides-Demos, LL; Li, SC; McLean, AJ; Spelman, DW; Spicer, WJ; Tong, N, 1992) | 0.48 |
| "1% and 64% of all aminoglycoside courses during the first and second audits respectively, with clinician acceptance of dosage recommendations at 83." | ( Prospective audit of an aminoglycoside consultative service in a general hospital. Ioannides-Demos, LL; Li, SC; McLean, AJ; Spelman, DW; Spicer, WJ; Tong, N, 1992) | 0.28 |
| " However, the optimal aminoglycoside dosing regimen remains controversial." | ( Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis. Carbon, C; Cremieux, AC; Devine, C; Muffat-Joly, M; Saleh-Mghir, A; Vallois, JM, 1992) | 0.53 |
| "To report a case of Pseudomonas aeruginosa endocarditis that was successfully treated with high-dose imipenem/cilastatin and to discuss dosage modification based on individual pharmacokinetic parameters." | ( Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis. Hrdy, DB; Kailath, EJ; King, JH, 1992) | 0.28 |
| " Dosage may need to be adjusted to body size in order to obtain optimal serum concentrations and activity." | ( Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis. Hrdy, DB; Kailath, EJ; King, JH, 1992) | 0.28 |
| " Group A patients had tobramycin dosage regimens decided by clinicians based on pre-existing protocols using serum tobramycin assay data determined three times weekly." | ( Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients. Bowes, G; Hooper, RE; Ioannides-Demos, LL; Li, SC; McLean, AJ; Spelman, DW; Spicer, WJ; Tong, N, 1991) | 0.83 |
| " three times daily with dosage adjustment according to renal function and body weight (group 2)." | ( Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. Maiche, AG; Teerenhovi, L, 1991) | 0.28 |
| "Traditional antibiotic dosage adjustments target predetermined serum concentrations, whereas a host of in vitro studies and recent clinical trials establish that bacteria vary in their susceptibility." | ( Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Adelman, MH; Nix, DE; Schentag, JJ, 1991) | 0.47 |
| " Teicoplanin in the dosage employed was tolerated better than vancomycin in the empirical treatment of fever and neutropenia in our patient population." | ( Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Chow, AW; Cole, CD; Jewesson, PJ; Kureishi, A; Phillips, GL; Reece, DE; Rubinger, M; Smith, JA, 1991) | 0.49 |
| " To identify measures that might prevent aminoglycoside nephrotoxicity, we investigated the influence of various dosage regimens on the renal cortical accumulation of amikacin and tobramycin in man." | ( Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. De Broe, ME; Verbist, L; Verpooten, GA, 1991) | 0.7 |
| "The efficacy and toxicity of a shortened tobramycin dosing interval in the treatment of exacerbations of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis patients were evaluated prospectively." | ( Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients. Cooper, JA; Cowan, RG; Lepow, M; Mayer, D; Winnie, GB; Witson, J, 1991) | 0.84 |
| " Regimen B was the best treatment since the low dosage of vancomycin proved effective." | ( [Prevention of septicemia caused by gastrointestinal tract organisms in patients with granulopenia. Comparison of three gastrointestinal tract decontamination treatments]. Boyer, G; Darbas, H; Donadio, D; Monnet, P; Ramounau-Pigot, A, 1991) | 0.28 |
| " The phenomenon has implications for effective initial dosing with aminoglycoside antibiotics." | ( The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. Daikos, GL; Jackson, GG; Lolans, VT, 1990) | 0.28 |
| " Ciprofloxacin 10 mg/kg/d was as efficacious as tobramycin irrespective of dosage schedule." | ( Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin. Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin-Eliopoulos, C, 1990) | 0.75 |
| " No additional alteration in dosing over those necessary to adjust for a decrease in renal function is necessary when giving this combination." | ( Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function. Aronoff, GR; Brier, ME; Brier, RA; Sloan, RS, 1990) | 0.56 |
| "9 gm) were administered intravenously every 8 hours while T dosage was adjusted to maintain peak (5-8 mg/L) and trough (less than 2 mg/L) concentrations." | ( Ceftazidime/clindamycin versus tobramycin/clindamycin in the treatment of intra-abdominal infections. Appleman, MD; Berne, TV; Bubrick, MP; Cocchetto, DM; Heim-Duthoy, KL; Heseltine, PN; Matzke, GR; Yellin, AE, 1990) | 0.57 |
| " Although no adjustment in netilmicin dosing is required, tobramycin should be administered more frequently when given concomitantly with piperacillin to hemodialysis patients to avoid prolonged periods of subtherapeutic concentrations." | ( Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease. Abraham, PA; Halstenson, CE; Heim-Duthoy, KL; Hirata, CA; Matzke, GR, 1990) | 0.74 |
| "An assessment of the dosage regimens prescribed for potentially nephrotoxic antibiotics (amikacin, gentamicin, tobramycin, and vancomycin) was undertaken on surgical intensive care unit patients." | ( Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. Crotchett, J; Fischer, RP; Miller-Crotchett, P; Reed, RL; Wu, AH, 1989) | 0.49 |
| "In 43 ICU patients undergoing continuous volume constant hemofiltration (CVHF), the pharmacokinetics of 12 drugs were investigated to ensure correct dosage adjustments." | ( [Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study]. Dehne, M; el Abed, K; Hofmann, W; Kroh, U; Lennartz, H, 1989) | 0.28 |
| " Furthermore, toxic concentrations did not occur in patients who were underdosed, justifying dosage increases prior to obtaining serum concentrations in these patients." | ( Probability assessment approach to therapeutic drug monitoring: tobramycin. Slaughter, RL, 1989) | 0.52 |
| " Population pharmacokinetic parameters of tobramycin were determined in a heterogenous group of 97 patients using serum samples drawn for the routine monitoring of tobramycin concentrations, following multiple dosing regimens." | ( Population pharmacokinetics of tobramycin. Aarons, L; Follath, F; Vozeh, S; Weiss, P; Wenk, M, 1989) | 0.83 |
| " Serial pharmacokinetic dosing has been proposed as a method to achieve these goals." | ( Serial pharmacokinetic dosing of aminoglycosides: a community hospital experience. Hoffa, DE, 1989) | 0.28 |
| "We assessed the performance of a predictive algorithm for dosing aminoglycoside antibiotics in 75 pediatric patients and Bayesian feedback in 36." | ( Aminoglycoside dosing in pediatric patients. Bowman, L; Brater, DC; Carlstedt, BC; Day, RB; Uaamnuichai, M, 1989) | 0.28 |
| " Although adequate maintenance dosing requires individualization based on pharmacokinetic analyses, large aminoglycoside doses can be used safely in patients with blunt trauma if appropriate monitoring is employed." | ( Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Fink, MP; Murphy, SG; Stein, KL; Townsend, PL, 1989) | 0.28 |
| " Variables analyzed to determine the cost of the therapy included duration of treatment, dosage and number of doses administered, side effects, and laboratory tests." | ( Cost comparison of ceftazidime versus tobramycin/ticarcillin therapy in three hospitals. Hansen, LA; Parr, MD; Rapp, RP, ) | 0.4 |
| " During the next three months, pharmacists provided physicians with recommendations for choice of drug, coordinated blood sampling times, and designed individualized dosage regimens for all patients treated with gentamicin or tobramycin." | ( Cost-benefit analysis of an aminoglycoside monitoring service. Aggour, T; Bradbury, K; Chodoff, L; Kimelblatt, BJ; Mehl, B, 1986) | 0.46 |
| "To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed." | ( Cefotaxime vs nafcillin and tobramycin for the treatment of serious infection. Comparative cost-effectiveness. Holloway, JJ; Lietman, PS; Moore, RD; Smith, CR, 1986) | 0.78 |
| "On the basis of our clinical impression that aminoglycoside serum concentration measurements did not result in dosage changes in many children with normal renal function, data collected during pharmacokinetic consultations were evaluated to identify pediatric patients for whom routine serum concentration monitoring would not be cost effective." | ( Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective. Hendeles, L; Massey, KL; Neims, A, 1986) | 0.27 |
| "This article reviews the clinical pharmacokinetics, clinical toxicity and cost-effectiveness analysis of aminoglycosides and of dosing services for aminoglycosides." | ( Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. Bailie, GR; Mathews, A, 1987) | 0.27 |
| "The influence of dosage regimen on the nephrotoxicity, ototoxicity, and antibacterial efficacy of tobramycin was assessed in Fisher rats with Pseudomonas aeruginosa subcutaneous abscesses." | ( The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. Bennett, WM; Brummett, RE; Gilbert, DN; Houghton, DC; Kohlhepp, SJ; Kohnen, PW; Norton, DR; Porter, GA; Wood, CA, 1988) | 0.83 |
| "Current antimicrobial dosing regimens are designed to maintain active drug levels for most of the dosing interval and are based on 40-y-old observations." | ( Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Craig, WA; Ebert, S; Gudmundsson, S; Leggett, J; Turnidge, J; Vogelman, B, 1988) | 0.27 |
| " The dosage of this antibiotic had to be changed frequently." | ( Comparison of serum concentrations of ceftazidime and tobramycin in newborn infants. Brorson, JE; Tessin, I; Thiringer, K; Trollfors, B, 1988) | 0.52 |
| "The efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella bronchopneumonia was compared." | ( Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. Letarte, R; Pechère, JC; Pechère, M, 1987) | 0.8 |
| "Individualized dosage regimens have recently been recommended for patients treated with aminoglycoside antibiotics." | ( Individualized aminoglycoside dosage regimens in patients with cystic fibrosis. Delage, G; Desautels, L; Lamarre, A; Lapierre, JG; Lasalle, R; Legault, S; Masson, P; Spier, S, 1988) | 0.27 |
| " Thus, we compared various aminoglycoside dosing schedules in neutropenic (n = 153) and nonneutropenic (n = 192) guinea pigs with Pseudomonas aeruginosa pneumonia." | ( Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. Carpenter, T; Chambers, HF; Hackbarth, CJ; Kapusnik, JE; Sande, MA, 1988) | 0.52 |
| "Aminoglycoside (gentamicin, tobramycin) dosage regimens and subsequent serum concentrations were compared in 30 patients treated initially using traditional physician-determined methods and then switched to a pharmacokinetic-based treatment program." | ( Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods. Ausman, RK; Bubrick, J; Franson, TR; Quebbeman, EJ; Rosenberger, SL; Thomson, R; Whipple, J, 1988) | 0.57 |
| " Contractile responses were measured and dose-response curves calculated by a polynomial regression analysis." | ( Human myocardial responses to antibiotics: gentamicin, tobramycin and cephalothin. Hendry, PJ; Keon, WJ; Taichman, GC; Taichman, SJ, ) | 0.38 |
| " A total of 56 dosing regimens (37 gentamicin, 19 tobramycin) were predicted from these parameters and the efficacy of this approach was examined by comparing the predicted peak (8 mg/l) and trough (1." | ( Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Denaro, CP; Ravenscroft, PJ, 1987) | 0.53 |
| " It should be emphasized, however, that the standard dosage of aminoglycosides in patients with cystic fibrosis frequently results in serum concentrations that are lower than anticipated because of a relatively larger volume of drug distribution and a greater urinary excretion rate." | ( Aminoglycoside toxicity in infants and children. McCracken, GH, 1986) | 0.27 |
| " Our results show that the 2 mg/kg dosage is too low and that, in preterm neonates, the 12-hour interval between infusions is too short." | ( [Kinetics of tobramycin in newborn infants in intensive care]. Alix, D; Guedes, Y; Guillois, B; Le Bot, MA; Le Guen, E; Riche, C, 1986) | 0.64 |
| " Every 2 days and at least 5 times during therapy, ODMF serum levels were determined (peak and trough levels) for dosage adjustment." | ( [Clinical and bacteriological study of O-demethylfortimicin A sulfate in urinary infection]. Bergogne-Bérézin, E; Delcercq, D; Prokocimer, P; Serieys, C, 1986) | 0.27 |
| " A graded dose-response effect was found between an increasing maximal peak concentration/MIC ratio and clinical response." | ( Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Lietman, PS; Moore, RD; Smith, CR, 1987) | 0.27 |
| " Individual dosage with control of serum levels is, therefore, recommended." | ( [Serum level of antibiotics in burn patients]. Csiba, A; Firr, M; Gráber, H; Novák, J; Syposs, T, 1986) | 0.27 |
| " Dosage varied according to severity of disease, body size, and the susceptibility of the Pseudomonas isolate to ciprofloxacin; the dose ranged from 750 to 2,250 mg daily (mean, 1,800 mg)." | ( Ciprofloxacin therapy in cystic fibrosis. Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) | 0.27 |
| " The application of dosing methods utilizing first-dose pharmacokinetics has been advocated as a means for rapidly attaining therapeutic serum concentrations." | ( Tobramycin elimination rate change from first to later doses in older cystic fibrosis patients. Horner, GW; Stempel, DA, 1987) | 1.72 |
| " Ideal dosing was then calculated to attempt to provide peak serum levels between 5 and 8 micrograms/mL and trough serum levels less than 2 micrograms/mL." | ( Tobramycin dosing in the puerperal patient. Pastorek, JG; Phelan, M; Ragan, FA, 1987) | 1.72 |
| " It is suggested that standard doses of tobramycin be used initially in patients with mild-to-moderate CF with dosage adjustment based on serum concentration data to achieve the desired goals." | ( Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis. Folli, HL; Harralson, AF; Kelly, PC; Kildoo, CW; Nussbaum, E, ) | 0.71 |
| " We attempted to determine whether acceptable blood levels of gentamicin or tobramycin are obtained with dosage regimens and dosage techniques which are generally recommended." | ( Therapeutic monitoring as an aid in rationalizing aminoglycoside dosage techniques in the neonate. Kirsten, GF; Kriegler, A; Müller, GJ; Parkin, DP; Spruyt, LL, 1987) | 0.5 |
| " The a priori computer-predicted dosage requirements of the critically ill patients were also compared with the dosages derived from their individualized pharmacokinetic values, and intrapatient variation in the critically ill patients was studied." | ( Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Awang, R; Cerra, FB; Fuhs, DW; Mann, HJ; Ndemo, FA, 1987) | 0.27 |
| "The efficacy of the dosing regimen of tobramycin was investigated in 28 patients with cystic fibrosis who had an acute exacerbation of chronic pulmonary infection with Pseudomonas aeruginosa." | ( Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. de Witte, J; Degener, JE; Driessen, O; Dzoljic-Danilovic, G; Hop, WC; Horrevorts, AM; Kerrebijn, KF; Michel, MF, 1987) | 1.99 |
| " With dosing regimens derived from previously determined factors, "within admission" predicted peaks and troughs would result in 60 and 35% of patients outside the therapeutic range for Admissions 1 and 2, respectively." | ( Variability of tobramycin pharmacokinetics in cystic fibrosis. Commissaris, RL; Hsu, MC; Massoud, N; Munzenberger, PJ, 1987) | 0.63 |
| " Due to the variability in the relationship between dosage and serum drug levels, monitoring through the acquisition of serum drug levels is mandatory." | ( Evaluation of a microcomputer program (OPT) for parameter optimisation in clinical pharmacokinetics: gentamicin and tobramycin. Derkx, FH; Michel, MF; Wagenvoort, JH; Zantvoort, FA, 1987) | 0.48 |
| " The Bayesian method may be useful in providing aminoglycoside dosing recommendations." | ( Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for tobramycin. Blum, RA; Rodvold, KA, ) | 0.36 |
| " The dosage requirement for tobramycin was quite variable, necessitated monitoring of aminoglycoside serum concentrations and in most cases resulted in at least one dosage adjustment." | ( Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. Jackson, MA; Kramer, RI; Kusmiesz, H; Nelson, JD; Prestidge, C; Shelton, S, ) | 0.68 |
| " Since drug uptake kinetics determine the extent of cortical concentrations achieved, dosing strategies may affect cortical accumulation of aminoglycosides." | ( Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. De Broe, ME; Giuliano, RA; Verpooten, GA, 1986) | 0.27 |
| "Twelve elderly institutionalized patients (mean age of 81 years) received intramuscular injections of tobramycin for infections at regular dosage intervals." | ( Intramuscular tobramycin pharmacokinetics in geriatric patients. Brown, CH; Carter, RA; Eberhard, NK; Mayer, PR; Millikan, MD; Welty, TE, ) | 0.71 |
| " This may be clinically important in the care of patients and may at least in part explain the large variation in serum concentrations and difficulty in prediction of dosage requirements from routine monitoring." | ( Interlot variability in gentamicin and tobramycin concentration and its possible significance. Clotz, M; Hipple, TF; Nahata, MC, 1986) | 0.54 |
| " Treatment groups included controls receiving diluent and groups receiving vancomycin alone at a dosage of 200 mg/kg (body weight) per day, tobramycin alone at a dosage of 80 mg/kg per day, and a combination of vancomycin and tobramycin at the above dosages." | ( Vancomycin enhancement of experimental tobramycin nephrotoxicity. Gilbert, DN; Houghton, DC; Kohlhepp, SJ; Kohnen, PW; Wood, CA, 1986) | 0.74 |
| " The use of concomitant penicillins and changes in dosing strategy seem to be particularly exciting new leads toward elimination of clinical aminoglycoside nephrotoxicity." | ( Modification of experimental aminoglycoside nephrotoxicity. Bennett, WM; Gilbert, DN; Houghton, DC; Wood, CA, 1986) | 0.27 |
| "The influence of three different dosage schedules on kidney cortical accumulation of aminoglycosides was studied in rats." | ( The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. De Broe, ME; Giuliano, RA; Verpooten, GA, 1986) | 0.27 |
| " In critically ill patients with changing hemofiltration flow rates, measurement of multiple serum aminoglycoside concentrations is necessary to accurately assess dosing requirements and avoid ototoxicity and nephrotoxicity." | ( Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. Anandan, JV; Dumler, F; Jayashankar, J; Levin, N; Zarowitz, BJ, ) | 0.13 |
| "Three strategies are implemented for controlling serum concentrations by determining individualized dosage regimens." | ( Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics. D'Argenio, DZ; Katz, D, 1986) | 0.27 |
| " These observations suggest that spurious aminoglycoside serum concentration results may sometimes be obtained when blood sampling is performed from central venous Silastic catheters, and can result in improper drug dosage alterations." | ( Aminoglycoside serum concentration sampling via central venous catheters: a potential source of clinical error. Franson, TR; Quebbeman, EJ; Ritch, PS, ) | 0.13 |
| " The pharmacokinetic profile of ceftazidime during a steady-state dosing interval was ascertained in 21 patients." | ( Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Drusano, GL; Forrest, A; Joshi, J; Leslie, J; Ruxer, R; Schimpff, S; Standiford, H; Wade, J, 1985) | 0.5 |
| " The need for adjustment of drug dosage in patients with endstage renal disease and the need for supplemental dosages following haemodialysis are well recognised." | ( Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations. Cornish, WR; Hardy, BG; Manuel, MA; Paton, TW, ) | 0.13 |
| " A single pharmacokinetic study was performed over one dosing interval after steady-state conditions were achieved." | ( Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vigano, A; Wels, PB; Winslade, NE, ) | 0.13 |
| "5 g of drug over 49 days and the dosage was adjusted to maintain peak serum concentrations of 15-20 mg/l." | ( Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. Boike, SC; Erickson, SR; Levine, DP; Rybak, MJ, 1986) | 0.54 |
| "We assessed the accuracy of a Bayesian method in providing dosing regimens to achieve desired serum aminoglycoside concentrations." | ( A Bayesian feedback method of aminoglycoside dosing. Brater, DC; Burton, ME; Chen, PS; Day, RB; Huber, PJ; Vasko, MR, 1985) | 0.27 |
| " Hematologic, serum chemical, and drug-serum (24-hr postdose) assays were performed at approximate monthly intervals during the dosing period." | ( Comparative ototoxicity of netilmicin, gentamicin, and tobramycin in cats. McCormick, GC; Schwartz, E; Szot, RJ; Weinberg, E, 1985) | 0.52 |
| "0 mg/100 ml in serum, the risk of inadequate therapy is high if standard dosing guidelines are followed." | ( Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Creger, RJ; Ellner, JJ; King, CH, 1985) | 0.59 |
| " We conclude that saliva cannot be used as a noninvasive indirect method of measuring aminoglycoside serum concentrations to guide dosage adjustments." | ( Measurement of tobramycin concentrations in saliva. Hendeles, L; Hill, M; Iafrate, RP, 1985) | 0.62 |
| " This interpatient variation has clinical implications for tobramycin therapy in CF, in particular for the dosing interval." | ( Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval. Degener, JE; Driessen, O; Dzoljic-Danilovic, G; Hermans, J; Horrevorts, AM; Kerrebijn, KF; Michel, MF, 1985) | 0.84 |
| " However, repeated dosing of vancomycin (single dose: 50 mg/kg) led to renal accumulation when combined with fosfomycin (single dose: 250 mg/kg); renal vancomycin concentrations were lower." | ( Influence of fosfomycin and tobramycin on vancomycin-induced nephrotoxicity. Hedtke, D; Marre, R; Sack, K; Schulz, E, ) | 0.43 |
| " The Sawchuck-Zaske method of dosing tobramycin was used and resulted in good agreement between the desired and measured peak (8." | ( Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis. Corbin, RP; Fraser, GL; Grimes, GR; Valenti, AJ, 1985) | 0.85 |
| "0 micrograms/ml with a dosing interval of every six hours." | ( Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Canafax, DM; Cipolle, RJ; Daniels, CE; Mann, HJ; Warwick, WJ; Zaske, DE, ) | 0.41 |
| "Variations in the actual doses with vials and ampules due to causes of dosage forms and human operations have been discussed." | ( [The problem in the incubation of injective solutions. The difference between ampule and vial]. Kawamura, N; Ohkoshi, M; Okada, K, 1985) | 0.27 |
| " We conclude that concentrations in capillary samples are precise and unbiased estimators of venous concentrations and may be used in the adjustment of tobramycin dosage regimens." | ( Comparison of venous and capillary blood sampling for the clinical determination of tobramycin serum concentrations. Lewis, AS; Lewis, MH; Taylor, G; Williams, HO, 1985) | 0.69 |
| " Groups of ten patients each received either 2 g cefotaxime or 1 mg/kg body weight tobramycin or cefotaxime and tobramycin in the same dosage every eight hours intravenously for at least seven days." | ( Tobramycin nephrotoxicity: failure of cefotaxime to potentiate renal toxicity. Grötsch, H; Kuhlmann, J; Seidel, G, 1982) | 1.93 |
| "317 patients with suspected or documented infections other than cystitis were randomly assigned to receive gentamicin or tobramycin dosed according to the Sawchuk/Zaske method or a modification of the McHenry method." | ( Controlled comparison of gentamicin and tobramycin nephrotoxicity. Lucarotti, RL; Matzke, GR; Shapiro, HS, ) | 0.61 |
| "Aerobic gram-negative infections are treated with aminoglycosides, but it is difficult to achieve safe yet effective dosages in individual patients using a standard dosing formula." | ( Serum aminoglycoside monitoring by enzyme immunoassay, biological, and fluorescence immunoassay procedures. Albritton, WL; Buchanan, AG; Witwicki, E, 1983) | 0.27 |
| " In the other 27 courses there was an excellent clinical response, judged to be as good as our former high dosage carbenicillin and tobramycin combination though with much greater patient acceptability." | ( Ceftazidime - a significant advance in the treatment of cystic fibrosis. Connor, PJ; David, TJ; Phillips, BM, 1983) | 0.47 |
| " These results, within the limitation of the study, suggest that ceftazidime given alone at a dosage of 1 g tds is not significantly worse than tobramycin 120 mg tds plus ticarcillin 2 g tds." | ( Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients. Bellingham, AJ; Bennet, C; Brada, M; Hart, CA; Reilly, JT, 1983) | 0.77 |
| " It was concluded that the RIA kit is useful for clinical application of TDM for the adequate dosage regimen of TOB." | ( [Evaluation of radioimmunoassay of the blood tobramycin level for the purpose of setting the dosage based on the clinical pharmacokinetic theory and a comparison of radioimmunoassay with other assay methods]. Sakaki, T; Sano, T; Sasaki, Y; Shinozaki, K; Someya, K; Takahashi, S; Yamada, Y, 1983) | 0.53 |
| " On the basis of this correlation a nomogram providing a decrease in the percentage of the errors in determining the dosage intervals was plotted." | ( [Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney]. Belorusov, OS; Bogomolova, NS; Firsov, AA; Navashin, SM; Treskina, OS, 1983) | 0.55 |
| " The degree of reduction in tobramycin concentrations may be dramatic and potentially can alter a patients apparent tobramycin dosing requirements." | ( Heparin interferes with tobramycin serum concentration determinations by Emit. Abraham, PA; Halstenson, CE; Matzke, GR; Piveral, K, 1984) | 0.87 |
| " Concurrently, physicians were instructed in the proper use and dosage of gentamicin via lectures and dosing nomograms provided by the clinical pharmacist." | ( Effect of aminoglycoside-use restrictions on drug cost. DeTorres, OH; White, RE, 1984) | 0.27 |
| " Although slight elevation of BUN and creatinine in plasma and hyaline casts in lumen of the distal tubules were observed in animals receiving 2,000 mg/kg of LMOX or CET when dosed with FUR, no histological changes were found in renal tissues." | ( [Comparative nephrotoxicity of latamoxef and other cephalosporins in rabbits. Combined administration with furosemide or tobramycin. (author's transl)]. Harada, Y; Okamoto, T; Teshima, K, 1981) | 0.47 |
| " These data indicate that these infants may require a change in dosing interval with continued tobramycin therapy during the first week of postnatal age." | ( Intrapatient variation in tobramycin kinetics in low birth weight infants during first postnatal week. Durrell, DE; Glazer, JP; Miller, MA; Nahata, MC; Powell, DA, 1984) | 0.79 |
| " Although this colorimetric method is not expected to be stability-indicating, it is convenient and should be useful in content uniformity determinations for pharmaceutical dosage forms (e." | ( Colorimetric determination of gentamicin, kanamycin, tobramycin, and amikacin aminoglycosides with 2,4-dinitrofluorobenzene. Ryan, JA, 1984) | 0.52 |
| " In light of the high trough levels observed during the first week of life in premature infants, it may be judicious to monitor serum tobramycin concentration and to decrease the dosage or to prolong the dose interval in order to maintain trough concentrations below 2 mcg/ml." | ( Serum tobramycin levels in low- and very low-birthweight infants. Arwood, L; Cordero, L; Hann, C; Visconti, J, 1984) | 0.95 |
| " An underestimation of the volume of distribution in critically ill patients best explains the low serum aminoglycoside levels produced by the currently recommended dosage schedule." | ( Initial aminoglycoside levels in the critically ill. Lipsky, JJ; Michael, JR; Summer, WR, 1983) | 0.27 |
| " To study the influence of dosage regimens, Wistar rats were injected for 8 days with a total daily dose of 10, 20, or 50 mg/kg tobramycin intraperitoneally either in one single (1) or in thrice (3) daily injections." | ( Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach. Fillastre, JP; Morin, JP; Olier, B; Viotte, G, 1983) | 0.73 |
| "A spectrophotometric assay method for the quantitative determination of amikacin, kanamycin, neomycin, and tobramycin in pharmaceutical dosage forms has been developed." | ( Quantitation of amikacin, kanamycin, neomycin, and tobramycin in pharmaceutical dosage forms using the Hantzsch reaction. Gunter, JM; Gupta, VD; Stewart, KR, 1983) | 0.73 |
| " Plasma exchange provides an additional route of elimination for tobramycin which should be considered when dosing the drug in patients undergoing this procedure." | ( A pharmacokinetic evaluation of the effect of plasma exchange on tobramycin disposition. Kennedy, MS; Ouellette, SM; Visconti, JA, 1983) | 0.74 |
| " Major sections provide empiric dosing recommendations based on population data and allow determination of dosage from measured serum concentrations." | ( A microcomputer program for tobramycin consult services, based on the two-compartment pharmacokinetic model. Adelman, MH; Schentag, JJ, ) | 0.43 |
| "The dosing frequency of aminoglycoside antibiotics may alter efficacy and toxicity independent of total daily dose." | ( Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Bloxham, DD; Cash, HA; DiScenna, AO; Groden, DL; Grossniklaus, DA; Jacobs, MR; Klinger, JD; Luthe, MA; Powell, SH; Stern, RC; Thompson, WL, 1983) | 0.47 |
| "The provision of pharmacokinetic dosing services has become a cornerstone of clinical pharmacy practice in many institutions." | ( Gentamicin and tobramycin dosing guidelines: an evaluation. Burkle, WS; Lucarotti, RL; Matzke, GR, 1983) | 0.62 |
| " Because of the prolonged serum elimination half-lives, a calculated extended dosage interval, sometimes greater than 24 hours, was necessary to obtain a predose trough of less than or equal to 2 micrograms/ml." | ( Tobramycin sulfate elimination in premature infants. Arbeter, AM; Eisner, S; Saccar, CL; Sarni, E; Yaffe, SJ, 1983) | 1.71 |
| " We describe an aminoglycoside panel consisting of three serum levels drawn across one dosage interval." | ( The aminoglycoside panel: a new approach to monitoring aminoglycoside therapy. Gorsky, JE; Latts, JR, 1983) | 0.27 |
| " However, the optimal duration for which the serum concentration should exceed the MIC or MBC during each dosing interval and the detrimental effect of prolonged subinhibitory drug concentrations have not been evaluated." | ( Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. Evans, WE; Yee, GC, ) | 0.13 |
| " When the dosage was adjusted according to the patient's weight and serum creatinine, some nephrotoxicity occurred, possibly due to drug accumulation." | ( Netilmicin treatment of complicated urinary tract infections. Baumueller, A; Frimodt-Møller, N; Hoyme, U; Lau, C; Madsen, PO; Maigaard, S; Nielsen, OS; Welling, PG, 1980) | 0.26 |
| " A standard regimen of 45 mg/kg/day with constant intravenous infusion and once daily dosing of each aminoglycoside was used, and in subsequent dogs netilmicin daily dose was increased to an average of 73 mg/kg/day." | ( Aminoglycoside nephrotoxicity in dogs: dependence on drug, dose and regimen. Powell, S; Thompson, WL, 1980) | 0.26 |
| " In normal subjects, a dosage of 50 mg/8 h failed to produce cochlear and vestibular dysfunction; but with dosages of 75 mg/8 h and 100 mg/8 h, changes in vestibular reflectivity occurred frequently, mostly of the irritative type." | ( Ototoxicity of tobramycin in humans - influence of renal impairment. Brogard, JM; Collard, M; Conraux, C; Lavillaureix, J, 1982) | 0.62 |
| " Although intermittent injections can result in higher levels of aminoglycosides within the bronchial secretions, such levels cannot be maintained for prolonged periods unless the dosage is increased." | ( Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria. Klastersky, J; Mombelli, G; Thys, JP, ) | 0.13 |
| " Thus, in the dosage used, gentamicin elicits greater impairment in glomerular function than does tobramycin, and by mechanism(s) that are at least partially responsive to suppression of AII generation." | ( Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Brenner, BM; Ichikawa, I; Rennke, HG; Schor, N; Troy, JL, 1981) | 0.48 |
| " Diminished renal function and activity of some hepatic enzymes alter the half-lives of various drugs, making extrapolation from adult dosage impossible." | ( Antimicrobial therapy and the neonate. Yaffe, SJ, 1981) | 0.26 |
| " In special paragraphs the intrinsic ototoxic potential of the newer aminoglycoside antibiotics, the influence of the dosage and route of administration, of renal function, preexisting hearing disturbances, individual and familial sensitivity, pregnancy, newborn age and the combination with sound exposure, diuretics and cephalosporins are considered." | ( Drug-induced sudden hearing loss and vestibular disturbances. Federspil, P, 1981) | 0.26 |
| " All patients received individualized dosing regimens of the drugs based on pharmacokinetic parameters measured after the initial dose." | ( Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens. Compty, C; Heissler, J; Pancorbo, S, ) | 0.42 |
| " Groups of patients judged nontoxic did not differ from groups judged nephrotoxic in age, sex, weight, initial creatinine clearance, total dose given, duration of treatment, initial aminoglycoside trough serum levels, number of dosage adjustments, concurrent use of furosemide, or concurrent cephalosporins." | ( Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Cerra, FB; Plaut, ME; Schentag, JJ, 1982) | 0.26 |
| "576 serum levels at peak and before the next dosage (end level) were determined during clinical treatment conditions using radioimmunoassay in 131 patients treated with tobramycin or amikacin because of life-threatening infections." | ( [Control of serum levels of tobramycin and amikacin during clinical routine treatment conditions (author's transl)]. Daschner, F; Eiermann, T; Langmaack, H; Stark, GB, 1982) | 0.75 |
| "The objective of this study was to determine whether differences in tissue accumulation observed upon multiple dosing of aminoglycosides in hospitalized patients could be identified in appropriate single-dose studies in normal volunteers." | ( Two-compartment comparison of gentamicin and tobramycin in normal volunteers. Adelman, M; Evans, E; Schentag, JJ, 1982) | 0.52 |
| " Measured peak and trough serum concentrations resulting from individualized dosage regimens closely matched desired peak and trough concentrations." | ( Hospital acquired gram-negative pneumonias: response rate and dosage requirements with individualized tobramycin therapy. Cipolle, RJ; Seifert, RD; Strate, RG; Zaske, DE, 1980) | 0.48 |
| "General one-compartment model equations for computing peak drug concentrations following uniform and nonuniform dosing are discussed." | ( Mathematical considerations in the estimation of peak drug concentrations under uniform and nonuniform dosing conditions. Hull, JH, ) | 0.13 |
| " From data recorded on the form, pharmacists calculate ideal body weight, creatinine clearance, predicted rate of elimination, half-life, volume of distribution, serum peak (Cmax) and serum trough (Cmin) concentrations, dosing interval, and maintenance dose." | ( Aminoglycoside monitoring program. Clayman, AE; Miller, PB; Stein, GE; Vakoutis, J, 1981) | 0.26 |
| " As groups, the patients given gentamicin and tobramycin did not differ in age, weight, creatine clearance, total dose given, duration of treatment, initial aminoglycoside through serum levels, number of dosage adjustments, concurrent use of furosemide, or concurrent cephalosporins." | ( Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Cerra, FB; Plaut, ME; Schentag, JJ, 1981) | 0.78 |
| " According to the dosage groups, rate of good score was 50% in the dose of 60 mg three times a day, 0% in the dose of 90 mg twice a day and 62." | ( [Clinical studies on tobramycin by intravenous drip infusion for Pseudomonas aeruginosa infection in chronic respiratory diseases (author's transl)]. Hiraga, Y; Kikuchi, K; Nakahashi, M, 1981) | 0.58 |
| "Pharmacokinetic-based adjustment of individual aminoglycoside dosage regimens is currently being utilized in the clinical setting in an attempt to avoid toxicity and/or enhance efficacy." | ( Aminoglycoside dosage in pediatric patients:considerations regarding pharmacokinetic-based dose adjustment in patients requiring high versus low dose therapy. Leff, RD; Roberts, RJ, 1981) | 0.26 |
| " Furthermore, many of these assessments have used only one or two dose levels and have not described a dose-response comparison among antibiotics." | ( Comparative low-dose nephrotoxicities of gentamicin, tobramycin, and amikacin. Gordon, LL; Hottendorf, GH, 1980) | 0.51 |
| " Dibekacin and gentamicin show reproducibly higher renal cortical tissue concentrations than tobramycin in both the acute infusion studies and multiple dosing studies." | ( Dibekacin intrarenal distribution characteristics and renal cortical elution kinetics. Comparison with gentamicin and tobramycin. Bryant, HH; Carter, GG; Herbst, DV; Stout, RL; Walker, G; Whelton, A, ) | 0.56 |
| "Tobramycin dosage regimens were individually calculated from serum concentration-time data in 64 patients." | ( Systematically individualizing tobramycin dosage regimens. Cipolle, RJ; Seifert, RD; Strate, RG; Zaske, DE, 1980) | 1.99 |
| " The method appeared to be more precise than empirical dosing at achieving the target AUC even though the final recommended dose had more variability than the starting dose." | ( Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Barclay, ML; Begg, EJ; Buttimore, RC; Duffull, SB, 1995) | 0.29 |
| "The AUC method was practical, and more appropriate for once-daily dosing than the conventional method of aiming for target peak and trough concentrations." | ( Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Barclay, ML; Begg, EJ; Buttimore, RC; Duffull, SB, 1995) | 0.29 |
| " The dosage regimen of ornidazole therefore requires no adjustment during pregnancy." | ( Disposition of ornidazole and its metabolites during pregnancy. Bourget, P; Dechelette, N; Desmaris, VQ; Fernandez, H, 1995) | 0.29 |
| " Thus, monitoring of serum creatinine and aminoglycoside levels is recommended, especially for those with renal failure, in order to maintain an optimal dosage between toxic and noneffective serum aminoglycoside levels." | ( Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure. Emre, S; Eti, S; Nayir, A; Sirin, A; Yeşilbek, T, ) | 0.39 |
| " Collagen shield delivery of tobramycin with supplemental topical drops can eradicate staphylococci in this model with less frequent dosing intervals than are required with topical therapy alone." | ( Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Callegan, MC; Clinch, TE; Engel, LS; Hill, JM; Kaufman, HE; O'Callaghan, RJ, 1994) | 0.96 |
| "An in-vitro model of aminoglycoside dosing was used to demonstrate that the bactericidal activity of tobramycin against Pseudomonas aeruginosa is directly related to the peak concentration of the drug." | ( Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin. Bastone, EB; Cousins, VC; Hooper, RE; Ioannides-Demos, LL; Li, SC; McLean, AJ; Spelman, DW, 1994) | 0.72 |
| " Equal numbers of both genders were dosed at 30 mg/kg (F344) and 90 mg/kg (SD) twice daily for 9 days." | ( Tobramycin gender-related nephrotoxicity in Fischer but not Sprague-Dawley rats. Goodrich, JA; Hottendorf, GH, 1995) | 1.73 |
| " (3) The result of the dosage scheme proposed by the student is represented by a simulation of plotting antibiotic plasma concentrations vs." | ( Teaching individualized antibiotic dosage regimens by means of two computer-assisted learning programs. Caillon, J; Douet, MC; Drugeon, HB; Kergueris, MF; Le Normand, Y; Milpied, N; Potel, G; Raffi, F; Roźe, JC, 1994) | 0.29 |
| "To describe special dosage considerations for aminoglycoside antibiotics in critically ill patients from a pharmaceutical care perspective." | ( Aminoglycoside dosing in the critical care patient: a case report of tertiary pharmaceutical care. McCall, CY; Tyson, DW; Wade, WE, ) | 0.13 |
| "Tertiary pharmaceutical care provided by the pharmacist includes appropriate choice and monitoring of pharmacotherapy and pharmacokinetic drug dosing to promote good patient outcome." | ( Aminoglycoside dosing in the critical care patient: a case report of tertiary pharmaceutical care. McCall, CY; Tyson, DW; Wade, WE, ) | 0.13 |
| "A novel, in vitro, pharmacodynamic comparison of single and divided daily dosing regimens of aminoglycosides is described." | ( Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Davidson, RJ; Hoban, DJ; Karlowsky, JA; Zhanel, GG, 1994) | 0.29 |
| "We report an alternative dose-finding approach for the selection of optimal prophylactic aminoglycoside dosage in specific (sub)populations of patients." | ( Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches. Jiménez, NV; López, R; Ordovás, JP; Poveda, JL; Ronchera, CL, 1994) | 0.29 |
| "Drug dosage in end-stage renal disease (ESRD) patients undergoing haemodialysis is a very complex problem because of numerous variables relating to the patient, the type of drug administered and the type of dialysis and dialyser." | ( Drug dosage in end-stage renal disease (ESRD) patients undergoing haemodialysis. A predictive study based on a microcomputer program. Dominguez-Gil, A; Mac-Kay, MV; Martinez-Lanao, J; Sanchez Burson, J, 1993) | 0.29 |
| " It may be important to take account of the PAE when designing dosing regimens." | ( Postantibiotic effect of aminoglycosides on staphylococci. Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1993) | 0.29 |
| "The correlation between Ke of AG and vancomycin may be beneficial for predicting Ke of vancomycin when AG concentrations have already been obtained or vice versa, and may give more accurate estimations of dosing intervals and require less time adjusting, ordering, and interpreting concentrations and dosages." | ( Correlation of aminoglycoside and vancomycin pharmacokinetic parameters. Cooper, BE; Wragge, TM, 1993) | 0.29 |
| "Poor empiric dosing of aminoglycosides continues to be a problem in many hospitals." | ( Development and implementation of simplified aminoglycoside empiric dosing guidelines. Baker, A; Jewesson, P; Mamdani, F; Reesor Nimmo, C, ) | 0.13 |
| "Continuous veno-venous hemofiltration increased the clearance of vancomycin and tobramycin requiring dosage modifications." | ( Vancomycin and tobramycin clearance in an infant during continuous hemofiltration. Armstrong, DK; Eldadah, M; Hidalgo, HA, 1993) | 0.87 |
| "The predictive performance of a dosage calculation method for the optimization of tobramycin therapy was studied retrospectively in 29 patients with cystic fibrosis." | ( Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Bakker, W; Heijerman, HG; Touw, DJ; Vinks, AA, 1993) | 0.87 |
| " The corneas in a second set of rabbits were anesthetized and then chemically abraded with n-heptanol before receiving the same two dosing regimens as in the groups with intact corneas." | ( Enhancement of the ocular bioavailability of topical tobramycin with use of a collagen shield. Chen, CC; Duzman, E; Takruri, H, 1993) | 0.54 |
| " Once-daily aminoglycosides result in higher peak and lower trough plasma concentrations than conventional multiple daily dosing regimens; once-daily aminoglycoside therapy is equally effective, generally less toxic and much less expensive and therefore this regimen is more and more frequently used for treatment of suspected or confirmed gram-negative bacillary infections and of febrile episodes in neutropenic patients, in particular in combination with an appropriate betalactam antibiotic." | ( Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Corti, G; Paradisi, F, 1995) | 0.29 |
| " The article includes a discussion of various dosing regimens of the aminoglycosides, focussing on efficacy and toxicity arising from once-daily administration." | ( The place of tobramycin in lower respiratory tract infections (LRTI). Gialdroni Grassi, G, 1995) | 0.66 |
| " These results suggest that tobramycin might be conveniently used with once-daily dosing for the treatment of infections due to sensitive pathogens." | ( In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. Cassetta, MI; Conti, S; Fallani, S; Mazzei, T; Novelli, A, 1995) | 0.82 |
| "3 mg/l in alveolar lining fluid (ALF) and macrophages (AM), respectively, thus demonstrating that the once-daily dosage schedule leads to high and persistent levels in the bronchial alveolar tree, exceeding the minimum inhibitory concentrations in vitro for susceptible respiratory pathogens." | ( Tissue penetration and pulmonary disposition of tobramycin. De Lalla, F; Mazzei, T; Mini, E; Novelli, A; Periti, P, 1995) | 0.55 |
| " To investigate this, a prospectively randomised open label therapeutic trial was undertaken in stratified groups of patients with cystic fibrosis to examine the efficacy and toxic potential of an aminoglycoside dosing regimen designed to generate high peak drug concentrations at 12 hourly intervals compared with conventional dosing at eight hourly intervals." | ( Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Hickey, B; Hooper, RE; Ioannides-Demos, LL; Li, SC; McLean, AJ; Spicer, WJ; Williams, TJ; Wood, PJ, 1996) | 0.29 |
| "These results suggest that 12 hourly high peak aminoglycoside dosing may be less toxic than equivalent eight hourly dosing, without any apparent difference in efficacy." | ( Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Hickey, B; Hooper, RE; Ioannides-Demos, LL; Li, SC; McLean, AJ; Spicer, WJ; Williams, TJ; Wood, PJ, 1996) | 0.29 |
| " The fully implemented program resulted in a 40% decrease in the request for gentamicin and tobramycin serum concentrations as compared with historic ordering patterns for conventional aminoglycoside dosing regimens." | ( Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Chow, MS; Finocchiaro, S; Nicolau, DP; Nightingale, CH; Quintiliani, R; Udeh, E; Wu, AH, 1996) | 0.51 |
| "Once-daily dosing has been suggested as an alternative method of dosing aminoglycosides that would reduce their toxicity while maintaining efficacy." | ( Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Hawa, Z; Koo, J; Rajkumar, V; Tight, R, 1996) | 0.29 |
| "Ninety-six patients were randomly assigned to either the once-daily dosing group (4 mg/kg) or the pharmacokinetic dosing group (initial dose of 2 mg/kg every 12 hours)." | ( Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Hawa, Z; Koo, J; Rajkumar, V; Tight, R, 1996) | 0.29 |
| "Once-daily dosing and pharmacokinetic dosing of aminoglycosides appear to have equal efficacy and toxicity." | ( Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Hawa, Z; Koo, J; Rajkumar, V; Tight, R, 1996) | 0.29 |
| " three times daily) and tobramycin (80 mg three times daily) for two weeks, followed by penicillin G in the same dosage for four more weeks." | ( [Infectious thyroiditis as initial manifestation of embolizing endocarditis of the aortic valve]. Heufelder, AE; Hofbauer, LC; Spitzweg, C; Tammen, AR, 1996) | 0.6 |
| " The presence and time course of adaptive resistance in humans may have implications for improving aminoglycoside dosing regimens." | ( Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Barclay, ML; Begg, EJ; Chambers, ST; Grimwood, K; Pattemore, PK; Thornley, PE, 1996) | 0.6 |
| "The kinetics of the postantibiotic effect (PAE) during one dosing interval of tobramycin against Staphylococcus aureus and Pseudomonas aeruginosa was investigated." | ( Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model. den Hollander, JG; Mouton, JW; van Goor, MP; Verbrugh, HA; Vleggaar, FP, 1996) | 0.76 |
| "To present a systematic evaluation of the are under the inhibitory curve (AUIC) approach for the optimization of antibiotic dosing schedules for three major antibiotic classes (beta-lactams, quinolones, aminoglycosides)." | ( AUIC--a general target for the optimization of dosing regimens of antibiotics? Dalla Costa, T; Derendorf, H, 1996) | 0.29 |
| " Moreover, a specific equation is derived for the situation that results in a trough concentration at the end of the dosing interval equal to the minimum inhibitory concentration (MIC)." | ( AUIC--a general target for the optimization of dosing regimens of antibiotics? Dalla Costa, T; Derendorf, H, 1996) | 0.29 |
| "It does not seem valid to accept the proposed breakpoint AUIC target of at least 125 as an applicable value for determining the appropriate dosing schedule of these classes of antibiotics." | ( AUIC--a general target for the optimization of dosing regimens of antibiotics? Dalla Costa, T; Derendorf, H, 1996) | 0.29 |
| "Assessment of renal function and relating this parameter to amino-glycoside clearance is important for an appropriate individualization of dosage regimens in patients with impaired renal function." | ( Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Bakker, W; Heijerman, HG; Jacobs, F; Town, DJ; Vinks, AA, 1996) | 0.57 |
| "There is no established dosing schedule for once-daily aminoglycoside dosing regimens, and accepted guidelines for monitoring therapy are lacking." | ( Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. de Blok, K; Prins, JM; Speelman, P; van Ketel, RJ; Weverling, GJ, 1996) | 0.29 |
| " The dosing schedule for both treatment groups was 1 to 2 drops of the first study medication (ciprofloxacin or fortified tobramycin) every 30 minutes for 6 hours, then hourly for the remainder of day 1; 1 to 2 drops every hour on days 2 and 3; 1 to 2 drops every 2 hours on days 4 and 5, followed by 1 to 2 drops every 4 hours on days 6 to 14." | ( Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Adenis, JP; Badrinath, SS; Caldwell, DR; Eiferman, RA; Hyndiuk, RA; Katz, HR; Klauss, V; Reddy, MK; Rosenwasser, GO; Santos, CI, 1996) | 0.74 |
| " A longer dosage interval may decrease the risk of nephrotoxicity because higher transient serum aminoglycoside levels appear to be less nephrotoxic than lower but more persistent serum concentrations." | ( [Tobramycin--clinical pharmacology and chemotherapy]. Periti, P, 1996) | 1.2 |
| " bolus dosing were determined by reverse phase HPLC." | ( The disposition of five therapeutically important antimicrobial agents in llamas. Christensen, JM; Hollingshead, N; Murdane, SB; Smith, BB, 1996) | 0.29 |
| " In the present study we determined whether synergism between tobramycin and ceftazidime can be found at declining concentrations below the MIC, and whether change in dosing sequence of the antibiotics would result in differences in killing." | ( Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. den Hollander, JG; Horrevorts, AM; Mouton, JW; van Goor, ML; Verbrugh, HA, 1997) | 0.87 |
| " Specific physiologic criteria of sepsis may be used to identify critically ill patients who will most likely benefit from aggressive initial aminoglycoside dosing when these drugs are used to treat gram-negative infections." | ( Aminoglycoside levels in critically ill surgical patients: the implications of physiologic criteria of sepsis. Asensio, JA; Belzberg, H; Berne, TV; Cornwell, EE; Demetriades, D; Henriques, G; Kern, JW, 1997) | 0.3 |
| " This method would cause a delay in ampicillin dosing in the treatment of serious bacterial infections and unnecessarily complicate nursing procedures." | ( Effect of time and temperature on inactivation of aminoglycosides by ampicillin at neonatal dosages. Bednarek, FJ; Daly, JS; Dodge, RA; Glew, RH; Keroack, MA; Whalen, M, ) | 0.13 |
| " The rationale for single, daily-dose aminoglycoside therapy is to produce an optimal ratio between aminoglycoside peak concentrations (Cmax) and pathogen minimal inhibitory concentration to maximize bacterial killing and to produce an aminoglycoside-free period during the 24-hour dosing interval." | ( Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. Guay, DR; Hoey, LL; Rotschafer, JC; Tschida, SJ; Vance-Bryan, K, ) | 0.13 |
| "The use of inhaled antibiotics in the treatment of cystic fibrosis has become widespread despite controversy in the literature as to the appropriate dosing regimen and its effectiveness." | ( The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Coates, AL; Kelemen, S; MacDonald, J; MacNeish, CF; Meisner, D; Thibert, R; Vadas, E, 1997) | 0.52 |
| "One hundred eight pediatric cystic fibrosis patients (ages 5 to 17 years) with acute bronchopulmonary exacerbations entered a randomized multicenter trial designed to compare the safety and efficacy of antipseudomonas therapy with oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily) or intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days." | ( Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Hampel, BJ; Nousia-Arvanitakis, S; Richard, DA; Schaad, UB; Sollich, V; Sommerauer, B, 1997) | 0.72 |
| " The information collected included patient-related demographic variables (age, weight, gender, and other underlying illness), the individual's dosing regimens (dose and dosing interval), time of blood drawn, and the resulting tobramycin concentration." | ( Application of neural networks to population pharmacokinetic data analysis. Chen, H; Chow, HH; Elsberry, V; Roe, DJ; Tolle, KM, 1997) | 0.48 |
| "The availability of personal computer programs for individualizing drug dosage regimens has stimulated the interest in modelling population pharmacokinetics." | ( Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Neef, C; Touw, DJ; Vinks, AA, 1997) | 0.56 |
| " aeruginosa, the CPO-AG combination is bactericidal at concentrations achievable with standard dosing regimens in man." | ( [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance]. Canis, F; Cavallo, JD; Husson, MO, 1997) | 0.3 |
| "To establish a tobramycin dosing schedule for neonates of various gestational ages." | ( Tobramycin population pharmacokinetics in neonates. de Hoog, M; Mouton, JW; Schoemaker, RC; van den Anker, JN, 1997) | 2.09 |
| " Individual empirical Bayes estimates were generated on the basis of the population estimates and used to calculate predicted peak and trough levels for different doses and dosing intervals." | ( Tobramycin population pharmacokinetics in neonates. de Hoog, M; Mouton, JW; Schoemaker, RC; van den Anker, JN, 1997) | 1.74 |
| " With use of population estimates, the following dosing regimen was recommended: gestational age below 32 weeks, 4 mg/kg every 48 hours; gestational age between 32 and 37 weeks, 4 mg/kg every 36 hours, gestational age above 37 weeks, 4 mg/kg every 24 hours." | ( Tobramycin population pharmacokinetics in neonates. de Hoog, M; Mouton, JW; Schoemaker, RC; van den Anker, JN, 1997) | 1.74 |
| " We designed a study to determine the pharmacokinetics and safety of once-daily dosing of tobramycin in this population." | ( Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Barson, WJ; Bates, RD; Cox, S; Jones, JW; McCoy, K; Nahata, MC; Young, G, 1997) | 0.8 |
| "The purpose of this study was to compare once daily (To24) and thrice daily (To8) tobramycin dosing regimens alone and in combination with ceftazidime, ciprofloxacin and imipenem against a clinical and ATCC strain of Pseudomonas aeruginosa." | ( Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model. Hoban, DJ; Kabani, A; Karlowsky, JA; Zelenitsky, SA; Zhanel, GG, ) | 0.66 |
| "We compared pharmacokinetic parameters derived from three aminoglycoside serum concentration sampling methods and evaluated their effects on recommended aminoglycoside dosing regimens in 60 critically ill surgery patients." | ( Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients. Baghaie, AA; Cerra, FB; Mann, HJ; Wittbrodt, ET, ) | 0.13 |
| " We studied various tobramycin and ceftazidime dosing regimens against four resistant Pseudomonas aeruginosa strains in an in vitro pharmacokinetic model to determine the usability of combination therapy for the treatment of infections due to resistant bacterial strains." | ( Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. den Hollander, JG; Mouton, JW; Verbrugh, HA, 1998) | 0.62 |
| "The influence of half-life on the postantibiotic effect (PAE) of tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus was investigated during one dosing interval." | ( Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. den Hollander, JG; Fuursted, K; Mouton, JW; Verbrugh, HA, 1998) | 0.54 |
| " Dosing principles for relatively resistant (higher-MIC) organisms are suggested from the data." | ( Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure. Ioannides-Demos, LL; Liolios, L; McLean, AJ; Spicer, WJ; Wood, P, 1998) | 0.54 |
| " By using the six hour post-dose level we were able to compare dosage recommendations made using methods known as ALADDIN, DOSECALC and the Australian Antibiotic Guidelines nomogram (AAGN)." | ( Monitoring of serum aminoglycoside levels with once-daily dosing. Paterson, DL; Peters, M; Robson, JM; Wagener, MM, 1998) | 0.3 |
| "To evaluate the effect of dosage regimen (once-daily vs." | ( Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. Hermenegildo, M; Poveda, JL; Querol, JM; Quintana, MB; Rocher, A; Sánchez-Alcaraz, A; Vargas, A, 1998) | 0.59 |
| "This small study suggests that a once-daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice-daily regimen." | ( Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. Hermenegildo, M; Poveda, JL; Querol, JM; Quintana, MB; Rocher, A; Sánchez-Alcaraz, A; Vargas, A, 1998) | 0.83 |
| " Chemistry and histopathology revealed the increased sensitivity to the toxic effects of tobramycin in old rats, which is important for the discussion of the most appropriate dosing regimen for aminoglycoside in humans." | ( Comparison of tobramycin nephrotoxicity in young adult and aged female rats. Dortant, PM; Peters-Volleberg, GW; Speijers, GJ, 1999) | 0.89 |
| " Subsequently, physician acceptability of the pharmacist's recommendations for dosage regimen modification was assessed." | ( Utilizing the clinical pharmacist to modify tobramycin dosage regimens: accuracy of prediction and potential cost effectiveness. Baptista, RJ; Sesin, GP, 1984) | 0.53 |
| " The target trough level was achieved in 99%, in less than 3% the dosing interval was extended up to 72 hours." | ( [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study]. Hoffmann, A; Meier-Hellmann, A; Pfeifer, R; Reimann, IR; Reinhart, K; Schilling, A; Stein, G; Traut, T, 1999) | 0.3 |
| " Unlike IT dosing, CI cefepime alone or in combination with ODT optimizes bactericidal activity by maximizing the percent of the dosing interval that concentrations remained above the MIC resulting in undiminished bacterial inhibition when compared to IT regimens." | ( Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Nicolau, DP; Nightingale, CH; Onyeji, CO; Tessier, PR, ) | 0.34 |
| " It was concluded that only three jet nebulizers [Porta-Neb Sidestream (PNS), Porta-Neb Ventstream (PNV) and Pariboy Pari LC+ (PLC)] have a reasonable output and an acceptable particle size distribution for the administration of a 10% tobramycin solution in the therapeutic dosage range." | ( Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer. de Boer, AH; Frijlink, HW; Gjaltema, D; Hagedoorn, P; Heijerman, HG; Le Brun, PP, 1999) | 0.85 |
| " Using the jet nebulizer and the 20% solution, it is possible to administer a dosage of 1000 mg tobramycin by inhalation within 30 min." | ( Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. de Boer, AH; Frijlink, HW; Gjaltema, D; Hagedoorn, P; Heijerman, HG; Le Brun, PP, 1999) | 0.88 |
| " Advances in the understanding of the pharmacodynamics of antibiotics have led to the development of new dosing strategies to maximize the antibiotics' activity." | ( New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Beringer, PM, 1999) | 0.3 |
| "There is increasing use of intermittent dosing of antibiotics to treat peritoneal dialysis (PD)-related peritonitis." | ( Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. Bailie, GR; Frye, R; Hess, LD; Manley, HJ; McGoldrick, MD, 2000) | 0.55 |
| "A retrospective analysis of files of patients with cystic fibrosis and pulmonary exacerbations was performed to investigate whether an individual dosage of tobramycin once established by serum level determination allows a reliable prediction of the adequate dosage in a consecutive exacerbation." | ( Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring. Bärmeier, H; Bartel, K; Böwing, B; Habash, T; Heininger, U; Lugauer, S; Schoerner, C; Unsal, M, 1999) | 0.94 |
| " Based on the results, optimal dosing intervals for renal impaired patients were calculated and were comparable with the intervals derived from the previous established nomogram." | ( Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. Lu, JF; Nicolau, DP; Nightingale, CH; Xuan, D, 2000) | 0.59 |
| "Once-daily dosing regimens of aminoglycosides are routinely used in critically ill trauma patients." | ( Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. Barletta, JF; Erstad, BL; Johnson, SB; Nix, DE; Nix, LC, 2000) | 0.31 |
| " Individualized dosing of critically ill trauma patients on the basis of at least two serum-aminoglycoside concentrations seems indicated when using once-daily dosing regimens." | ( Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. Barletta, JF; Erstad, BL; Johnson, SB; Nix, DE; Nix, LC, 2000) | 0.31 |
| "The objective of this study is to determine the safety and efficacy of an extended interval aminoglycoside dosing guideline implemented in our neonatal intensive care unit (NICU)." | ( Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit. Fuller, L; Menke, JA; Ohler, KH, 2000) | 0.31 |
| " Increasing concentrations of tobramycin led to reduction in endotoxin release, which may be of benefit when dosing aminoglycosides once daily." | ( Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release. Bring, J; Goscinski, G; Lundholm, M; Odenholt, I; Sjölin, J, 2000) | 0.84 |
| "Aminoglycoside therapy dosed by either IPM or physicians' directions." | ( Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Bertino, AS; Destache, CJ; Nafziger, AN; Streetman, DS, 2001) | 0.31 |
| " Moreover, the final population pharmacokinetic model may be used to design a priori recommendations for tobramycin and to improve the dosing readjustments through Bayesian estimation." | ( Population kinetics of tobramycin in neonates. Buelga, DS; Falcão, AC; García, MJ; Méndez, ME; Pardo, M, 2001) | 0.84 |
| " While limited clinical data exist, our results suggest that the use of ceftazidime by CI administration maintains clinical efficacy, optimizes the pharmacodynamic profile and uses less antibiotic compared with the standard 2 g every 8 h intermittent dosing regimen." | ( Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Lacy, MK; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R, 2001) | 0.31 |
| "The prescribing, dosing and monitoring of aminoglycosides in CF across Australia varies greatly." | ( Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Bell, SC; Phillips, JA, ) | 0.13 |
| " These peak values are well below the accepted maximum trough concentration with parenteral dosing (2 microg/mL)." | ( Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. Borowitz, D; Burns, JL; Emerson, J; Gibson, R; Konstan, MW; McCoyd, KS; McNamara, S; Montgomery, AB; Ramsey, B; Retsch-Bogart, G; Rosenfeld, M; Shell, R; Vicini, P; Wilmott, RW, 2001) | 0.55 |
| "The aim of this study was to test the equivalence of once- and thrice-daily dosing with tobramycin by comparing efficacy and safety in adult patients with cystic fibrosis." | ( Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Bogle, S; Caldwell, NA; Conway, SP; Etherington, C; Setchfield, N; Whitehead, A, 2002) | 0.93 |
| "Our objective was to individualize tobramycin dosing regimens in neonates of various gestational ages with use of early therapeutic drug monitoring." | ( Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. de Hoog, M; Mouton, JW; Schoemaker, RC; van den Anker, JN; Verduin, CM, 2002) | 0.89 |
| "Routine early therapeutic drug monitoring does not improve the model-based prediction of initial tobramycin dosing intervals in neonates in the first week of life." | ( Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. de Hoog, M; Mouton, JW; Schoemaker, RC; van den Anker, JN; Verduin, CM, 2002) | 0.83 |
| " A group of 470 neonates who had received tobramycin according to a gestational age (GA)-dependent dosing interval was analyzed according to a one-compartment model with NONMEM and NPEM2." | ( NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates. de Hoog, M; Schoemaker, RC; van den Anker, JN; Vinks, AA, 2002) | 0.82 |
| "The clinical and bacteriologic efficacy of fusidic acid viscous drops combined with the convenience of a twice-daily dosage regimen establishes this antibiotic as first-line treatment for suspected acute bacterial conjunctivitis and a favourable alternative to other broad-spectrum antibiotics." | ( Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Dattani, D; Jackson, WB; Leeder, RG; Low, DE; MacDougall, R; Whitsitt, PF, 2002) | 0.54 |
| " The recommended dosing interval based on the Hartford Hospital nomogram and one-serum concentration at 6 h was correct in only 62% of all cases." | ( Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Bruining, HA; Buijk, SE; Gyssens, IC; Mouton, JW; Verbrugh, HA, 2002) | 0.31 |
| " In this study we compare the distribution and elimination patterns of traditional dosing (3." | ( Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. Aminimanizani, A; Beringer, PM; Jelliffe, RW; Kang, J; Shapiro, BJ; Tsang, L, 2002) | 0.6 |
| " Measurable tobramycin levels due to inhalational therapy with conventional dosing in the reported patient indicate that the drug can be systemically absorbed, and renal tubular toxicity may occur." | ( Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Bitzan, MM; Hoffmann, IM; Iskandar, SS; Nagaraj, SK; Rubin, BK; Schechter, MS, 2002) | 0.93 |
| "There were no significant differences between treatments in the change in FEV(1) 30 min after dosing or in the frequency of adverse events." | ( Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Geller, DE; Rosenfeld, M; Waltz, DA; Wilmott, RW, 2003) | 0.58 |
| "Because of a lack of data supporting traditional dosing regimens for aminoglycosides, especially in extremely low-birth-weight infants, the authors developed revised dosing guidelines." | ( Gentamicin and tobramycin in neonates: comparison of a new extended dosing interval regimen with a traditional multiple daily dosing regimen. Avent, ML; Istre, GR; Kinney, JS; Whitfield, JM, 2002) | 0.67 |
| " More importantly, the collective assessment of these four factors would allow more optimal evaluation of dosage regimens." | ( The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics. Li, RC; Zhu, ZY, 2002) | 0.31 |
| "The therapy of critically ill patients with aminoglycoside antibiotics requires a careful dosing to achieve effective drug concentrations and to avoid toxic effects." | ( Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients. Hoffmann, A; Meier-Hellmann, A; Reimann, IR; Reinhart, K; Traut, T, 2003) | 0.53 |
| "To evaluate if a single blood sample per dosing interval 3 or 8 hours after infusion of tobramycin is appropriate to estimate the actual serum concentration 30 minutes after infusion (Cpeak30) and at the end of the dosing interval (C22h) in critically ill patients." | ( Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients. Hoffmann, A; Meier-Hellmann, A; Reimann, IR; Reinhart, K; Traut, T, 2003) | 0.75 |
| "A total of 32 patients of the intensive care unit (ICU) with an individualized once-daily dosing regimen involved in an intensified drug monitoring of tobramycin were analyzed retrospectively." | ( Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients. Hoffmann, A; Meier-Hellmann, A; Reimann, IR; Reinhart, K; Traut, T, 2003) | 0.73 |
| "In the critically ill, C3h but not C8h of tobramycin permitted the estimation of the Cpeak30 in most cases with satisfactory bias and precision starting with 2nd monitored dosing interval." | ( Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients. Hoffmann, A; Meier-Hellmann, A; Reimann, IR; Reinhart, K; Traut, T, 2003) | 0.8 |
| "We conducted a randomized, double-blind controlled study of tobramycin dosing among children 18 years or younger who had fever and neutropenia while undergoing stem cell transplantation." | ( Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation. Abdolell, M; Allen, U; Bliss, B; Doyle, J; Dupuis, LL; Rolland, M; Sung, L; Taddio, A; Taylor, T; Tong, A, 2003) | 0.81 |
| " The effect of dosing using the proposed method was compared with a weight-based (7 mg/kg) dosing method." | ( Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation. Borras-Blasco, J; Gonzalez-Delgado, M; Peris-Marti, JF; Rosique-Robles, JD, 2004) | 0.63 |
| "The results from the current study explain why weight-based daily dosing of tobramycin in critically ill patients with Clcr>60 mL/min achieved the Cpeak/MIC target values of 10." | ( Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation. Borras-Blasco, J; Gonzalez-Delgado, M; Peris-Marti, JF; Rosique-Robles, JD, 2004) | 0.86 |
| " This investigation was carried out in terms of a dose-response study." | ( Effects of mushroom and herb polysaccharides, as alternatives for an antibiotic, on the cecal microbial ecosystem in broiler chickens. Guo, FC; Kwakkel, RP; Li, HS; Li, WK; Li, XP; Luo, JY; Verstegen, MW; Williams, BA, 2004) | 0.32 |
| " Ceftazidime plus ciprofloxacin and ceftazidime plus tobramycin were dosed every 12 h for 48 h using simultaneous or staggered administration." | ( Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model. Ariano, RE; Harding, GK; Iacovides, H; Zelenitsky, SA, 2004) | 0.57 |
| "To describe the pharmacokinetic disposition of tobramycin in children undergoing stem cell transplantation (SCT) after intravenous administration either every 24 hours or every 8 hours, and to use this information to create initial dosing guidelines for administration every 24 hours in this patient population." | ( Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Abdolell, M; Allen, U; Doyle, J; Dupuis, LL; Sung, L; Taddio, A; Taylor, T, 2004) | 2.02 |
| " Initial guidelines for dosing every 24 hours were derived using the parameters from all patients to achieve a maximum serum concentration (Cmax) of 20-22." | ( Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Abdolell, M; Allen, U; Doyle, J; Dupuis, LL; Sung, L; Taddio, A; Taylor, T, 2004) | 1.77 |
| " Further validation of the proposed dosing guidelines is required." | ( Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Abdolell, M; Allen, U; Doyle, J; Dupuis, LL; Sung, L; Taddio, A; Taylor, T, 2004) | 1.77 |
| "[1] To quantify the random and predictable components of variability for aminoglycoside clearance and volume of distribution [2] To investigate models for predicting aminoglycoside clearance in patients with low serum creatinine concentrations [3] To evaluate the predictive performance of initial dosing strategies for achieving an aminoglycoside target concentration." | ( Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Holford, N; Kirkpatrick, C; Matthews, I, 2004) | 0.32 |
| "Aminoglycoside demographic, dosing and concentration data were collected from 697 adult patients (> or =20 years old) as part of standard clinical care using a target concentration intervention approach for dose individualization." | ( Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Holford, N; Kirkpatrick, C; Matthews, I, 2004) | 0.32 |
| "To determine the incidence of nephrotoxicity of once-daily dosing (ODD) and multiple daily dosing (MDD) regimens of tobramycin in critically ill patients." | ( Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Gelmont, D; Hara, J; Mehdian, R; Nelson, C; Olsen, KM; Rebuck, JA; Rudis, MI; Rupp, ME, 2004) | 0.78 |
| " Tobramycin administered by ODD may be the preferred dosing method in selected critically ill medical patients to reduce the incidence and extent of renal damage." | ( Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Gelmont, D; Hara, J; Mehdian, R; Nelson, C; Olsen, KM; Rebuck, JA; Rudis, MI; Rupp, ME, 2004) | 1.48 |
| " The impact of these variables should not be overlooked when clinical dosing regimens are optimized." | ( Post-antibiotic effect induced by an antibiotic combination: influence of mode, sequence and interval of exposure. Li, RC; Tang, MC, 2004) | 0.32 |
| " These include loss of motion during and after treatment, bone loss, generation of cement debris, inadequate dosing of cement with the appropriate antibiotic, and biologic failure." | ( Successful treatment of total hip and knee infection with articulating antibiotic components: a modified treatment method. Evans, RP, 2004) | 0.32 |
| " From the dosage regimen proposed by the user, the model simulates a plotting of antibiotic plasma concentrations vs." | ( [An example of simulation for a better understanding of PK/PD relationship of antibiotics]. Abbas, S; Drugeon, H; Ganiere-Monteil, C; Kergueris, MF; Le Normand, Y; Mazeas, M, 2004) | 0.32 |
| " Stochastic simulation was used to predict the expected concentration 95th percentiles after the recommended 7 mg/kg dose and for minimum inhibitory concentration (MIC) = 1 mg/L, as well as alternative once-daily dosing regimens for MIC = 2 mg/L." | ( Bicompartmental kinetics of tobramycin analysed with a wide range of covariates. Aguirre, C; Calvo, R; Gazouli, M; Inclan, G; Lukas, JC; Macheras, P; Suarez, E, 2005) | 0.62 |
| "To report aminoglycoside pharmacokinetic observations in a consecutive series of patients receiving intermittent hemodialysis (IHD), including treatment impact of patient-specific dosing regimens." | ( Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Dager, WE; King, JH, 2006) | 0.33 |
| " Analysis included pharmacokinetic parameters in stage 5 CKD, ARF, impact of the dialysis prescription, and treatment results of individualized dosing regimens lasting more than 4 days." | ( Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Dager, WE; King, JH, 2006) | 0.33 |
| " Dosage or duration of aminoglycosides use did not relate to SNHL." | ( Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Cheung, PY; Etches, PC; Peliowski, A; Robertson, CM; Tyebkhan, JM, 2006) | 0.33 |
| " Recommendations for agent selection, agent concentration, length of treatment, dosing schedule, and methods of irrigation are presented." | ( Evidence-based recommendations for antimicrobial nasal washes in chronic rhinosinusitis. Elliott, KA; Stringer, SP, ) | 0.13 |
| ": Once daily intravenous aminoglycoside dosing (ODD) is widely used to treat acute Pseudomonas aeruginosa exacerbations in patients with cystic fibrosis." | ( Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations. Bell, J; Conway, SP; Coulthard, KP; Peckham, DG; Smith, CA; Turnidge, J, 2007) | 0.6 |
| "Once-daily administration of aminoglycosides in cystic fibrosis (CF) patients is considered equally efficacious and potentially less nephrotoxic than dosing three times a day." | ( Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? Burkhardt, O; Derendorf, H; Kumar, V; Lehmann, C; Madabushi, R; Welte, T, 2006) | 0.72 |
| " For equal values of AUC24/MIC, however, Q24 treatment provided better improvement in lung function than Q8 dosing, whereas C(max)/MIC did not show any dosing interval dependence." | ( Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? Burkhardt, O; Derendorf, H; Kumar, V; Lehmann, C; Madabushi, R; Welte, T, 2006) | 0.72 |
| " aeruginosa resistance after once-daily administration is linked to a long dosing interval." | ( Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? Burkhardt, O; Derendorf, H; Kumar, V; Lehmann, C; Madabushi, R; Welte, T, 2006) | 0.72 |
| "Once-daily tobramycin in patients with cystic fibrosis (CF) is a more convenient dosing regimen than thrice daily dosing." | ( Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. Cranswick, N; Massie, J, 2006) | 0.98 |
| " Due to its twice daily dosing regimen for 3 days, azithromycin represents a step forward in the management of purulent bacterial conjunctivitis, especially in children." | ( 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Amraoui, A; Bourcier, T; Cochereau, I; Delval, L; Garg, P; Goldschmidt, P; Khairallah, M; Meddeb-Ouertani, A; Pop, M; Pouliquen, P; Tandon, R; Zaghloul, K, 2007) | 0.57 |
| " Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process." | ( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A, ) | 0.13 |
| "This study was designed to determine an optimal dose range for the once-daily dosing (ODD) of tobramycin in the treatment of an acute pulmonary exacerbation in paediatric cystic fibrosis (CF) patients." | ( Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. Atenafu, E; Bitnun, A; Dekker, A; Lam, W; Ratjen, F; Seto, W; Solomon, M; Tjon, J; Waters, V; Wong, C; Yau, Y, 2007) | 0.79 |
| "Patient characteristics and pharmacokinetic parameters of patients receiving tobramycin three times daily from 1 January 1992 to 31 October 2005 were analysed using univariate analysis and multiple linear regression to determine statistically significant relationships and to derive dosing models." | ( Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. Atenafu, E; Bitnun, A; Dekker, A; Lam, W; Ratjen, F; Seto, W; Solomon, M; Tjon, J; Waters, V; Wong, C; Yau, Y, 2007) | 0.8 |
| " These dosing guidelines will require prospective evaluation for safety and efficacy." | ( Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. Atenafu, E; Bitnun, A; Dekker, A; Lam, W; Ratjen, F; Seto, W; Solomon, M; Tjon, J; Waters, V; Wong, C; Yau, Y, 2007) | 0.57 |
| " We next asked what dosage of antibiotic would cause reductions in osteoblast and chondrocyte cell numbers." | ( Antibiotics for local delivery systems cause skeletal cell toxicity in vitro. Adams, CS; Antoci, V; Hickok, NJ; Parvizi, J; Shapiro, IM, 2007) | 0.34 |
| " On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar C(max) but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis." | ( Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen. Ayres, JW; Bennett, WM; Earle, SB; Kamel Mohamed, OH; Munar, MY; Wahba, IM; Watnick, S, 2007) | 0.92 |
| " Results of this study thus show that the mathematical ASL model combined with the lung deposition model can be an effective tool for helping decide the optimum dosage of inhaled antibiotic drugs delivered during human clinical trials." | ( Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. Hasan, MA; Lange, CF, 2007) | 0.34 |
| " * The simulations from this model clearly show that current dosing and monitoring methods will not achieve the necessary targets to maximize the pharmacokinetic-pharmacodynamic relationships of aminoglycosides in this patient group." | ( Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. Hennig, S; Kirkpatrick, CM; Norris, R, 2008) | 0.6 |
| "3-fold increase in tobramycin concentration in the rabbit tear film 10 minutes after dosing with TobraDex ST compared with TobraDex." | ( Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension. Bell, B; Bernal-Perez, LF; Brooks, AC; Faulkner, R; Jamison, T; Kabat, AG; Kabra, BP; Kulshreshtha, AK; Nguyen, VA; Owen, GR; Rusk, C; Scoper, SV; Stroman, DW, 2008) | 0.67 |
| "To examine the effects of computerized requests for pharmacist-to-dose (PTD), an advanced clinical decision support tool for dosing guidance, on antimicrobial therapy with vancomycin and aminoglycosides, describe PTD request utilization, and identify factors that may prolong this process." | ( Effects of a pharmacist-to-dose computerized request on promptness of antimicrobial therapy. Gatz, J; Lewis, DA; Martin, CA; Smith, KM; Vincent, WR; Winstead, PS, ) | 0.13 |
| "Pharmacists completed pharmacist-to-dose consultations for dosing guidance of vancomycin and aminoglycosides within a median of 30 minutes." | ( Effects of a pharmacist-to-dose computerized request on promptness of antimicrobial therapy. Gatz, J; Lewis, DA; Martin, CA; Smith, KM; Vincent, WR; Winstead, PS, ) | 0.13 |
| " To date, the use of these formulas in determining drug dosage and estimating drug elimination has not been thoroughly investigated." | ( Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Bookstaver, PB; Johnson, JW; McCoy, TP; Stewart, D; Williamson, JC, 2008) | 0.35 |
| "The 6-variable MDRD performs better than the CG(m) formula in predicting aminoglycoside clearance and may be considered as a tool in aminoglycoside dosing recommendations." | ( Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Bookstaver, PB; Johnson, JW; McCoy, TP; Stewart, D; Williamson, JC, 2008) | 0.35 |
| " Based on these data, the majority of critically ill patients would not be predicted to achieve the PD target under current dosing regimens." | ( Suboptimal aminoglycoside dosing in critically ill patients. Bies, R; Bigos, KL; Capitano, B; Lee, H; Rea, RS; Smith, R, 2008) | 0.35 |
| " Cl and t(1/2) are influenced by development, and this must be taken into consideration when planning a dosage regimen with aminoglycosides in the neonate." | ( Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Pacifici, GM, 2009) | 0.35 |
| " Therefore, the effect of the volume of saline flush used prior to drawing blood on tobramycin levels obtained from CVADs was investigated to determine the potential for inappropriate drug dosing decisions." | ( Accuracy of tobramycin levels obtained from central venous access devices in patients with cystic fibrosis is technique dependent. Carson, KA; Joplin, R; Loehr, K; McMahan, S; McNeil, A; Mills, J; Mogayzel, PJ; Pierce, E, ) | 0.73 |
| " Use of CVAD-obtained levels would have caused inappropriate dosing changes in 43% of cases." | ( Accuracy of tobramycin levels obtained from central venous access devices in patients with cystic fibrosis is technique dependent. Carson, KA; Joplin, R; Loehr, K; McMahan, S; McNeil, A; Mills, J; Mogayzel, PJ; Pierce, E, ) | 0.51 |
| "The purpose of this study was to quantify the prevalence of once-daily dosage of tobramycin (ODDT) among Cystic Fibrosis Foundation-accredited care centers and affiliated programs (CFFACCs) and characterize the ODDT approaches used by these institutions." | ( A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Ahern, JW; Corriveau, M; Lahiri, T; Van Meter, DJ, 2009) | 0.87 |
| " Using a combination of gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS), a global, nontargeted metabolomics analysis was performed on urine and kidney samples collected after one, five, and twenty-eight dosing days." | ( Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Boudonck, KJ; Keresztes, L; Mitchell, MW; Német, L; Nyska, A; Rosenstock, M; Shinar, D, 2009) | 0.35 |
| "In our ICUs where multidrug resistant bacteria are common, an approach considering ICU-specific antibiotic MICs coupled with pharmacodynamic dosing strategies resulted in improved outcomes and shorter duration of treatments." | ( Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E, 2010) | 0.36 |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | ( Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) | 0.35 |
| "We conclude that continuous or thrice-daily dosing of intravenous ceftazidime, both combined with once-daily tobramycin, are equally effective application regimens for elective antipseudomonal therapy in clinically stable patients with CF." | ( Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Ballmann, M; Broemme, S; Claass, A; Doering, G; Franke, P; Hebestreit, A; Jeschke, R; Junge, S; Koetz, K; Kuemmerer, K; Riethmueller, J; Schroeter, TW; Staab, D; Stern, M, 2009) | 0.57 |
| "Extended-interval once-daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice-daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years." | ( Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Nagel, JL; Prescott, WA, 2010) | 0.6 |
| "To assess the effectiveness and safety of once-daily versus multiple-daily dosing of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations in cystic fibrosis." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Smyth, AR, 2010) | 0.36 |
| "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Smyth, AR, 2010) | 0.36 |
| " All studies compared once-daily dosing with thrice-daily dosing." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Smyth, AR, 2010) | 0.36 |
| " Azyter, with its convenient dosing (bid for 3 days), is a step forward in the management of purulent bacterial conjunctivitis." | ( [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]. Amraoui, A; Bhagat, Y; Bourcier, T; Cochereau, I; Khairallah, M; Meddeb-Ouertani, A; Pop, M; Robert, PY; Zaghloul, K, 2010) | 0.6 |
| " Caution should be exercised when attempting to use predicted pharmacokinetic parameters to dose aminoglycosides in this patient population, and first-dose pharmacokinetics should be considered to optimize the dose and dosing interval early in the course of therapy." | ( Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Mercer, JM; Neyens, RR, 2010) | 0.36 |
| "Once daily dosing of aminoglycosides is widely used but is limited by the inconvenience of the slow infusion it requires and the associated three-times daily infusion of a beta-lactam." | ( Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Adeboyeku, D; Hodson, ME; Jones, AL, 2011) | 0.37 |
| "This study confirms that twice daily dosing of both tobramycin and ceftazidime is safe and effective and may be considered more convenient than current dosing schedules." | ( Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Adeboyeku, D; Hodson, ME; Jones, AL, 2011) | 0.62 |
| " We recommend in adapting the dosage to the estimated creatinine clearance rather than solely to the patient's weight." | ( Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Buclin, T; Gautier, E; Jacobi, M; Livio, F; Wahl, P, 2011) | 0.69 |
| " When the dosage of prednisone was reduced, symptoms returned." | ( Autoimmune dysfunction and subsequent renal insufficiency in a collegiate female athlete: a case report. Colandreo, RM; Kern, A; Leone, JE; Williamson, JD, ) | 0.13 |
| " Aerosol administration of levofloxacin as in the form of the investigational formulation MP-376 results in higher concentrations in lung tissues that are higher than those that can be attained with oral or intravenous dosing of levofloxacin." | ( Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. Dudley, MN; Griffith, DC; Lomovskaya, O; Sabet, M; Tarazi, Z; Tsivkovskii, R, 2011) | 0.37 |
| " The other group of 61 subjects received azithromycin and dosed with 1 drop twice daily (BID) for 2 days followed by once daily (QD) dosing for 12 days." | ( Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Cockrum, P; Hammonds, WM; Meier, E; Silverstein, B; Silverstein, S; Torkildsen, GL, 2011) | 0.63 |
| " In a median ICU patient, simulations were performed at various dosage regimens and peak and AUC pharmacodynamic targets could not be reached simultaneously in more than 45% of the ICU patient population." | ( Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Conil, JM; Cougot, P; Fourcade, O; Georges, B; Pharmd, GH; Rival, T; Ruiz, S; Saivin, S; Seguin, T, 2011) | 1.81 |
| "The aim of this study was to evaluate the disposition of tobramycin (TOB) in critically ill patients (ICU) by a population pharmacokinetic approach, to determine the covariates involved, and to simulate tobramycin dosage regimens." | ( Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Conil, JM; Cougot, P; Fourcade, O; Georges, B; Pharmd, GH; Rival, T; Ruiz, S; Saivin, S; Seguin, T, 2011) | 2.06 |
| "A complex CDS advisor to provide guidance on initial dosing and monitoring of aminoglycoside orders, using both traditional-dosing and extended-interval-dosing strategies, was integrated into a computerized prescriber-order-entry (CPOE) system and compared with a control group whose aminoglycoside orders were closely monitored by pharmacists." | ( Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Cox, ZL; McCoy, JA; Nelsen, CL; Peterson, JF; Waitman, LR, 2011) | 0.6 |
| "An advisor for aminoglycoside dosing and monitoring integrated into a CPOE system significantly improved selection of initial doses and intervals and resulted in an improvement in the rate of trough serum drug concentrations at goal compared with standard provider dosing." | ( Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Cox, ZL; McCoy, JA; Nelsen, CL; Peterson, JF; Waitman, LR, 2011) | 0.6 |
| " Dosing of aminoglycosides is typically based on total body weight." | ( Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Bertino, JS; Nafziger, AN; Pai, MP, 2011) | 0.37 |
| " The rabbits received ciprofloxacin 10 times a day at a 2-hour dosing interval." | ( [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. Li, Y; Liu, MT; Sheng, MY; Zhang, Y, 2011) | 0.63 |
| "To compare the pharmacokinetics (PK) of tobramycin in patients with cystic fibrosis (CF) before and after bilateral lung transplantation, in order to evaluate optimal dosing practices post transplant." | ( Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Davis, GA; Flynn, JD; Hayes, D; Kuhn, RJ; Walsh, KA; Weant, KA, 2011) | 2.08 |
| " Dosage requirements after transplantation were significantly lower, 10." | ( Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Davis, GA; Flynn, JD; Hayes, D; Kuhn, RJ; Walsh, KA; Weant, KA, 2011) | 1.81 |
| " The sample amounted to a total of 112 drugs, representing 131 dosage forms." | ( [Outpatient use of topical antimicrobials in Spain associated with other drugs (2005-2007)]. Cerro, EP; Hernández, DM; Montesinos, JV; Núñez, JG; Vara, PM, 2011) | 0.37 |
| "To assess the effectiveness and safety of once-daily versus multiple-daily dosing of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations in cystic fibrosis." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Smyth, AR, 2012) | 0.38 |
| "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Smyth, AR, 2012) | 0.38 |
| " All studies compared once-daily dosing with thrice-daily dosing." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Smyth, AR, 2012) | 0.38 |
| " However, the optimal aminoglycoside or the optimal dosage remains uncertain." | ( The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model. Asseray, N; Bugnon, D; Caillon, J; Dubé, L; Jacqueline, C; Potel, G, 2012) | 0.38 |
| "No evidence of significant drug accumulation in respiratory secretions with repeat dosing of TSI was seen." | ( Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. Anderson, G; Burns, JL; Emerson, J; Genatossio, A; McNamara, S; Moss, R; Rosenfeld, M; Ruddy, J, 2013) | 0.84 |
| " We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing." | ( Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. Bullington, WM; Flume, PA; Heh, JL; Stenbit, AE, 2013) | 0.72 |
| " Despite the efficacy of antibiotic cement spacers in the treatment of infected total knee arthroplasty, questions remain regarding the dosing of the antibiotic cement." | ( Articulating spacers for the treatment of infected total knee arthroplasty: effect of antibiotic combinations and concentrations. Bernasek, TL; Gustke, KA; Lyons, ST; Nettrour, JF; Polikandriotis, JA, 2013) | 0.39 |
| " Variations in tobramycin dosing between CF and non-CF patients should therefore reflect target concentrations or exposures based on differences in expected pathogen sensitivity and not the presence of CF." | ( Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Hennig, S; Staatz, CE; Standing, JF; Thomson, AH, 2013) | 1.03 |
| "64%, indicating that no interference was observed from concomitants usually present in pharmaceutical dosage forms." | ( Spectrofluorimetric determination of tobramycin in human serum and pharmaceutical preparations by derivatization with fluorescamine. Önal, A; Sağırlı, AO; Tekkeli, SE, 2014) | 0.68 |
| " There is a need for long-term randomised controlled trials of these technologies to determine patient-focused outcomes (such as quality of life and burden of care), safe and effective dosing levels of medications and clinical outcomes (such as hospitalisations and need for antibiotics) and an economic evaluation of their use." | ( Nebuliser systems for drug delivery in cystic fibrosis. Daniels, T; Mills, N; Whitaker, P, 2013) | 0.39 |
| " tobramycin dosing protocols are predicted through modeling and simulation to be suboptimal." | ( Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Beegle, S; Butterfield, JM; Farkas, J; Lodise, TP; Pai, MP; Rosen, J, 2013) | 1.53 |
| " The literature supports dosing ranges for amikacin and tobramycin of 30-35 and 7-15 mg/kg/day, respectively, given once daily, with subsequent doses determined by therapeutic drug concentration monitoring." | ( Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013) | 0.64 |
| " Monte Carlo Simulation was used to evaluate initial mg/kg TBW dosing regimens to determine whether a clinically useful once-daily tobramycin recommendation could be made." | ( Determination of tobramycin pharmacokinetics in burn patients to evaluate the potential utility of once-daily dosing in this population. Daneman, N; Simor, A; Vella, D; Walker, SA; Walker, SE, ) | 0.68 |
| " Higher initial dosing resulted in a higher likelihood of achieving the pharmacodynamic goal." | ( Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis. Cios, D; DeGrado, JR; Greenwood, BC; Kubiak, DW; Szumita, PM, 2014) | 0.64 |
| "This study aimed to characterize the pharmacokinetics of tobramycin administered one, two, or three times daily and to develop an optimal dosing scheme for children with cystic fibrosis." | ( Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. Ampofo, K; McCrory, BE; Olson, J; Sherwin, CM; Spigarelli, MG; Stockmann, C; Wisdom, M; Young, DC; Zobell, JT, 2014) | 0.89 |
| "3% eye drops in the treatment of purulent bacterial conjunctivitis in children, with a more convenient twice-a-day dosing regimen." | ( Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. Bianchi, PE; Bremond-Gignac, D; Chiambaretta, F; Delval, L; Hartani, D; Kaercher, T; Kocyla-Karczmarewicz, B; Lazreg, S; Messaoud, R; Murta, J; Nezzar, H; Renault, D; Speeg-Schatz, C; Voinea, L, 2014) | 0.4 |
| "The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations." | ( A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Prescott, WA, 2014) | 0.4 |
| " More than 95% of programs reported frequently or always using this dosing method." | ( A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Prescott, WA, 2014) | 0.4 |
| "This study indicates that the use of EID of aminoglycosides across United States adult CF programs has increased considerably since the publication of the CF pulmonary exacerbation guidelines and now appears to be the most common method for dosing aminoglycosides in adults with CF." | ( A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Prescott, WA, 2014) | 0.4 |
| "Based on an integrated analysis of gentamicin, tobramycin and vancomycin, a semi-physiological function for GFR mediated clearance was derived that can potentially be used to establish evidence based dosing regimens of renally excreted drugs in children." | ( Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Allegaert, K; Brussee, JM; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Mulla, H; Sherwin, CM; van den Anker, JN, 2014) | 0.91 |
| "New, sensitive, and selective spectrofluorimetric method was developed for determination of three aminoglycoside drugs in different dosage forms, namely; neomycin sulfate (NEO), tobramycin (TOB) and kanamycin sulfate (KAN)." | ( Validated spectrofluorimetric method for determination of selected aminoglycosides. Ahmed, HM; Derayea, SM; Hammad, MA; Omar, MA, 2015) | 0.61 |
| "Several dosage adjustment methods are currently available to individualize intravenous tobramycin dosing." | ( Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Hennig, S; Holthouse, F; Staatz, CE, 2015) | 0.89 |
| " To be included in the analysis, each patient had to have at least one pair of tobramycin plasma concentration-time measurements recorded over a dosing interval." | ( Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Hennig, S; Holthouse, F; Staatz, CE, 2015) | 0.9 |
| "The Therapeutic Guidelines nomogram recommended significantly greater mean doses for dosage adjustment (27." | ( Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Hennig, S; Holthouse, F; Staatz, CE, 2015) | 0.67 |
| "The log-linear regression method and Massie nomogram are likely to be suitable alternative methods for tobramycin dosage adjustment when Bayesian forecasting software is unavailable." | ( Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Hennig, S; Holthouse, F; Staatz, CE, 2015) | 0.88 |
| " The proposed method was successfully applied for the analysis of cited drugs in dosage forms with high accuracy (98." | ( Development of spectrofluorimetric method for determination of certain aminoglycoside drugs in dosage forms and human plasma through condensation with ninhydrin and phenyl acetaldehyde. Aly, AA; Hammad, MA; Nagy, DM; Omar, MA, 2015) | 0.42 |
| "Aminoglycoside clearance depends on kidney function, but the Australian Therapeutic Guidelines for antibiotics (version 14, 2010) recommend initial dosing based on weight without consideration of kidney function." | ( Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Larmour, I; Lim, AK; Mathanasenarajah, G, 2015) | 0.63 |
| "To determine the performance of current guideline dosing in achieving target area-under-the-curve and examine the relative precision of the estimated glomerular filtration rate equations compared with traditional Cockroft-Gault creatinine clearance in predicting aminoglycoside clearance." | ( Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Larmour, I; Lim, AK; Mathanasenarajah, G, 2015) | 0.63 |
| " Conformity with antibiotic guideline dosing was achieved if the discrepancy between prescribed and recommended dose was less than 15%." | ( Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Larmour, I; Lim, AK; Mathanasenarajah, G, 2015) | 0.63 |
| "Conformity with guideline dosing was not associated with achieving target area-under-the-curve." | ( Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Larmour, I; Lim, AK; Mathanasenarajah, G, 2015) | 0.63 |
| "Current guideline dosing may be suboptimal for achieving target area-under-the-curve." | ( Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Larmour, I; Lim, AK; Mathanasenarajah, G, 2015) | 0.63 |
| " The two mechanisms of aminoglycoside action and the new quantitative model hold great promise to rationally design novel, synergistic aminoglycoside combination dosage regimens." | ( Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Bulitta, JB; Forrest, A; Landersdorfer, CB; Ly, NS; Martin, L; Oliver, A; Shin, BS; Tsuji, BT; Velkov, T; Wanigaratne, NA; Yadav, R, 2015) | 0.66 |
| "In the heterogeneous group of preterm and term neonates, gentamicin and tobramycin are mainly dosed according to empirical guidelines, after which therapeutic drug monitoring and subsequent dose adaptation are applied." | ( Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. Allegaert, K; de Cock, RF; de Hoog, M; Knibbe, CA; Mouton, JW; Simons, SH; Valitalo, PA; van den Anker, JN, 2015) | 0.9 |
| " The proposed dosing guideline (4." | ( Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. Allegaert, K; de Cock, RF; de Hoog, M; Knibbe, CA; Mouton, JW; Simons, SH; Valitalo, PA; van den Anker, JN, 2015) | 0.66 |
| "The proposed neonatal dosing guideline for gentamicin and tobramycin results in improved attainment of target concentrations and should be prospectively evaluated in clinical studies to evaluate the efficacy and safety of this treatment." | ( Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. Allegaert, K; de Cock, RF; de Hoog, M; Knibbe, CA; Mouton, JW; Simons, SH; Valitalo, PA; van den Anker, JN, 2015) | 0.91 |
| "In order to improve the efficacy and safety of treatments, drug dosage needs to be adjusted to the actual needs of each patient in a truly personalized medicine approach." | ( Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance. Beyeler, M; Bianchessi, M; Buclin, T; Cappi, G; Decosterd, L; Ferretti, A; Guiducci, C; Moncada, Y; Spiga, FM, 2015) | 0.72 |
| " These efforts revealed increased levels of heat shock proteins and proteases were present at higher dosage treatments (0." | ( Dynamic Proteome Response of Pseudomonas aeruginosa to Tobramycin Antibiotic Treatment. Bruce, JE; Chavez, JD; Eng, JK; Held, K; Manoil, C; Singh, PK; Staudinger, BJ; Weisbrod, CR; Wu, X; Zheng, C, 2015) | 0.66 |
| " The risk of toxicity is reduced by extended-interval dosing of aminoglycosides, defined as 5 - 7 mg/kg given intravenously in intervals of 24 hours or greater based on serum drug concentrations." | ( Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. Barns, B; Block, C; Burrill, S; Chuk, AC; Fu, J; Katrych, O; Kousar, N; Lahey, T; Rickrode, G; Saeed, F; Saunders-Hao, P, 2015) | 0.67 |
| "We evaluated the pharmacokinetics of extended-interval dosing of gentamicin and tobramycin in 9 critically ill patients on continuous venovenous hemofiltration at Dartmouth-Hitchcock Medical Center between April 2007 and September 2011." | ( Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. Barns, B; Block, C; Burrill, S; Chuk, AC; Fu, J; Katrych, O; Kousar, N; Lahey, T; Rickrode, G; Saeed, F; Saunders-Hao, P, 2015) | 0.9 |
| "Extended interval aminoglycoside dosing during continuous venovenous hemofiltration yields unpredictable half-lives and drug levels among high-risk critically ill patients." | ( Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. Barns, B; Block, C; Burrill, S; Chuk, AC; Fu, J; Katrych, O; Kousar, N; Lahey, T; Rickrode, G; Saeed, F; Saunders-Hao, P, 2015) | 0.67 |
| " However, the difference in values was not enough to impact antibiotic dosing and therefore was not clinically significant." | ( A Comparison of Antibiotic Serum Concentrations Drawn Simultaneously from Peripherally Inserted Central Catheters and Peripheral Veins in Children with Respiratory Infection. Board, R; Feldman, HA; Green, ME; McCabe, M; Sullivan, KJ; Wells, S, ) | 0.13 |
| "Since 2001, the frequency of AG administration and dosing declined, but the incidence of AG-AKI remained constant." | ( Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study. Ammann, H; Bernier-Jean, A; Bouchard, J; Brunette, V; Lavergne, V; Paquette, F; Pichette, V; Troyanov, S, 2015) | 0.42 |
| "The optimal dosing of intravenous tobramycin for treatment of pulmonary exacerbations in paediatric cystic fibrosis (CF) patients has not been completely delineated." | ( Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis. Biondo, L; Brigg Turner, R; Elbarbry, F, 2016) | 0.95 |
| "The aim of this study was to apply quality by design (QbD) for development of dexamethasone sodium phosphate (DSP) and tobramycin sulfate (TS)-loaded thermoresponsive ophthalmic in situ gel containing Poloxamer 407 and hydroxyl propyl methyl cellulose (HPMC) K4M for prolonging the pre-corneal residence time, ocular bioavability and decreases the frequency of administration of dosage form." | ( Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Baldaniya, L; Gandhi, T; Gohel, M; Metalia, V; Patel, N; Thakkar, V, 2016) | 0.64 |
| " Before the implementation of these models in clinical practice for dosage adjustment, their predictive performance should be externally evaluated." | ( Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Bloomfield, C; Hennig, S; Staatz, CE; Unwin, S, 2016) | 0.65 |
| " The method was further evaluated in a motivating example of optimal dosage prediction of tobramycin." | ( A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data. Hennig, S; Klein, K; Paul, SK, 2016) | 0.66 |
| "To evaluate the success of an initial tobramycin dosing regimen to achieve target peak and trough concentrations in adult patients with pulmonary exacerbations of cystic fibrosis (CF)." | ( Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis. Metzger, NL; Peasah, SK; Staubes, BA; Walker, SD, 2016) | 1.01 |
| " The primary outcome evaluated the success of the initial tobramycin dosing regimen in attaining the target peak concentration." | ( Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis. Metzger, NL; Peasah, SK; Staubes, BA; Walker, SD, 2016) | 0.98 |
| " Optimization of the initial CF tobramycin dosing regimen is warranted." | ( Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis. Metzger, NL; Peasah, SK; Staubes, BA; Walker, SD, 2016) | 1.02 |
| " The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF." | ( The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS, 2017) | 0.67 |
| " Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day." | ( The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS, 2017) | 0.46 |
| "Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects." | ( The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS, 2017) | 0.46 |
| "To assess the effectiveness and safety of once-daily versus multiple-daily dosing of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations in cystic fibrosis." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Nevitt, SJ; Smyth, AR, 2017) | 0.46 |
| "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Nevitt, SJ; Smyth, AR, 2017) | 0.46 |
| " All studies compared once-daily dosing with thrice-daily dosing." | ( Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt, J; Nevitt, SJ; Smyth, AR, 2017) | 0.46 |
| " Further research is needed to determine the optimal local antibiotic type and dosing to maximize infection clearance and minimize potential side effects." | ( Acute Kidney Injury After First-Stage Joint Revision for Infection: Risk Factors and the Impact of Antibiotic Dosing. Chen, A; Cunn, G; Geller, JA; Herschmiller, T; Murtaugh, T, 2017) | 0.46 |
| " However, systemic exposure is not predictive of clinical efficacy due to direct dosing at the infection site." | ( Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. Anumolu, SS; Koehne-Voss, S; Wang, X; Yu, J, 2017) | 0.74 |
| "Once-daily aminoglycoside dosing (ODA) is used in most patient populations to optimize antibacterial activity and reduce toxicity." | ( A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Jeschke, M; Lee, C; Seto, W; Simor, A; Walker, SAN; Walker, SE, 2017) | 0.74 |
| "To determine the adequacy of once daily tobramycin dosed at 10mg/kg in adult burn patients." | ( A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Jeschke, M; Lee, C; Seto, W; Simor, A; Walker, SAN; Walker, SE, 2017) | 1.01 |
| " The bactericidal efficacy of tobramycin is known to be concentration-dependent and hence changing the dosing regimen from a twice-daily (q12h) inhalation to a once-daily (q24h) inhaled double dose could improve treatment outcomes." | ( Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? Andrinopoulou, ER; Bos, AC; Janssens, HM; Mouton, JW; Tiddens, HAWM; van Westreenen, M, 2017) | 1.01 |
| " The following q12h and q24h dosing regimens were evaluated: Akita® (150 and 300 mg) and PARI-LC® Plus (300 and 600 mg)." | ( Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? Andrinopoulou, ER; Bos, AC; Janssens, HM; Mouton, JW; Tiddens, HAWM; van Westreenen, M, 2017) | 0.72 |
| " Small airway concentrations were 762-2999 mg/L for the q12h dosing regimen and 1523-5997 mg/L for the q24h dosing regimen, well above the MIC for WT Pa strains." | ( Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? Andrinopoulou, ER; Bos, AC; Janssens, HM; Mouton, JW; Tiddens, HAWM; van Westreenen, M, 2017) | 0.72 |
| " Ultimately, the q24h dosing regimen appears more effective against subpopulations with high MICs (i." | ( Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? Andrinopoulou, ER; Bos, AC; Janssens, HM; Mouton, JW; Tiddens, HAWM; van Westreenen, M, 2017) | 0.72 |
| " A twice- or three-times daily dosage regimen and alkalising co-medication may further improve urinary bactericidal activity." | ( Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption. Loose, M; Naber, KG; Reinhart, H; Shields, P; Wagenlehner, FME, 2018) | 0.73 |
| "A consistent approach to the dosing of aminoglycosides across the modern body size distribution has been elusive." | ( Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. Crass, RL; Derstine, BA; Lichty, M; Pai, MP; Ross, BE; Su, GL; Sullivan, JA; Wang, SC, 2018) | 0.48 |
| " Identifying and understanding these changes may assist in optimizing antibiotic dosing during APE treatment." | ( Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Deka, R; Hong, LT; King, JB; Liou, TG; Stevens, V; Young, DC, 2018) | 0.48 |
| " Continuous infusion BL and tobramycin clearance can change dramatically during the treatment of an APE, which may necessitate significant changes in dosing to achieve optimal antibiotic levels." | ( Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Deka, R; Hong, LT; King, JB; Liou, TG; Stevens, V; Young, DC, 2018) | 0.77 |
| " Validation of this relationship in larger studies of adult patients with CF is needed before application to the precision dosing of piperacillin/tazobactam in this patient population." | ( Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? Crass, RL; Lodise, TP; Pai, MP, 2019) | 0.73 |
| " PNDJ hydrogels containing tobramycin and vancomycin were administered in four dosing sites in rabbits (intramedullary in the femoral canal, soft tissue defect in the quadriceps, intramuscular injection in the hamstrings, and intra-articular injection in the knee)." | ( Temperature-responsive PNDJ hydrogels provide high and sustained antimicrobial concentrations in surgical sites. Badha, VS; Childers, EP; Heffernan, JM; McLaren, AC; Moore, RC; Overstreet, DJ; Vernon, BL, 2019) | 0.81 |
| " To ensure similar exposure across body weights, we propose a MDRD-based dosing nomogram for obese patients." | ( Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Brüggemann, RJM; Knibbe, CAJ; Mouton, JW; Smit, C; van Dongen, HPA; Wasmann, RE; Wiezer, MJ, 2019) | 1.96 |
| "To determine the outcomes of weight- and height-based tobramycin dosing regimens for patients with cystic fibrosis (CF)." | ( Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. Alghanem, SS; Thomson, AH; Touw, DJ, 2019) | 1 |
| "Cyclical dosing of once-daily ALIS was noninferior to cyclical twice-daily TIS in improving lung function." | ( Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Bilton, D; Cipolli, M; Clancy, JP; Eagle, G; Fajac, I; Galeva, I; Gupta, R; Konstan, MW; Liu, K; McGinnis, JP; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A, 2020) | 0.56 |
| " Future studies are needed to define optimal dosing in paediatric patients with ARC." | ( Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. Avedissian, SN; Bradley, J; Kim, Y; Le, J; Rhodes, NJ; Valdez, JL, 2020) | 0.56 |
| "In the era of multiple daily dosing of systemic aminoglycosides, a circadian rhythm in the clearance of these vital antibiotics has been demonstrated in animals and healthy volunteers." | ( Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis? Heijerman, HGM; Neef, C; Touw, DJ; van der Meer, R; van Maarseveen, EM, 2020) | 0.8 |
| " This presents issues when attempting to determine antimicrobial dosing as traditional antibiotic susceptibility tests (ASTs) are typically designed around planktonic bacteria and thus offer information that is not relevant to the biofilm phenotype present in the patient." | ( Nanodiagnostics to monitor biofilm oxygen metabolism for antibiotic susceptibility testing. Cash, KJ; David, AA; Harris, JK; Jewell, MP; Saccomano, SC; Zemanick, ET, 2020) | 0.56 |
| "The Dutch Pediatric Formulary (DPF) increasingly bases its guidelines on model-based dosing simulations from pharmacokinetic studies." | ( External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. de Hoop, M; de Wildt, SN; Hartman, SJF; Orriëns, LB; Poel, T; Zwaag, SM, 2020) | 0.78 |
| " The first therapeutic drug monitoring concentration for each patient was collected, as was clinical and dosing information." | ( External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. de Hoop, M; de Wildt, SN; Hartman, SJF; Orriëns, LB; Poel, T; Zwaag, SM, 2020) | 0.78 |
| "This study illustrates the need to validate model-based dosing advice in the real-world setting as both sub- and supratherapeutic concentrations of vancomycin, gentamicin, and tobramycin were very prevalent." | ( External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. de Hoop, M; de Wildt, SN; Hartman, SJF; Orriëns, LB; Poel, T; Zwaag, SM, 2020) | 0.98 |
| " Cumulative IV-AG dosing has been associated with a higher risk of ototoxic hearing loss, yet some individuals lose substantial hearing after a single IV-AG treatment, while others never seem to lose hearing." | ( Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin. Garinis, A; Gleser, M; Johns, A; Larsen, E; Vachhani, J, 2021) | 0.83 |
| " For bacterial infections, the choice of dosing regimen is typically relying on preclinical pharmacokinetic (PK) and pharmacodynamic (PD) data, because the bacterial load and disease severity, and consequently the PK/PD relationship, cannot be quantified well on clinical data, given the low-information end points used." | ( Pivotal Role of Translation in Anti-Infective Development. Friberg, LE, 2021) | 0.62 |
| " There are controversies and practice differences between institutions related to aminoglycoside dosing and monitoring strategies." | ( Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis. Caverly, LJ; Chaffee, VD; Dillman, NO; Ochs, MA, 2021) | 0.62 |
| "Pharmacists routinely interpret and optimize tobramycin dosing for people with cystic fibrosis (PwCF)." | ( Evaluating the Impact of Education on Pharmacist Tobramycin Dose Recommendations for Cystic Fibrosis and a Review of Perceptions on Pharmacist-Led Charting. Cheah, R; Le, T; Lord, L; Pignataro, S; Simioni, D, 2022) | 1.24 |
| "Extended-interval dosing of tobramycin is widely applied in patients with the Hartford nomogram as a representative, while this dosing approach has not been extensively evaluated in critically ill patients." | ( Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. Cheng, Z; Li, S; Peng, Y; Wang, Y; Xie, F, 2021) | 1.17 |
| " The percentage of patients who reached the non-toxicity target was quite low under the Hartford nomogram and a further extension of the dosing interval was necessary to minimize the toxicity." | ( Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. Cheng, Z; Li, S; Peng, Y; Wang, Y; Xie, F, 2021) | 0.88 |
| " Therefore, the aim of this study was to externally evaluate the predictability of tobramycin population pharmacokinetic models with an independent dataset and perform simulations using previously recommended height-based dosing regimens." | ( Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations. Cloutier, I; El Hassani, M; Marsot, A; Pilote, S; Simard, C; Soufsaf, S, 2022) | 1.23 |
| " are appropriate for simulation-based applications to aid individualized dosing in our population and that height-based dosing regimens could be considered in cystic fibrosis patients." | ( Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations. Cloutier, I; El Hassani, M; Marsot, A; Pilote, S; Simard, C; Soufsaf, S, 2022) | 1.01 |
| "Considering the aminoglycosides' characteristics in terms of efficacy and toxicity, multiple dosing recommendations and nomograms have been suggested over several decades." | ( Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals. Duong, A; Marsot, A; Simard, C; Thirion, DJG; Williamson, D, 2022) | 0.72 |
| " Emerging drug resistance and changing pharmacokinetic profile in an aging population involve a reevaluation of tobramycin dosing recommendations." | ( New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis. Koloskoff, K; Marsot, A; Matouk, E; Thirion, DJG, 2023) | 1.37 |
| "This study demonstrated that height of the patients seems to be more suitable than their weight for dosing adjustments in adult patients with CF." | ( New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis. Koloskoff, K; Marsot, A; Matouk, E; Thirion, DJG, 2023) | 1.16 |
| "Children with cystic fibrosis (CF) pulmonary exacerbations receive IV tobramycin therapy, with dosing guided by either log-linear regression (LLR) or Bayesian forecasting (BF)." | ( Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods. Fitzgerald, DA; Imani, S; Lai, T; Robinson, PD; Sandaradura, I; Selvadurai, H, 2022) | 1.32 |
| " However, BF can significantly reduce the number of blood collections required during each admission, improve dosing accuracy, and provide more reliable target concentration attainment in CF children." | ( Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods. Fitzgerald, DA; Imani, S; Lai, T; Robinson, PD; Sandaradura, I; Selvadurai, H, 2022) | 1.09 |
| " Likewise, de-indexation of eGFR to body surface area (BSA) has been recommended by regulatory guidance for drug dosing in renal impairment." | ( Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles. Abdelnabi, M; Pai, MP; Sitaruno, S, 2023) | 0.91 |
| " Confirmation of these results for other drugs can support the harmonization of dosing by kidney function." | ( Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles. Abdelnabi, M; Pai, MP; Sitaruno, S, 2023) | 0.91 |
| " This study aimed to develop a height-based initial dosing nomogram and evaluate its performance in peak concentration (Cmax) precision relative to standard and fixed dosing." | ( Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations. Cloutier, I; El Hassani, M; Koloskoff, K; Marsot, A; Matouk, E; Pilote, S; Simard, C; Thirion, DJG, 2023) | 1.17 |
| " aeruginosa to develop tolerance which may result in therapeutic failures if inappropriate dosing regimens are used to treat keratitis." | ( Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. Khan, M; Ma, K; Wan, I; Willcox, MD, 2023) | 0.91 |
| " Some of these models have been used to develop a priori dosing regimens for their respective populations." | ( Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable? Duong, A; Marsot, A; Simard, C; Williamson, D, 2023) | 2.35 |
| " Dosing regimens were simulated and compared between the best-performing model and its re-estimated counterparts." | ( Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable? Duong, A; Marsot, A; Simard, C; Williamson, D, 2023) | 2.35 |
| " Similar percentages of target attainment were obtained for the original and re-estimated models after the dosing regimen simulations." | ( Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable? Duong, A; Marsot, A; Simard, C; Williamson, D, 2023) | 2.35 |
| " This study aimed to investigate the AUC-guided dosing of TOB based on population pharmacokinetic analysis in the treatment of infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia." | ( Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria. Hashiguchi, Y; Jono, H; Matsumoto, N; Oda, K; Saito, H, 2023) | 1.16 |
| "This study suggests that TOB use encourages the replacement of trough- and peak-targeted dosing with AUC-guided dosing." | ( Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria. Hashiguchi, Y; Jono, H; Matsumoto, N; Oda, K; Saito, H, 2023) | 1.16 |
| " Long-term RCTs are needed to evaluate different nebuliser systems to determine patient-focused outcomes (such as QoL and burden of care), safe and effective dosing levels of a wide variety of medications, clinical outcomes (such as hospitalisations and need for antibiotics), and an economic evaluation of their use." | ( Nebuliser systems for drug delivery in cystic fibrosis. Brown, C; Morrison, L; Stanford, G, 2023) | 0.91 |
| Role | Description |
|---|---|
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| toxin | Poisonous substance produced by a biological organism such as a microbe, animal or plant. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| amino cyclitol glycoside | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Tobramycin Action Pathway | 1 | 4 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein Rev | HIV-1 M:B_HXB2R | Kd | 4.1100 | 0.1800 | 2.1450 | 4.1100 | AID82302 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID325978 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count at 100 ug/ml by rotating disk reactor method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin. |
| AID283540 | Antibacterial activity against Pseudomonas aeruginosa FE57Z with inactivated rplY and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID573199 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T380C mutant gene selected at 0.5 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID283548 | Antibacterial activity against Pseudomonas aeruginosa FE63 containing inactivated rplY and PA5471 genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID564468 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1093 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID446139 | Antibacterial activity against R-methylase expressing Citrobacter amalonaticus 06AB0010 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID559054 | Antibacterial activity against Streptococcus agalactiae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID283547 | Antibacterial activity against Pseudomonas aeruginosa FE60 containing inactivated mexXY gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID563523 | Antibacterial activity against Pseudomonas aeruginosa NY220 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. |
| AID522933 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a D268N mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1716767 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 32 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID564686 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID561323 | Antimicrobial activity against Klebsiella pneumoniae isolate 132 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID532083 | Antimicrobial against Pseudomonas aeruginosa 1494 harboring phnA allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID1318937 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 85322 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID573536 | Antibacterial activity against Serratia marcescens Sm2723 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID519183 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 4 ug/ml of cefepime exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID534194 | Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. |
| AID1580091 | Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. |
| AID559484 | Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559050 | Antibacterial activity against Staphylococcus hominis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID68696 | In vitro inhibitory activity against Escherichia coli ATCC 25922; Value ranges from 0.25-1 ug/mL | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID326536 | Antimicrobial activity against Mycobacterium abscessus CH10 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID396030 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID164370 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-21509 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID525556 | Cmax in 15 hrs fasted BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID573533 | Antibacterial activity against Enterobacter cloacae El3518 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1629135 | Selectivity ratio, ratio of IC50 for cytosolic eukaryotic translation in rabbit reticulocyte S30 extract to IC50 for 16S rRNA A-site in Escherichia coli S30 extract | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID285611 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID126452 | Dissociation constant for binding to mitochondrial 12S rRNA construct M5 was determined | 2002 | Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16 | Decoding region bubble size and aminoglycoside antibiotic binding. |
| AID460799 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 16 to 20 hrs by microdilution susceptibility test | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID560274 | Toxicity in Pseudomonas aeruginosa ATCC 27853 infected Swiss mouse | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID559043 | Antibacterial activity against vancomycin- resistant Enterococcus faecium by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID564451 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1036 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID780476 | Antimicrobial activity against Pseudomonas aeruginosa PaM02 assessed as growth inhibition at 0.008 umol/ml by microtitre plate reader analysis | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22 | Spectroscopic identification and anti-biofilm properties of polar metabolites from the medicinal plant Helichrysum italicum against Pseudomonas aeruginosa. |
| AID622389 | Antibacterial activity against colistin-sensitive Pseudomonas aeruginosa after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID285587 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID525570 | AUC (0 to infinity) in normally fed BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID523068 | Activity of Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1056842 | Antibacterial activity against TEM-1/SHV-12/CTX-15 expressing Enterobacter intermedius isolate 243 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID573535 | Antibacterial activity against Enterobacter cloacae El1573 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID774219 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID1716635 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 1024 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID330985 | Antimicrobial activity against Staphylococcus epidermis | 2007 | Nature, May-03, Volume: 447, Issue:7140 | PTC124 targets genetic disorders caused by nonsense mutations. |
| AID530322 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID559061 | Antibacterial activity against Streptococcus anginosus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559065 | Antibacterial activity against Streptococcus mitis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID554434 | Ratio of MIC for Pseudomonas aeruginosa 2715 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1447591 | Disruption of proton motive force in Pseudomonas aeruginosa PAO1 cytoplasmic membrane assessed as repression of bacterial swimming motility at 0.0156 to 0.125 MIC after 20 hrs | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID509866 | Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID283220 | Antimicrobial activity against Pseudomonas aeruginosa PA0905 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID559260 | Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID496006 | Antimicrobial activity against imipenem resistant Pseudomonas aeruginosa isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. |
| AID1881518 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID559077 | Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559084 | Antibacterial activity against Proteus mirabilis by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID65060 | Concentration required for half maximum rate of enhanced [3H]DHS (Dihydrostreptomycin) uptake in Escherichia coli K12 (ATCC 25868)was estimated from dose-response curves | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID529159 | Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID559070 | Antibacterial activity against Acinetobacter calcoaceticus by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID572137 | Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID523494 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID544955 | Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID1846502 | Antibacterial activity against Pseudomonas aeruginosa NC02 cystic fibrosis assessed as tobramycin MIC in presence of berberine | |||
| AID774215 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID1318925 | Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 101243 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID560598 | Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID1716634 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 128 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID519179 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 4ug/ml of gentamycin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1653587 | Anti-leprotic activity against Mycobacterium leprae infected in BALB/c weanling mouse assessed as bacteria killing at 20 mg/kg, ip administrated for 60 days and measured after 1 year by Spearman-Karber technique analysis relative to control | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID278810 | Antibacterial activity against Escherichia coli BL21(DE3) expressing Pseudomonas aeruginosa APH(3')-2b | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID563519 | Antibacterial activity against Pseudomonas aeruginosa NY214 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. |
| AID508731 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3D2 GM2 harboring acquired beta-lactamase BEL-3 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID523071 | Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID565279 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID394683 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID560262 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID498107 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559058 | Antibacterial activity against levofloxacin-susceptible Streptococcus pneumoniae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID518817 | Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID1422369 | Antibacterial activity against Pseudomonas aeruginosa PA22 harboring surexp MexXY by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID425070 | Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID559584 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1056852 | Antibacterial activity against CTX-15 expressing Stenotrophomonas maltophilia isolate 125 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID622395 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microbroth dilution method in presence of Mg2+ | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID1873910 | Antibacterial activity against Enterococcus faecium incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID1846516 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa NC06 assessed as fold reduction in MIC in presence of berberine by broth microdilution method | |||
| AID585435 | Antimicrobial activity against Pseudomonas aeruginosa PA14 mutS gene hypermutant by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. |
| AID540236 | Phospholipidosis-positive literature compound observed in human | |||
| AID519180 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 1 ug/ml of oflaxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID521593 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 7.0 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID374112 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS6 transconjugant from Escherichia coli 650 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID559059 | Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498126 | Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1422364 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID559075 | Antibacterial activity against Enterobacter cloacae by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573532 | Antibacterial activity against Klebsiella pneumoniae Kp2730 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID534167 | Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG1 expressing RmtB, TEM-1, and QepA gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1459347 | Antibacterial activity against Staphylococcus aureus 209P incubated at room temperature for 30 mins followed by incubation at 37 degC for 12 hrs by two-fold dilution method | 2016 | Journal of natural products, 10-28, Volume: 79, Issue:10 | Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities. |
| AID565066 | Antibacterial activity against CTX-M-15 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID519181 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 1 ug/ml of Norfloxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID571919 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID559512 | Antibacterial activity against Lancefield Streptococcus sp. 'group G' assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285577 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1873906 | Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID768035 | Antibacterial activity against Bacillus subtilis 168 harboring AAC(6')/APH(2'')-pRB374 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID326548 | Antimicrobial activity against Mycobacterium abscessus R53 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID497947 | Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573546 | Antibacterial activity against Klebsiella oxytoca Ko0426 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1846515 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa AR48 assessed as fold reduction in MIC in presence of berberine by broth microdilution method | |||
| AID496005 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. |
| AID497943 | Antibacterial activity against Pseudomonas aeruginosa by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID554391 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1422374 | Antibacterial activity against Escherichia coli PAZ505H8101 harboring AAC6'-1B by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID573523 | Antibacterial activity against Enterobacter cloacae isolate El216 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1139968 | Binding affinity to menin (unknown origin) by isothermal titration calorimetry analysis | 2014 | Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9 | Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface. |
| AID278808 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID564691 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID498121 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID565065 | Antibacterial activity against CTX-M-14 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID573538 | Antibacterial activity against Citrobacter amalonaticus Ca38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID546619 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID573548 | Antibacterial activity against Escherichia coli Ec158 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID166713 | Tested for binding affinity against RNA construct B | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers. |
| AID560278 | Bactericidal activity against Pseudomonas aeruginosa NH57388A infected in Swiss neutropenic mouse assessed as reduction in lung bacterial load at 60 mg/kg BID administered 24 hrs post infection through aerosol | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID532079 | Antimicrobial against Pseudomonas aeruginosa 32455 harboring phzS allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID573520 | Antibacterial activity against Klebsiella pneumoniae isolate Kp266 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1824801 | Antibacterial activity against Pseudomonas aeruginosa 1129 assessed as bacterial growth inhibition by broth microdilution method | 2022 | Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1 | New |
| AID1716769 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 1024 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1716759 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID496008 | Antimicrobial activity against piperacillin-tazobactam resistant Pseudomonas aeruginosa isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. |
| AID498116 | Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID523499 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID573525 | Antibacterial activity against Klebsiella oxytoca isolate Ko238 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID446134 | Antibacterial activity against MexEF expressing Pseudomonas aeruginosa PA03 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID644960 | Displacement of ethidium bromide from human pre-hsa-mir-155 miRNA after 30 mins | 2012 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4 | Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing. |
| AID324854 | Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID521836 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID559081 | Antibacterial activity against Moraxella catarrhalis by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID561324 | Antimicrobial activity against Klebsiella pneumoniae isolate 132 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID531864 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction in bacterial count at 10 mg/L after 50 mins by CTC staining | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID544954 | Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID544958 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID162761 | In vitro inhibitory activity against Pseudomonas aeruginosa ATCC 27853 | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID498089 | Antibacterial activity against Pseudomonas aeruginosa PA881 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1881521 | Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID1322251 | Antibacterial activity against AAC6'-2A expressing Pseudomonas aeruginosa F03 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1374166 | Antibacterial activity against Escherichia coli ATCC 25922 incubated at 37 degC for 20 hrs by standard broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID571889 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID405819 | Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID283221 | Antimicrobial activity against Escherichia coli XL1-Blue pPA95S29 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID768027 | Antibacterial activity against Bacillus anthracis 34F2 Sterne by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID534178 | Antimicrobial activity against Escherichia coli TOP10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1422376 | Antibacterial activity against Klebsiella pneumoniae 700603 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1318903 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID203329 | Antibacterial activity expressed as MIC value was determined on Serratia marcescens A-20019 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID521600 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 infected in mouse J774A.1 cells at 50 ug/ml after 1hr | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID572129 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID560590 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID498304 | Antibacterial activity against Pseudomonas aeruginosa PA5063 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID498113 | Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID520698 | Antimicrobial activity against Escherichia coli isolate DH10B by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID573503 | Antibacterial activity against Escherichia coli isolate Ec9381 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID164254 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20897 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID573212 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID518816 | Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID559044 | Antibacterial activity against Listeria monocytogenes by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID162730 | Antibacterial activity expressed as MIC value was determined on Proteus mirabilis A-9900 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID498108 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1318933 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 79199 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID546620 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID1318923 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 264-104354 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID1780308 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Gly120Ala mutant assessed as resistance development by measuring fold increase in MIC | |||
| AID279941 | Antibiotic susceptibility by resistance against non-MDR Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID1422371 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID498117 | Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID326534 | Antimicrobial activity against Mycobacterium chelonae after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID533855 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium fortuitum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1447475 | Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID522932 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a N196D mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID559046 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID283538 | Antibacterial activity against Pseudomonas aeruginosa FE53G with inactivated mexZ and nuoG genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID584556 | Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID2940 | Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID523405 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID544957 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID573193 | Antimicrobial activity against mutS::lox,mexD::lox-deficient Pseudomonas aeruginosa PAOMSMxD biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1716661 | Antibacterial activity against Pseudomonas aeruginosa 200 harboring efflux mutant assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID533861 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium septicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID544965 | Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID533565 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID326539 | Antimicrobial activity against Mycobacterium abscessus NTU445 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID573517 | Antibacterial activity against Serratia marcescens isolate Sm203 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID498085 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559528 | Antibacterial activity against Citrobacter koseri assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1364568 | Bactericidal activity against multidrug-resistant Acinetobacter baumannii ATCC BAA 18002 after 48 hrs by resazurin dye based broth microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. |
| AID1318909 | Antibacterial activity against gentamicin-resistant Escherichia coli isolate CAN-ICU 61714 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID559051 | Antibacterial activity against Staphylococcus lugdunensis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID424862 | Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID559069 | Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498119 | Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID498131 | Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID428872 | Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID519407 | Antibacterial activity against 16S rRNA methylase rmtB and CTX-M-65 ESBL producing rifampin resistant Escherichia coli isolate ECRB1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID559483 | Antibacterial activity against Serratia marcescens by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID562810 | Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID1846511 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C31 assessed as reduction in MIC in presence of berberine by broth microdilution method | |||
| AID1666867 | Inhibition of swarming motility of Escherichia coli clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID542044 | Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID1678759 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 using cyrene as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID544956 | Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID509870 | Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID561315 | Antimicrobial activity against Enterobacter cloacae isolate 101 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID573401 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID546621 | Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID1318924 | Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 91433 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID2937 | Dissociation constant with dimeric 16S rRNA RNA construct B | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel synthesis and RNA-binding properties of aminoglycoside dimers conjugated via a naphthalene diimide-based intercalator. |
| AID531754 | Antibacterial activity against Pseudomonas aeruginosa 2439 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1873907 | Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID1056836 | Antibacterial activity against CTX-15 expressing Escherichia coli isolate 235 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID571909 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID561321 | Antimicrobial activity against Escherichia coli isolate 48 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID531865 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction in bacterial count at 10 mg/L after 50 mins by BacLight Live/Dead staining | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID529643 | Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID562811 | Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID375076 | Binding affinity to A-site RNA | 2009 | Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12 | Design and implementation of an ribonucleic acid (RNA) directed fragment library. |
| AID523492 | Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID768031 | Antibacterial activity against Staphylococcus aureus expressing NorA by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID1139967 | Binding affinity to menin (unknown origin) assessed as thermal stability at 400 uM by differential scanning fluorimetry (Rvb = 40.46 degC) | 2014 | Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9 | Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface. |
| AID559518 | Antibacterial activity against Streptococcus constellatus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1319017 | Ratio of MIC for Pseudomonas aeruginosa PAO1 after 25 serial passages to MIC for Pseudomonas aeruginosa PAO1 prior to 25 serial passages | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID324311 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID498302 | Antibacterial activity against Pseudomonas aeruginosa PA1054 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID530330 | Antimicrobial activity against Escherichia coli XL1-Blue by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID544949 | Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID1873909 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID559056 | Antibacterial activity against Lancefield Streptococcus sp. group F by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID326541 | Antimicrobial activity against Mycobacterium abscessus R51 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID498127 | Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559502 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID572127 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID559513 | Antibacterial activity against levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498297 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 2 times MIC up to 48 hrs in presence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID166717 | Tested for binding affinity against RNA construct D | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers. |
| AID324862 | Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID1265777 | Antibacterial activity against Escherichia coli assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents. |
| AID564015 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID534176 | Antimicrobial activity against armA positive Klebsiella pneumoniae DU producing beta lactamase CTX-M-3 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1056834 | Antibacterial activity against GIM-1 expressing Pseudomonas aeruginosa isolate 197 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID236835 | Maximum Frel value for binding to 3'-Fl-AM1A-Rhd in Bacillus subtilis tyr | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA. |
| AID1846505 | Antibacterial activity against Pseudomonas aeruginosa NC06 cystic fibrosis assessed as reduction in bacterial growth | |||
| AID561313 | Antimicrobial activity against Enterobacter cloacae isolate 37 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID559524 | Antibacterial activity against Acinetobacter baumannii assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1873913 | Antibacterial activity against Escherichia coli incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID1318964 | Antibacterial activity against extremely drug-resistant Pseudomonas aeruginosa isolate 104354 infected in Galleria mellonella assessed as larvae survival at 75 mg/kg administered as single dose measured after 96 hrs | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID554385 | Antimicrobial activity against Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID326547 | Antimicrobial activity against Mycobacterium abscessus R65 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID394700 | Antibacterial activity against MexXY-OprM pump-independent aminoglycoside-resistant Pseudomonas aeruginosa isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID573194 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring duplication mutation at nucleotide 333 in nfxB gene selected at 0.5 ug/ml of azithromycin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1447465 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID542063 | Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID326545 | Antimicrobial activity against Mycobacterium abscessus R54 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID559598 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of tobramycin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID622391 | Antibacterial activity against Colistin resistant Burkholderia cepacia after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID573210 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID529645 | Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID559072 | Antibacterial activity against Citrobacter freundii by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1318932 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 108590 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID523507 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID67421 | In vitro inhibitory activity against Enterococcus faecalis ATCC 29212; Value ranges from 8-32 ug/mL | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID1450010 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as ratio of MIC after 25 serial passages at sub-MIC to MIC after 1 passage by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
| AID1231668 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth incubated for 72 hrs by CLSI based method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Colloidal and antibacterial properties of novel triple-headed, double-tailed amphiphiles: exploring structure-activity relationships and synergistic mixtures. |
| AID1447582 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as ratio of MIC after 25 serial passages to MIC before 25 serial passages by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID573209 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G539A mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID573516 | Antibacterial activity against Serratia marcescens isolate Sm201 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID324866 | Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID257552 | Antibacterial activity against Escherichia coli | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID285586 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1716657 | Antibacterial activity against Stenotrophomonas maltophilia CAN-ICU 62584 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID529516 | Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico. |
| AID572133 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1780306 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 RS21000 and RS21005 mutant assessed as reduction in bacterial growth by broth microdilution assay | |||
| AID531868 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as planktonic cells assessed as concentration and time required inactivate 2 log bacterial cells | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID65067 | Percent killing of the total Escherichia coli K12 (ATCC 25868)cells at the C50 concentration was determined. | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID531756 | Antibacterial activity against Pseudomonas aeruginosa 2126 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID523516 | Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1139964 | Inhibition of N-terminal FITC-labeled MBM1 interaction to menin (unknown origin) after 1 hr by fluorescence polarization assay | 2014 | Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9 | Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface. |
| AID577222 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring phoU::ISphoA/haha mutation by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID1629130 | Antimicrobial activity against aminoglycoside-resistant Burkholderia cepacia ATCC 25416 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID559541 | Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559047 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID497949 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID584563 | Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID573542 | Antibacterial activity against Escherichia coli Ec9381 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1716891 | Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID559055 | Antibacterial activity against Lancefield Streptococcus sp. 'group C' by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID555557 | Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID1716768 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 16 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID425071 | Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID519188 | Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa clinical isolate | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID405818 | Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID510963 | Antimicrobial activity against ESBL producing Escherichia coli assessed as nonsusceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. |
| AID1716709 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID508487 | Antimicrobial activity against Pseudomonas aeruginosa isolate BNL-1681 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID498099 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1716651 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID496007 | Antimicrobial activity against Ceftazidime resistant Pseudomonas aeruginosa isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. |
| AID520639 | Antimicrobial activity against Escherichia coli MRY05-3283 expressing qepA and rmtB gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID571691 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1374177 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated at 37 degC for 20 hrs by agar dilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID559543 | Antibacterial activity against levofloxacin susceptible Serratia marcescens assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1716711 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID525557 | AUC (0 to infinity) in normally fed BALB/c mouse at 10 mg/kg, iv | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID1322248 | Antibacterial activity against NorA expressing Staphylococcus aureus 1 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID283543 | Antibacterial activity against Pseudomonas aeruginosa FE57UZ with inactivated rplY, galU and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID544960 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID584575 | Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID285582 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID446132 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID534173 | Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid MEZ by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1271376 | Antimicrobial activity against Gram-positive Bacillus anthracis str. Sterne after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID285608 | Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID768037 | Antibacterial activity against Streptococcus pyogenes Serotype M12 MGAS9429 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID544959 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID559048 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1906414 | Antibacterial activity against Methicillin resistant Staphylococcus aureus ATCC BAA -1556 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | Amphiphilic cyclic peptide [W |
| AID625836 | Antibacterial activity against Escherichia coli by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID508480 | Antimicrobial activity against Pseudomonas aeruginosa isolate AK5493 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID571899 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID283531 | Antibacterial activity against Pseudomonas aeruginosa FE49 with inactivated galU gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID774221 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID396031 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID372844 | Antibacterial activity against Acinetobacter baumannii isolate C expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID1318929 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86079 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID525572 | Tmax in normally fed BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID573521 | Antibacterial activity against Serratia marcescens isolate Sm211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID165224 | In vitro inhibitory activity against Pseudomonas aeruginosa ATCC 35151 | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID573402 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID561318 | Antimicrobial activity against Enterobacter cloacae isolate 153 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID584555 | Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID409954 | Inhibition of mouse brain MAOA | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID497948 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID498137 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 4 times MIC up to 48 hrs in absence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID283542 | Antibacterial activity against Pseudomonas aeruginosa FE57GU with inactivated rplY, nuoG and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID532087 | Antimicrobial against Pseudomonas aeruginosa 8666 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID571690 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID340859 | Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. |
| AID573513 | Antibacterial activity against Escherichia coli isolate Ec158 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID534170 | Antimicrobial activity against armA positive Escherichia coli TOP10 harboring plasmid COP1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID396026 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID544951 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID559600 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of ciprofloxacin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID446137 | Antibacterial activity against TriABC expressing MexAB, MexCD, MexEF, MexXY deleted Pseudomonas aeruginosa PA405 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID544962 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID283533 | Antibacterial activity against Pseudomonas aeruginosa FE57 with inactivated rplY gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1364627 | Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. |
| AID425073 | Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID559063 | Antibacterial activity against Streptococcus constellatus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285601 | Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID565071 | Antibacterial activity against CTX-M-15 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID584573 | Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1721429 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17 | Synthesis of novel lignan-like compounds and their antimicrobial activity. |
| AID554397 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID69749 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20683 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1850994 | Binding affinity to human double stranded DNA by SPR analysis | 2022 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 73 | Identification of sugar-containing natural products that interact with i-motif DNA. |
| AID554396 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID559514 | Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID164372 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-9834A organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1716654 | Antibacterial activity against gentamicin, tobramycin, ciprofloxacin-resistant Escherichia coli ATCC 97615 harboring aac(3')IIa gene assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID560263 | Antimicrobial activity against Pseudomonas aeruginosa isolate NH57388A by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID1873908 | Antibacterial activity against Cronobacter sakazakii ATCC 29544 incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID1780305 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Gly120Ala mutant assessed as reduction in bacterial growth by broth microdilution assay | |||
| AID544952 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID561329 | Antimicrobial activity against azide-resistant Escherichia coli J53 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID1459349 | Antifungal activity against Candida albicans FIM709 incubated at room temperature for 30 mins followed by incubation at 32 degC for 12 hrs by two-fold dilution method | 2016 | Journal of natural products, 10-28, Volume: 79, Issue:10 | Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities. |
| AID1716715 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID495511 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID1716659 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID564465 | Antimicrobial activity against Pseudomonas aeruginosa isolate 971 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID533853 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium chelonae after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID573331 | Antibacterial activity against Klebsiella pneumoniae isolate Kp1945 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID434366 | Antibacterial activity against Escherichia coli after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID572123 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1780304 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Ser150Ala mutant assessed as reduction in bacterial growth by broth microdilution assay | |||
| AID559596 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of tobramycin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID498112 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID163076 | Antibacterial activity expressed as MIC value was determined on Proteus stuartii A-21210 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID285598 | Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID446133 | Antibacterial activity against MexCD expressing Pseudomonas aeruginosa PA01 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID564464 | Antimicrobial activity against Pseudomonas aeruginosa isolate 968 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID330982 | Antimicrobial activity against Escherichia coli BAS849 | 2007 | Nature, May-03, Volume: 447, Issue:7140 | PTC124 targets genetic disorders caused by nonsense mutations. |
| AID1716649 | Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID496004 | Antimicrobial activity against drug resistant Pseudomonas aeruginosa isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. |
| AID322313 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1716872 | Antibacterial activity against Pseudomonas aeruginosa 114228 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID559060 | Antibacterial activity against Streptococcus pyogenes by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID534299 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID573515 | Antibacterial activity against Serratia marcescens isolate Sm220 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1322253 | Antibacterial activity against triABC deficient Pseudomonas aeruginosa PA406 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID554398 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2804 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID495517 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID1678765 | Antibacterial activity against Escherichia coli ATCC 25922 using cyrene as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID405425 | fAUC (0 to 24 hrs) in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID564461 | Antimicrobial activity against Pseudomonas aeruginosa isolate 856 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID508479 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA66 producing metallo-beta-lactamase VIM4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID405825 | Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID1629131 | Antimicrobial activity against aminoglycoside-resistant Escherichia coli ATCC BAA-2452 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID1318906 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID285607 | Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID278861 | Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID529649 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID1716650 | Antibacterial activity against Enterococcus faecium ATCC 27270 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID532080 | Antimicrobial against Pseudomonas aeruginosa 3208 harboring phzM allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID394701 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID405455 | Antibacterial activity against Escherichia coli 1540 isolate by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID525555 | Half life in 15 hrs fasted BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID373987 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS4 transconjugant from Enterobacter cloacae 91 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID565069 | Antibacterial activity against SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID559066 | Antibacterial activity against Streptococcus oralis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID69756 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-22356 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID573549 | Antibacterial activity against Klebsiella pneumoniae Kp149 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID498295 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 8 times MIC up to 48 hrs in absence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1322247 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID496009 | Antimicrobial activity against tobramycin resistant Pseudomonas aeruginosa isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. |
| AID1318901 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86052 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID559086 | Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID531755 | Antibacterial activity against Pseudomonas aeruginosa 2126 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID544966 | Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID525553 | AUClast in 15 hrs fasted BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID544961 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID573499 | Antibacterial activity against Citrobacter amalonaticus isolate Ca38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID65071 | Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868) | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID495510 | Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID768032 | Antibacterial activity against Mycobacterium smegmatis str. MC2 155 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID1846503 | Antibacterial activity against Pseudomonas aeruginosa NC04 cystic fibrosis assessed as reduction in bacterial growth | |||
| AID529647 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID326546 | Antimicrobial activity against Mycobacterium abscessus R61 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID1271381 | Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 1 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID245161 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH24; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID498122 | Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1716729 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID326538 | Antimicrobial activity against Mycobacterium abscessus R39 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID559587 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as microbial doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID405450 | Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS infected in C57BL/6J mouse assessed as lung bacterial count at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID1716655 | Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa CAN-ICU 62308 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID530348 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID572121 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1846495 | Bactericidal activity against Pseudomonas aeruginosa K1525 mexY mutant assessed as reduction in log increase in tolerant cells at 1000 times MIC measured after 24 hrs | |||
| AID559064 | Antibacterial activity against Streptococcus intermedius by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID394685 | Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID561317 | Antimicrobial activity against Enterobacter cloacae isolate 153 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID1716871 | Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID521590 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 5.7 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID622394 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microbroth dilution method in presence of Mg2+ | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID405453 | Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID374113 | Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID561325 | Antimicrobial activity against Klebsiella pneumoniae isolate 135 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID495513 | Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID1447484 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 91433 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID405823 | Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID554393 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID559520 | Antibacterial activity against Streptococcus mitis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1846520 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa C54 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID495518 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID424857 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID571687 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID497944 | Antibacterial activity against Burkholderia cepacia clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573495 | Antibacterial activity against Citrobacter amalonaticus isolate Ca3927 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID164252 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20717 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1322257 | Antibacterial activity against AAC6'-IB expressing Escherichia coli PAZ505H8101 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID278806 | Antimicrobial activity against Stenotrophomonas maltophilia K279a (aph FS) mutant | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID544823 | Antimicrobial activity against Pseudomonas aeruginosa Xen 5 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 200 microamperes of electric current by bioelectric effect assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID1475190 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12 | Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC. |
| AID460803 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BAA-1605 after 16 to 20 hrs by microdilution susceptibility test | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii. |
| AID532085 | Antimicrobial against Pseudomonas aeruginosa 8564 harboring pyrX allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID1271385 | Antimicrobial activity against Mycobacterium smegmatis MC2-155 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID525551 | AUC (0 to infinity) in 15 hrs fasted BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID207038 | Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-20240 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID405817 | Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID535691 | Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID509865 | Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID330983 | Antimicrobial activity against Pseudomonas aeruginosa 27853 | 2007 | Nature, May-03, Volume: 447, Issue:7140 | PTC124 targets genetic disorders caused by nonsense mutations. |
| AID564459 | Antimicrobial activity against Pseudomonas aeruginosa isolate 988 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID563518 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. |
| AID564452 | Antimicrobial activity against Pseudomonas aeruginosa isolate 944 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID573207 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G461A mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID559076 | Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425074 | Antimicrobial activity against Escherichia coli DH10B in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID521597 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 5.7 by bioluminescence assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID522928 | Antibacterial activity against Escherichia coli JM83 producing aminoglycoside 2''-2a phosphotransferase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1056841 | Antibacterial activity against TEM-1/SHV-12 expressing Aeromonas hydrophila isolate 268 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID559068 | Antibacterial activity against Streptococcus sanguinis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559536 | Antibacterial activity against Moraxella catarrhalis assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498125 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1716658 | Antibacterial activity against Acinetobacter baumannii CAN-ICU 63169 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID561319 | Antimicrobial activity against Escherichia coli isolate 17 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID544967 | Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID405824 | Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID523493 | Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1873905 | Antibacterial activity against Staphylococcus aureus incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID285606 | Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573509 | Antibacterial activity against Citrobacter amalonaticus isolate Ca1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID523497 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID495516 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID283535 | Antibacterial activity against Pseudomonas aeruginosa FE10U with inactivated nuoG and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID529160 | Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID1459350 | Antifungal activity against Aspergillus niger R330 incubated at room temperature for 30 mins followed by incubation at 32 degC for 12 hrs by two-fold dilution method | 2016 | Journal of natural products, 10-28, Volume: 79, Issue:10 | Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities. |
| AID1318935 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 83182 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID531870 | Ratio of antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as concentration and time required inactivate 2 log bacterial cells to antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as planktonic cells asses | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID1716653 | Antibacterial activity against Escherichia coli CAN-ICU 63074 (AMK 32) assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID278804 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD [aph(3')-2] in the presence of arabinose | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID1447476 | Antibacterial activity against Acinetobacter baumannii isolate CAN-ICU 63169 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID573195 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring deletion mutation at nucleotide 231-244 in nfxB gene selected at 1 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID559079 | Antibacterial activity against Klebsiella pneumoniae by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1447483 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P264-104354 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID285691 | Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID577221 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gatA::ISphoA/haha mutation by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID1780309 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 RS21000 and RS21005 mutant assessed as resistance development by measuring fold increase in MIC | |||
| AID577224 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring mmsA::ISphoA/haha mutation by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID573722 | Antibacterial activity against Klebsiella oxytoca Ko238 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID584568 | Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1716737 | Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID768029 | Antibacterial activity against Escherichia coli MC1061 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID573724 | Antibacterial activity against Serratia marcescens Sm265 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1881516 | Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID326543 | Antimicrobial activity against Mycobacterium abscessus R47 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID571907 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1139966 | Binding affinity to menin (unknown origin) assessed as thermal stability at 200 uM by differential scanning fluorimetry (Rvb = 40.46 degC) | 2014 | Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9 | Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface. |
| AID1364634 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 infected in C57BL/6 mouse assessed as survival rate at 6 mg/kg, ip administered as single dose measured for 5 days (Rvb = <20%) | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. |
| AID245157 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH19; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID1906418 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27883 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | Amphiphilic cyclic peptide [W |
| AID559052 | Antibacterial activity against Staphylococcus saprophyticus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498133 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559062 | Antibacterial activity against Streptococcus bovis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559546 | Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia assessed as assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1422368 | Antibacterial activity against Pseudomonas aeruginosa FO3 harboring AAC6'-2A by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID533857 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mageritense after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID498111 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID508728 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C1 VAL6 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID530349 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID434368 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID534306 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID559067 | Antibacterial activity against Streptococcus salivarius by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID322316 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID498132 | Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529161 | FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID1846488 | Bactericidal activity against wild type Pseudomonas aeruginosa K767 persisters assessed as reduction in CFU at 20 times MIC incubated for 24 hrs by planktonic persistance assay | |||
| AID523072 | Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1716763 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1318916 | Antibacterial activity against Acinetobacter baumannii isolate CAN-ICU 63169 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID69748 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20665 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID565282 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID1846496 | Antibacterial activity against Pseudomonas aeruginosa C61 assessed as log reduction of bacterial population measured after 24 hrs | |||
| AID530329 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pGEM-T carrying aacA4 Ala108Thr mutant gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID559071 | Antibacterial activity against Acinetobacter lwoffii by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID561322 | Antimicrobial activity against Escherichia coli isolate 48 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID584561 | Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID446135 | Antibacterial activity against MexAB expressing Pseudomonas aeruginosa PA21 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID531747 | Antibacterial activity against Pseudomonas aeruginosa EryR by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1716652 | Antibacterial activity against gentamicin-resistant Escherichia coli CAN-ICU 61714 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID405427 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID523504 | Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID559073 | Antibacterial activity against Citrobacter koseri by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498361 | Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrB containing isogenic acrB knockout assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. |
| AID573192 | Antimicrobial activity against mexD::lox-deficient Pseudomonas aeruginosa PAOMxD biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID405444 | Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS infected in C57BL/6J mouse assessed as mortality at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1881517 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID425072 | Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID495514 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID559508 | Antibacterial activity against Staphylococcus warneri assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID564454 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1060 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID285592 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID584574 | Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID573537 | Antibacterial activity against Klebsiella pneumoniae Kp7564 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID588208 | Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset | 2010 | Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5 | Predicting phospholipidosis using machine learning. |
| AID497946 | Antibacterial activity against Alcaligenes xylosoxidans by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1447485 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 101243 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID521592 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 7.0 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID572131 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID573508 | Antibacterial activity against Klebsiella oxytoca isolate Ko1156 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1447461 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID1629124 | Antimicrobial activity against Haemophilus influenzae ATCC 49247 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID509867 | Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID163075 | Antibacterial activity expressed as MIC value was determined on Proteus stuartii A-20894 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1716864 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID577226 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISlacZ/haha mutation by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID1422367 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID554392 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID285605 | Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1056843 | Antibacterial activity against CTX-15 expressing Enterobacter cloacae isolate 51 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID573531 | Antibacterial activity against Klebsiella pneumoniae Kp1239 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID283541 | Antibacterial activity against Pseudomonas aeruginosa FE53GU with inactivated mexZ, nuoG and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID560276 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 infected in Swiss neutropenic mouse assessed as mouse survival rate at 120 mg/kg BID administered 24 hrs post infection through aerosol | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID559094 | Effect on survival of Escherichia coli K-12 BW25113 biofilm harboring pCA24N ptac::yafQ plasmid assessed as increase in cell survival after 24 hrs pretreated with 5 uM of IPTG for 4 hrs relative to wild-type Escherichia coli K-12 BW25114 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID1721428 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method | 2020 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17 | Synthesis of novel lignan-like compounds and their antimicrobial activity. |
| AID498096 | Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID525554 | Tmax in 15 hrs fasted BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID283529 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1233142 | Antibacterial activity against methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by microbroth dilution method | 2015 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13 | Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors. |
| AID1318910 | Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID1678763 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 using cyrene as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID559085 | Antibacterial activity against Proteus vulgaris by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID497945 | Antibacterial activity against Stenotrophomonas maltophilia by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID768030 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID245186 | Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 27853; Range is 0.25-1 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID245117 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH06; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID498298 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 4 times MIC up to 48 hrs in presence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID285603 | Antimicrobial activity against Pseudomonas aeruginosa 2B5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573500 | Antibacterial activity against Klebsiella pneumoniae isolate Kp38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1716766 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 64 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID245155 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH17; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID559057 | Antibacterial activity against Lancefield Streptococcus sp. 'group G' by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID394714 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID498109 | Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1265776 | Antibacterial activity against Staphylococcus aureus assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents. |
| AID523491 | Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1846524 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa NC06 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID559645 | Antimicrobial activity against Extended-spectrum beta-lactamase producing Escherichia coli clinical isolate assessed as resistant isolate | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. |
| AID405432 | fAUC (0 to 24 hrs)/MIC ratio in Pseudomonas aeruginosa PAOdeltamutS infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID573190 | Antimicrobial activity against nfxB gene-deficient Pseudomonas aeruginosa PAONB biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID326549 | Antimicrobial activity against Mycobacterium abscessus R49 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID523506 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1318930 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86141 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID559497 | Antibacterial activity against vancomycin- resistant Enterococcus faecalis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559042 | Antibacterial activity against vancomycin- resistant Enterococcus faecalis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID622393 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microbroth dilution method in absence of Mg2+ | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID394684 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID1716646 | Antibacterial activity against methicillin-resistance Staphylococcus aureus ATCC 33592 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID508725 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E3 PpA2 harboring acquired beta-lactamase OXA-101 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID544963 | Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID535694 | Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID2938 | Dissociation constant towards 16S rRNA construct A | 2000 | Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14 | Enhanced binding of aminoglycoside dimers to a "dimerized" A-site 16S rRNA construct. |
| AID561328 | Antimicrobial activity against Klebsiella pneumoniae isolate 202 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID1318931 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 92014 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID164251 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20653 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID498110 | Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1716735 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID622388 | Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID1629127 | Antimicrobial activity against Klebsiella pneumoniae ATCC 10031 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID245160 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH22; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID544636 | Antimicrobial activity against Staphylococcus aureus Xen 30 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID1318936 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 84745 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID428873 | Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1846508 | Antibacterial activity against Pseudomonas aeruginosa NC10 cystic fibrosis assessed as tobramycin MIC in presence of berberine | |||
| AID372846 | Antibacterial activity against Acinetobacter baumannii isolate E expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID424860 | Antimicrobial activity against Escherichia coli XL1-Blue by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID533854 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium peregrinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID559080 | Antibacterial activity against Legionella pneumophila by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID523513 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1716723 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID405419 | fCmax in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID405820 | Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID144015 | In vitro anti-mycobacterial activity expressed as minimum inhibitory concentration against Mycobacterium fortuitum ATCC 6841 | 2001 | Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13 | Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials. |
| AID1233138 | Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7386 after 18 to 20 hrs by microbroth dilution method | 2015 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13 | Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors. |
| AID573211 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 0.5 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID533860 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium porcinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID573497 | Antibacterial activity against Serratia marcescens isolate Sm2723 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID559078 | Antibacterial activity against Klebsiella oxytoca by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559585 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID554395 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID544953 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID565067 | Antibacterial activity against CTX-M-15 and SHV-27 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID326533 | Antimicrobial activity against Mycobacterium abscessus after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID283545 | Antibacterial activity against Pseudomonas aeruginosa FE57GUZ with inactivated rplY, nuoG, galU and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID508490 | Antimicrobial activity against Pseudomonas aeruginosa isolate K45-32 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1233136 | Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus B19506 after 18 to 20 hrs by microbroth dilution method | 2015 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13 | Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors. |
| AID521834 | Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID625923 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID1442617 | Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection assessed as reduction in log10CFU per gram of lung at 40 mg/kg, in bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untrea | 2017 | Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6 | Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa. |
| AID1678760 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 using DMSO as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID285600 | Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1716862 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth by measuring doxycycline MIC at 0.25 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 16 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID396028 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID573186 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID405090 | Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID405443 | Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in C57BL/6J mouse assessed as mortality at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID559074 | Antibacterial activity against Enterobacter aerogenes by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1422378 | Cytotoxicity against mouse J774 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID555554 | Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID584577 | Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1265778 | Antibacterial activity against Bacillus subtilis assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents. |
| AID394682 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID559095 | Bactericidal activity against Escherichia coli K-12 BW25113 biofilm harboring pCA24N ptac::yafQ plasmid assessed as log reduction of viable cells after 24 hrs pretreated with 5 uM of IPTG for 4 hrs | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID498104 | Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID68018 | Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-9656 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID774218 | Antibacterial activity against Pseudomonas aeruginosa F03 expressing AAC6'-2A after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID559589 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID559599 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of tobramycin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1322254 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID405437 | fCmax/MIC ratio in Pseudomonas aeruginosa PAOdeltamutS infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID1906417 | Antibacterial activity against imipenem resistant Klebsiella pneumoniae ATCC BAA 1705 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | Amphiphilic cyclic peptide [W |
| AID535850 | Antimicrobial against Pseudomonas aeruginosa 33410 harboring phoU allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID1846504 | Antibacterial activity against Pseudomonas aeruginosa NC04 cystic fibrosis assessed as tobramycin MIC in presence of berberine | |||
| AID559545 | Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID622384 | Antibacterial activity against Staphylococcus aureus after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID533568 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID1447467 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID324864 | Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID394706 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(3')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID460800 | Antibacterial activity against Acinetobacter baumannii UH8407 after 16 to 20 hrs by microdilution susceptibility test | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii. |
| AID554399 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2858 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1629126 | Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID523508 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID584566 | Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1846518 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C30 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID565073 | Antibacterial activity against CTX-M-14 ESBL producing Morganella morganii assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID497950 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573196 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring nfxB T248C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID534192 | Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. |
| AID554387 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY operon by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID559527 | Antibacterial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID560599 | Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf wild type gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID1447472 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID1846521 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa C59 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID1318938 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID573506 | Antibacterial activity against Klebsiella pneumoniae isolate Kp3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID521595 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 7.0 by bioluminescence assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID524003 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID522931 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID584571 | Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID245112 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH01; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID556760 | Antimicrobial activity against extended spectrum beta-lactamase CTX-M-2-producing Pseudomonas aeruginosa isolate P6208 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa. |
| AID532078 | Antimicrobial against Pseudomonas aeruginosa 30848 harboring phoU allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID530350 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID1447482 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P262-101856 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID1233137 | Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7425 after 18 to 20 hrs by microbroth dilution method | 2015 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13 | Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors. |
| AID559097 | Antimicrobial activity against yafQ gene-deficient Escherichia coli K-12 BW25113 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID424858 | Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID285612 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1410916 | Stabilization of pre-miR-21 RNA (unknown origin) assessed as increase in melting temperature at 10 uM by UV-spectrophotometric analysis | 2018 | Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14 | Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. |
| AID584554 | Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID559092 | Bactericidal activity against yafQ gene-deficient Escherichia coli K-12 BW25113 biofilm assessed as log reduction of viable cells after 24 hrs relative to wild-type Escherichia coli K-12 BW25113 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID244967 | Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 27853 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID394704 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1, ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID559544 | Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573198 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAA biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID559049 | Antibacterial activity against Staphylococcus haemolyticus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285689 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID1318963 | Antibacterial activity against extremely drug-resistant Pseudomonas aeruginosa isolate 104354 infected in Galleria mellonella assessed as larvae survival at 50 mg/kg administered as single dose measured after 24 hrs (Rvb = 27 %) | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID774220 | Antibacterial activity against Acinetobacter lwoffii AI.88-483 expressing APH3'-6A after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID768025 | Inhibition of protein synthesis in Escherichia coli S30 extracts after 90 mins by coupled transcription/translation assay | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID559082 | Antibacterial activity against Morganella morganii by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID529456 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID584570 | Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID498093 | Antibacterial activity against Pseudomonas aeruginosa PA861 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1428626 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis. |
| AID523892 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID340858 | Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. |
| AID1716662 | Antibacterial activity against Pseudomonas aeruginosa 750 harboring efflux mutant assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID324860 | Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID559521 | Antibacterial activity against Streptococcus oralis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1780303 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 assessed as reduction in bacterial growth by broth microdilution assay | |||
| AID322318 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID544824 | Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID584559 | Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1318921 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 260-97103 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID622398 | Bactericidal activity against Staphylococcus aureus DSM 799 assessed as log decrease in bacterial count at MIC after 2 hrs by time-kill assay | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID428871 | Antibacterial activity against Escherichia coli CSH-2 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID523495 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID283549 | Antibacterial activity against Pseudomonas aeruginosa FE64 containing inactivated rplY and mexXY genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID285583 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID164255 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-21294 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID532088 | Antimicrobial against Pseudomonas aeruginosa 3465 harboring tsaA allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID245158 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH20; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID519314 | Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID520697 | Antimicrobial activity against Escherichia coli DH10B harboring p05283 carrying qepA and rmtB gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID573539 | Antibacterial activity against Klebsiella pneumoniae Kp38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID570782 | Antimicrobial activity against multidrug-resistant Acinetobacter baumannii assessed as resistant isolates by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. |
| AID1318918 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID207039 | Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-21978 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID394699 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID555556 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID565072 | Antibacterial activity against SHV-12 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID534297 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID571901 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID563522 | Antibacterial activity against Pseudomonas aeruginosa NY219 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. |
| AID374111 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS5 transconjugant from Enterobacter cloacae 641 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID163066 | ntibacterial activity expressed as MIC value was determined on Proteus rettgeri A-21207 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID207043 | Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-9537 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID207041 | Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-22210 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID531863 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction in bacterial count at 10 mg/L after 50 mins by plate count method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID1716770 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 64 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1678762 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 using DMSO as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID534166 | Antimicrobial activity against rmtB positive Escherichia coli VOG producing beta lactamase CTX-M-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1318908 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID245154 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH07; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID525562 | Cmax in normally fed BALB/c mouse at 10 mg/kg, iv | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID564690 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID498100 | Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573725 | Antibacterial activity against Citrobacter youngae CyB38 transconjugant harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID554384 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID559506 | Antibacterial activity against Staphylococcus lugdunensis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID521599 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 assessed as log reduction in viable counts at 150 ug/ml after 1hr | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID573723 | Antibacterial activity against Klebsiella pneumoniae Kp204 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1716660 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID534303 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID199517 | Compound was tested for the inhibition of Rev-RBE RNA complex formation | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex. |
| AID498084 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID530328 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pGEM-T carrying aacA4 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID285576 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID498095 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID531749 | Antibacterial activity against Pseudomonas aeruginosa FK06 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1846510 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C30 assessed as reduction in MIC in presence of berberine by broth microdilution method | |||
| AID126451 | Dissociation constant for binding to mitochondrial 12S rRNA construct M4 was determined | 2002 | Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16 | Decoding region bubble size and aminoglycoside antibiotic binding. |
| AID559045 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573494 | Antibacterial activity against Enterobacter cloacae isolate El3518 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID562813 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID498129 | Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID554400 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID564462 | Antimicrobial activity against Pseudomonas aeruginosa isolate 913 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID257554 | Antibacterial activity against Staphylococcus aureus | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID573721 | Antibacterial activity against Escherichia coli Ec221 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID525561 | Half life in normally fed BALB/c mouse at 10 mg/kg, iv | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID523511 | Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1374182 | Antibacterial activity against Klebsiella pneumoniae CMCC 46117 incubated at 37 degC for 20 hrs by agar dilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID372847 | Antibacterial activity against Escherichia coli DH10B expressing Acinetobacter baumannii isolate B 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID498091 | Antibacterial activity against Pseudomonas aeruginosa PA5026 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID285597 | Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573400 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1716867 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID279939 | Antibiotic susceptibility by resistance against Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID68016 | Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-21006 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID564685 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID573530 | Antibacterial activity against Citrobacter youngae isolate CyB38 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID523067 | Activity of Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID565230 | Antimicrobial activity against Mycobacterium chelonae 9917 by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID498118 | Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559807 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene complemented with wild type DNA oxidative repair system mutY gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1716870 | Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID768026 | Antibacterial activity against biofilm negative Staphylococcus epidermidis ATCC 12228 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID542065 | Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID326535 | Antimicrobial activity against Mycobacterium fortuitum after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID542106 | Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID285574 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573191 | Antimicrobial activity against mutS::lox,nfxB gene-deficient Pseudomonas aeruginosa PAOMSNB biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID573333 | Antibacterial activity against Enterobacter cloacae isolate El3280 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID519406 | Antibacterial activity against Escherichia coli DH10B harboring pBCSK expressing rmtB gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID446140 | Antibacterial activity against R-methylase expressing Escherichia coli 06AB003 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID559515 | Antibacterial activity against Streptococcus pyogenes assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID498103 | Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID69757 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-9632 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1780307 | Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Ser150Ala mutant assessed as resistance development by measuring fold increase in MIC | |||
| AID554402 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID531867 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as respiratory activity by CTC-DAPI staining | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID521842 | Antibacterial activity against Escherichia coli J53 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID584576 | Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID573197 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAB biofilm harboring nfxB G125T mutant gene selected at 0.5 ug/ml of azithromycin after 1 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID559532 | Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573213 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T544C mutant gene selected at 4 ug/ml of azithromycin after 1 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID498092 | Antibacterial activity against Pseudomonas aeruginosa PA876 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1716706 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1442616 | Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection administered intranasally as bid for 2 to 12 hrs of post-infection measured after 24 hrs | 2017 | Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6 | Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa. |
| AID498134 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID531752 | Antibacterial activity against Pseudomonas aeruginosa 3308 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID573332 | Antibacterial activity against Klebsiella pneumoniae isolate Kp2730 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID533569 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID166711 | Tested for binding affinity against RNA construct A | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers. |
| AID559053 | Antibacterial activity against Staphylococcus warneri by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1691822 | Antibacterial activity against Pseudomonas aeruginosa PAO1 biofilm cells assessed as reduction in bacterial growth after 2 days by resazurin dye based assay | 2020 | European journal of medicinal chemistry, May-15, Volume: 194 | Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1. |
| AID1056835 | Antibacterial activity against SIM-1 expressing Acinetobacter baumannii isolate 170 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID322317 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID324868 | Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1881515 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID529457 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID532082 | Antimicrobial against Pseudomonas aeruginosa 3894 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID1318902 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID498097 | Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1319004 | Induction of cytoplasmic membrane depolarization in Pseudomonas aeruginosa PAO1 by DiSC3(5) dye based fluorescence assay | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID573188 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID534168 | Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG2 expressing CTX-M-14 and AAC(6 )-Ib gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1364567 | Growth inhibition of Acinetobacter baumannii ATCC 19606 after 48 hrs by resazurin dye based microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. |
| AID278859 | Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID584558 | Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID424863 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID1447477 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID324874 | Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID126450 | Dissociation constant for binding to mitochondrial 12S rRNA construct M3 was determined | 2002 | Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16 | Decoding region bubble size and aminoglycoside antibiotic binding. |
| AID1374179 | Antibacterial activity against Pseudomonas aeruginosa CMCC 10104 incubated at 37 degC for 20 hrs by agar dilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID525569 | Oral bioavailability in normally fed BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID571917 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID508485 | Antimicrobial activity against Pseudomonas aeruginosa isolate BU-43038 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID520638 | Antimicrobial activity against Escherichia coli MRY04-1060 expressing qepA gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID394702 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID564019 | Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID561320 | Antimicrobial activity against Escherichia coli isolate 17 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID285609 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1850992 | Binding affinity to human telomeric i-motif DNA by SPR analysis | 2022 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 73 | Identification of sugar-containing natural products that interact with i-motif DNA. |
| AID1385464 | Antimicrobial activity against Streptococcus agalactiae after 24 hrs by two-fold dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Helvolic Acid Derivatives with Antibacterial Activities against Streptococcus agalactiae from the Marine-Derived Fungus Aspergillus fumigatus HNMF0047. |
| AID554440 | Ratio of MIC for Pseudomonas aeruginosa 2933 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID326552 | Antimicrobial activity against Mycobacterium fortuitum V61 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID1447468 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID285578 | Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1716719 | Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID554401 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID498300 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 0.25 ug/ml up to 48 hrs in absence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID554390 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615S obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID498094 | Antibacterial activity against Pseudomonas aeruginosa PA5020 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID521596 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 7.0 by bioluminescence assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID498130 | Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1322259 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID534304 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID525574 | Cmax in normally fed BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID1322250 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID530345 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID508730 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C9 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID1678761 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 using cyrene as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID396032 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID285575 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID531751 | Antibacterial activity against Pseudomonas aeruginosa 3308 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID584579 | Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1233135 | Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7419 after 18 to 20 hrs by microbroth dilution method | 2015 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13 | Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors. |
| AID544821 | Antimicrobial activity against Pseudomonas aeruginosa Xen 5 biofilm assessed as log10 CFU/cm'2 in bacterial count | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID573526 | Antibacterial activity against Klebsiella pneumoniae isolate Kp204 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID523512 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID508722 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C3 PTOL1 harboring acquired beta-lactamase OXA-17 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID559592 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of Ceftazidime by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID531753 | Antibacterial activity against Pseudomonas aeruginosa 2439 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID326551 | Antimicrobial activity against Mycobacterium fortuitum V13 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID1271382 | Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 2 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID521591 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 5.7 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID95884 | Antibacterial activity expressed as MIC value was determined on Klebsiella pneumonia A-20468 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1447462 | Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 33592 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID424861 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pGTAAC-32 with cloned aac(6)'-32 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID1666868 | Inhibition of swarming motility of Burkholderia cepacia clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID1422373 | Antibacterial activity against Escherichia coli ATCC 25922 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID544820 | Antimicrobial activity against Staphylococcus epidermidis Xen 43 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1716645 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID285580 | Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1846514 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa C84 assessed as fold reduction in MIC in presence of berberine by broth microdilution method | |||
| AID285690 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID1580090 | Antibacterial activity against novobiocin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. |
| AID446141 | Antibacterial activity against R-methylase expressing Enterobacter aerogenes 06AB008 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID571697 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1629125 | Antimicrobial activity against Haemophilus influenzae ATCC 10211 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID207055 | In vitro inhibitory activity against Staphylococcus aureus ATCC 29213 | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID532081 | Antimicrobial against Pseudomonas aeruginosa 3434 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID554394 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID525559 | AUClast in normally fed BALB/c mouse at 10 mg/kg, iv | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID1319015 | Inhibition of circular DNA translation in Escherichia coli S30 extract after 60 mins by luciferase reporter gene assay | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID534296 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID508484 | Antimicrobial activity against Pseudomonas aeruginosa isolate BU-20287 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1271383 | Antimicrobial activity against Gram-negative Haemophilus influenzae ATCC 51907 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID529653 | Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID519177 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 8 ug/ml of amikacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1447474 | Antibacterial activity against gentamicin/tobramycin-resistant Pseudomonas aeruginosa isolate CANWARD-2011 96846 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID532090 | Antimicrobial against Pseudomonas aeruginosa 46396 harboring katA allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID564460 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1006 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID278801 | Antimicrobial activity against recombinant Escherichia coli DH5alpha expressing pBAD | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID525563 | AUC (0 to infinity) in normally fed BALB/c mouse at 10 mg/kg, im | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID573540 | Antibacterial activity against Morganella morganii Mm38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID245162 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH25; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID278809 | Antibacterial activity against Escherichia coli BL21(DE3) | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID577225 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring yaaA::ISphoA/haha mutation by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID285644 | Antimicrobial activity against Pseudomonas aeruginosa 15H5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID322314 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID571923 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID508481 | Antimicrobial activity against Pseudomonas aeruginosa isolate B4-25753 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID534298 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID163042 | Antibacterial activity expressed as MIC value was determined on Proteus rettgeri A-9637 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1318907 | Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID530321 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID1846509 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C25 assessed as fold reduction in MIC in presence of berberine by broth microdilution method | |||
| AID1716721 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID544950 | Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID542064 | Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID69753 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20895 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID560600 | Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf (TTG-ATG) mutant gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID561314 | Antimicrobial activity against Enterobacter cloacae isolate 37 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID1318911 | Antibacterial activity against gentamicin/tobramycin/ciprofloxacin-resistant Escherichia coli isolate CANWARD-2011 97615 harboring AAC3-2A after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID531869 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as concentration and time required inactivate 2 log bacterial cells | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID498124 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573204 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T41C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1881522 | Antibacterial activity against Enterococcus faecium ATCC 27270 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID396033 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID1824803 | Antibacterial activity against Pseudomonas aeruginosa FB assessed as bacterial growth inhibition by broth microdilution method | 2022 | Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1 | New |
| AID69754 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-21218 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID257551 | Antibacterial activity against Klebsiella pneumoniae | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID564697 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as resistance isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID207056 | In vitro inhibitory activity against Staphylococcus aureus MRSA 33591 | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID559601 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of ciprofloxacin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1716636 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 1024 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID554437 | Ratio of MIC for Pseudomonas aeruginosa 2729 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID554432 | Ratio of MIC for Pseudomonas aeruginosa 615R to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID571921 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID546618 | Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID1271380 | Antimicrobial activity against Gram-positive Staphylococcus aureus ATCC 29213 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID768028 | Antibacterial activity against Haemophilus influenzae ATCC 51907 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID278803 | Antimicrobial activity against recombinant Escherichia coli DHalpha expressing pBAD [aph(3')-2] | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID573547 | Antibacterial activity against Klebsiella oxytoca Ko1156 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID498301 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 0.25 ug/ml up to 48 hrs in presence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1271377 | Antimicrobial activity against Gram-positive Bacillus cereus ATCC 17788 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID584578 | Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1716648 | Antibacterial activity against methicillin-resistance Staphylococcus epidermidis CAN-ICU 61589 (CAZ>32) assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID285599 | Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1580092 | Antibacterial activity against novobiocin and test compound-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages in presence of novobiocin by checkerboard assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. |
| AID577004 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as viable bacterial count by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID1322249 | Antibacterial activity against healthcare-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID245282 | In vitro minimum inhibitory concentration against Staphylococcus aureus ATCC 29213; Range is 0.12-1 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID285688 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID498086 | Antibacterial activity against Pseudomonas aeruginosa PA899 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID394708 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID774213 | Antibacterial activity against Escherichia coli L58058.1 expressing ANT2''-1A after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID508483 | Antimicrobial activity against Pseudomonas aeruginosa isolate K34-7 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID565074 | Antibacterial activity against CTX-M-14 ESBL producing Proteus mirabilis assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID565231 | Antimicrobial activity against Mycobacterium chelonae 9917 harboring pZS01 carrying mspA gene by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID326540 | Antimicrobial activity against Mycobacterium abscessus NTU459 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID523488 | Antimicrobial activity against Pseudomonas aeruginosa R70 Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID508478 | Antimicrobial activity against Pseudomonas aeruginosa isolate U9-19005 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID561316 | Antimicrobial activity against Enterobacter cloacae isolate 101 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID498090 | Antibacterial activity against Pseudomonas aeruginosa PA1036 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID82302 | Tested for the ability to bind the HIV-1 RRE-RNA construct by fluorescence anisotropy | 2001 | Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9 | Binding of dimeric aminoglycosides to the HIV-1 rev responsive element (RRE) RNA construct. |
| AID559539 | Antibacterial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID564016 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID571893 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID544829 | Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 2000 microamperes of electric current by bioelectric effect assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID559523 | Antibacterial activity against Streptococcus sanguinis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID166716 | Tested for binding affinity against RNA construct C; n.b. means no observable binding | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers. |
| AID768036 | Antibacterial activity against Bacillus subtilis 168 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID625925 | Antibacterial activity against Pseudomonas aeruginosa by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID497951 | Antibacterial activity against Pseudomonas aeruginosa PA5063 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID207042 | Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-22231 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID1873911 | Antibacterial activity against Streptococcus dysgalactiae incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID534305 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID326544 | Antimicrobial activity against Mycobacterium abscessus R50 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID572135 | Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1809539 | Anti-bioflim activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bioflim formation incubated for 24 hrs by crystal violet staining based assay | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19 | Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID521840 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID622385 | Antibacterial activity against oxacillin-sensitive Staphylococcus aureus after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID531750 | Antibacterial activity against Pseudomonas aeruginosa FK06 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID534300 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID531745 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID565281 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID523398 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID1716637 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID573720 | Antibacterial activity against Citrobacter koseri Ck211 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID565280 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID1185007 | Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 after 18 to 20 hrs by microbroth dilution technique | 2014 | ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7 | Bioreductively Activated Reactive Oxygen Species (ROS) Generators as MRSA Inhibitors. |
| AID573187 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID564455 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1095 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID324872 | Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID1846507 | Antibacterial activity against Pseudomonas aeruginosa NC10 cystic fibrosis assessed as reduction in bacterial growth | |||
| AID69751 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20732 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID572139 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID285584 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1716643 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID424879 | Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID564456 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1846490 | Bactericidal activity against Pseudomonas aeruginosa K767 wild type assessed as decrease in cell fluorescence in presence of berberine by ethidium bromide efflux assay (Rvb = 10%) | |||
| AID559505 | Antibacterial activity against Staphylococcus hominis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1322261 | Cytotoxicity against mouse J774 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay relative to control | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID571692 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID486971 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 24 hrs by micro broth dilution method | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | 'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID325976 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count at 10 ug/ml by rotating disk reactor method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin. |
| AID324870 | Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID245113 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH02; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID1678767 | Antibacterial activity against Enterococcus faecalis ATCC 51299 using DMSO as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID1318913 | Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID523066 | Antibacterial activity against Escherichia coli JM83 harboring empty pHF022 vector by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID534771 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. |
| AID554433 | Ratio of MIC for Pseudomonas aeruginosa 3020R to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1716764 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID535849 | Antimicrobial against Pseudomonas aeruginosa PAO1 by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID245115 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH04; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID1540370 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of planktonic cells growth at >0.15 uM incubated for 24 to 25 hrs | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Glycocluster Tetrahydroxamic Acids Exhibiting Unprecedented Inhibition of |
| AID1846506 | Antibacterial activity against Pseudomonas aeruginosa NC06 cystic fibrosis assessed as tobramycin MIC in presence of berberine | |||
| AID519189 | Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa isolate PA/XY assessed as zone of inhibition by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1666869 | Inhibition of swarming motility of Salmonella enterica clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID523502 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID559583 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID460802 | Antibacterial activity against Acinetobacter baumannii AB0043 after 16 to 20 hrs by microdilution susceptibility test | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii. |
| AID774217 | Antibacterial activity against Pseudomonas aeruginosa PA22 (PT629) expressing MexXY after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID446131 | Antibacterial activity against ANT2'-2a expressing Escherichia coli L58058.1 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1716644 | Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID498115 | Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1447464 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID1271378 | Antimicrobial activity against Gram-positive Bacillus subtilis 168 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID285591 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1422370 | Antibacterial activity against Pseudomonas aeruginosa PA406 harboring triABC deletion mutant by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID573206 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T562C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID297186 | Antibacterial activity against multidrug resistant Staphylococcus aureus 49589 | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. |
| AID573522 | Antibacterial activity against Citrobacter koseri isolate Ck211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID498114 | Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID521583 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 infected in mouse J774A.1 macrophage assessed as log reduction in viable counts at 150 ug/ml after 1hr | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID573501 | Antibacterial activity against Morganella morganii isolate Mm38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID508489 | Antimicrobial activity against Pseudomonas aeruginosa isolate K44-24 producing metallo-beta-lactamase IMP14 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1716641 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1265779 | Antibacterial activity against Salmonella assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents. |
| AID164250 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20601 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID523396 | Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID565283 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID519186 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 4 ug/ml of cefepime exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1716713 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID278860 | Antiproliferative effect against HeLa cells after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID238131 | Binding dissociation constant towards 3'-Fl-AM1A-Rhd in Bacillus subtilis tyrS | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA. |
| AID245116 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH05; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID278857 | Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID563521 | Antibacterial activity against Pseudomonas aeruginosa NY217 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. |
| AID525558 | Oral bioavailability in normally fed BALB/c mouse at 10 mg/kg, iv | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID559530 | Antibacterial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID584569 | Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID324310 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID285593 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID498123 | Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID774214 | Antibacterial activity against Escherichia coli PAZ505H8101 expressing AAC6'-1B after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID564018 | Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID1716868 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID573524 | Antibacterial activity against Escherichia coli isolate Ec221 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID573189 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID768034 | Antibacterial activity against Listeria monocytogenes ATCC 19115 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID1271379 | Antimicrobial activity against Gram-positive Listeria monocytogenes ATCC 19115 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID573330 | Antibacterial activity against Klebsiella pneumoniae isolate Kp1239 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1447473 | Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID554438 | Ratio of MIC for Pseudomonas aeruginosa 2804 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID283536 | Antibacterial activity against Pseudomonas aeruginosa FE53U with inactivated mexZ and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID573399 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID322315 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID559806 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene complemented with wild type DNA oxidative repair system mutT gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID531862 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilms | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID508488 | Antimicrobial activity against Pseudomonas aeruginosa isolate OS-210 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID564466 | Antimicrobial activity against Pseudomonas aeruginosa isolate 821 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID577223 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISphoA/haha mutation by Etest | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins. |
| AID1716638 | Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1318914 | Antibacterial activity against gentamicin/tobramycin-resistant Pseudomonas aeruginosa isolate CANWARD-2011 96846 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID573529 | Antibacterial activity against Acinetobacter baumannii isolate AbN450 harboring IblaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID523503 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID573203 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID531866 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as membrane integrity by BacLight Live/Dead staining | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID1493078 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis 12 by dilution susceptibility test | 2017 | Journal of natural products, 11-22, Volume: 80, Issue:11 | Antibacterial 3,6-Disubstituted 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones from Serratia plymuthica MF371-2. |
| AID1846523 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa AR48 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID1653583 | Anti-leprotic activity against Mycobacterium leprae infected in BALB/c weanling mouse assessed as bacteria killing at 20 mg/kg, ip administrated for 60 days and measured after 1 year by most probable number technique analysis relative to control | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID1322258 | Antibacterial activity against ANT2''-IA expressing Escherichia coli L8058.1 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID520696 | Antimicrobial activity against Escherichia coli DH10B harboring p041060 carrying qepA gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID1447487 | Synergistic antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs in presence of minocycline by checkerboard assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID509869 | Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID529303 | Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID564453 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1050 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1846489 | Bactericidal activity against Pseudomonas aeruginosa K1525 mexY mutant persisters assessed as reduction in CFU at 20 times MIC incubated for 24 hrs by planktonic persistance assay | |||
| AID1385465 | Antimicrobial activity against Staphylococcus aureus after 24 hrs by two-fold dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Helvolic Acid Derivatives with Antibacterial Activities against Streptococcus agalactiae from the Marine-Derived Fungus Aspergillus fumigatus HNMF0047. |
| AID1846513 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa C59 assessed as fold reduction in MIC in presence of berberine by broth microdilution method | |||
| AID584572 | Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1139965 | Binding affinity to menin (unknown origin) assessed as thermal stability at 50 uM by differential scanning fluorimetry (Rvb = 40.46 degC) | 2014 | Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9 | Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface. |
| AID554441 | Ratio of MIC for Pseudomonas aeruginosa 2998 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID446128 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID521582 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 infected in mouse J774A.1 cells at 50 ug/ml after 1hr | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID559590 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID531746 | Antibacterial activity against Pseudomonas aeruginosa FE60 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1629129 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID533859 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium smegmatis after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID525573 | Half life in normally fed BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID1850993 | Binding affinity to human c-Myc promoter i-motif DNA by SPR analysis | 2022 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 73 | Identification of sugar-containing natural products that interact with i-motif DNA. |
| AID394707 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, AAC(3')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID559500 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID571905 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID405422 | Half life of free unbound fraction in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID498299 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 8 times MIC up to 48 hrs in presence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID523397 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID584557 | Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID534172 | Antimicrobial activity against armA positive Escherichia coli MEZ producing beta lactamase CTX-M-3 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID562809 | Antimicrobial activity against Escherichia coli J53 | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID405436 | fCmax/MIC ratio in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID555555 | Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID1629132 | Antimicrobial activity against aminoglycoside-resistant Klebsiella pneumoniae ATCC BAA-2470 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID565068 | Antibacterial activity against CTX-M-15 and SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID1846501 | Antibacterial activity against Pseudomonas aeruginosa NC02 cystic fibrosis assessed as reduction in bacterial growth | |||
| AID279940 | Antibiotic susceptibility by resistance against MDR Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID573201 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T533C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID534169 | Antimicrobial activity against armB positive Escherichia coli COP producing beta lactamase CTX-M-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1677266 | Antibacterial activity against Pseudomonas aeruginosa PAO200 harboring mexAB-oprM efflux deficient mutant | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21 | Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants. |
| AID1056839 | Antibacterial activity against TEM-1/CTX-M-15 expressing Aeromonas caviae isolate 260 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID559531 | Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559594 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of Ceftazidime by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID532084 | Antimicrobial against Pseudomonas aeruginosa 40198 harboring nirJ allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID1364571 | Growth inhibition of multidrug-resistant Acinetobacter baumannii ATCC BAA 18002 after 48 hrs by resazurin dye based broth microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. |
| AID340860 | Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. |
| AID564463 | Antimicrobial activity against Pseudomonas aeruginosa isolate 927 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1482267 | Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. |
| AID446127 | Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PT629 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID283544 | Antibacterial activity against Pseudomonas aeruginosa FE57GZ with inactivated rplY, nuoG and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID519405 | Antibacterial activity against 16S rRNA methylase RmtB and CTX-M-65 ESBL producing Escherichia coli isolate ECRB1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID572145 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID326550 | Antimicrobial activity against Mycobacterium abscessus V120 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID1318904 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis isolate CANWARD-2008 81388 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID1233139 | Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus K1 after 18 to 20 hrs by microbroth dilution method | 2015 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13 | Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors. |
| AID245118 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH23; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID207040 | Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-22058 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID285589 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1846498 | Antibacterial activity against Pseudomonas aeruginosa K1525 mexY mutant assessed as reduction in bacterial growth rate in presence of berberine | |||
| AID531758 | Antibacterial activity against Pseudomonas aeruginosa 1956 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1447478 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID523510 | Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID324858 | Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID533567 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID573511 | Antibacterial activity against Morganella morganii isolate Mm1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID521575 | Reduction in light emission by Salmonella enterica serovars virchow isolate 101591 infected in mouse J774A.1 cells after 5 mins | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID571689 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID573496 | Antibacterial activity against Enterobacter cloacae isolate El1573 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID571913 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID446124 | Antibacterial activity against APH30-VIa expressing Acinetobacter lwoffii AI.88-483 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID533852 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium abscessus after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID559510 | Antibacterial activity against Lancefield Streptococcus sp. 'group C' assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID571911 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID525552 | Oral bioavailability in 15 hrs fasted BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID372845 | Antibacterial activity against Acinetobacter baumannii isolate D expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1678769 | Antibacterial activity against Staphylococcus aureus ATCC 43300 using DMSO as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID584565 | Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1459348 | Antibacterial activity against Escherichia coli ATCC 0111 incubated at room temperature for 30 mins followed by incubation at 37 degC for 12 hrs by two-fold dilution method | 2016 | Journal of natural products, 10-28, Volume: 79, Issue:10 | Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities. |
| AID283546 | Antibacterial activity against Pseudomonas aeruginosa KJ7106 with inactivated PA5471 gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1629123 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID1322260 | Cytotoxicity against mouse J774 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1716733 | Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID510964 | Antimicrobial activity against CTX-M15/CTX-M14 ESBL producing Escherichia coli ST131 clonal complex isolate assessed as nonsusceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. |
| AID285594 | Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID563597 | Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolates by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. |
| AID559096 | Antimicrobial activity against Escherichia coli K-12 BW25113 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID625924 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID559803 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of ciprofloxacin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID544964 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. |
| AID498088 | Antibacterial activity against Pseudomonas aeruginosa PA880 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID571887 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID584562 | Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID542049 | Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID1447466 | Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID559529 | Antibacterial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559542 | Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1447587 | Induction of cytoplasmic membrane depolarization in Pseudomonas aeruginosa PAO1 up to 1200 secs by diSC3-5 staining based fluorescence assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID285573 | Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID509868 | Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID283539 | Antibacterial activity against Pseudomonas aeruginosa FE57G with inactivated rplY and nuoG genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID519408 | Antibacterial activity against 16S rRNA methylase RmtB and CTX-M-65 ESBL producing Escherichia coli DH10B by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID508482 | Antimicrobial activity against Pseudomonas aeruginosa isolate K34-73 producing metallo-beta-lactamase VIM4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID529651 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID1447479 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID1716705 | Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID525565 | AUClast in normally fed BALB/c mouse at 10 mg/kg, im | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID573403 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID523501 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1677265 | Antibacterial activity against Pseudomonas aeruginosa PAO750 harboring mexAB-oprM/mexCD-oprJ/mexEF-oprN/mexJK/mexXY/opmH efflux deficient mutant | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21 | Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants. |
| AID573205 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID283532 | Antibacterial activity against Pseudomonas aeruginosa FE53 with inactivated mexZ gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1271384 | Antimicrobial activity against Gram-negative Pseudomonas aeruginosa PAO1 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID1447488 | Synergistic antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs in presence of rifampicin by checkerboard assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID559509 | Antibacterial activity against Streptococcus agalactiae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1906415 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method | 2022 | European journal of medicinal chemistry, May-05, Volume: 235 | Amphiphilic cyclic peptide [W |
| AID326553 | Antimicrobial activity against Mycobacterium fortuitum V146 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID564017 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID559501 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID394703 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID559099 | Bactericidal activity against Escherichia coli K-12 BW25113 stationary-phase planktonic cell assessed as log reduction of viable cells after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID1449931 | Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by checker board assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
| AID257550 | Antibacterial activity against Streptococcus faecalis | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID565063 | Antibacterial activity against CTX-M-15 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID1678768 | Antibacterial activity against Staphylococcus aureus ATCC 43300 using Cyrene as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID585434 | Antimicrobial activity against Pseudomonas aeruginosa PA14 by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. |
| AID1809549 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bacterial growth for complete inhibition of bacterial growth incubated for 24 hrs | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19 | Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID1678766 | Antibacterial activity against Escherichia coli ATCC 25922 using DMSO as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID1447463 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis isolate CANWARD-2008 81388 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID622387 | Antibacterial activity against Escherichia coli after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID564458 | Antimicrobial activity against Pseudomonas aeruginosa isolate 896 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1493076 | Antibacterial activity against vancomycin-resistant Enterococcus faecium 7 by dilution susceptibility test | 2017 | Journal of natural products, 11-22, Volume: 80, Issue:11 | Antibacterial 3,6-Disubstituted 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones from Serratia plymuthica MF371-2. |
| AID498106 | Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1422372 | Antibacterial activity against Acinetobacter lwoffii AI.88-483 harboring APH3'-6A by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1449930 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 to 24 hrs by microbroth dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. |
| AID561327 | Antimicrobial activity against Klebsiella pneumoniae isolate 202 expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID1881520 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 61589 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID774216 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID559597 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of tobramycin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID573519 | Antibacterial activity against Escherichia coli isolate Ec211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID559517 | Antibacterial activity against Streptococcus bovis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573505 | Antibacterial activity against Enterobacter cloacae isolate El3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID405822 | Antimicrobial activity against Escherichia coli DH5alpha | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID1318917 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID285602 | Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523496 | Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID523490 | Antimicrobial activity against Pseudomonas aeruginosa AHP Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1322255 | Antibacterial activity against APH3'-VIA expressing Acinetobacter lwoffii AI.88-483 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID166719 | Tested for binding affinity against RNA construct E | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers. |
| AID571915 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID521580 | Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 assessed as log reduction in viable counts at 150 ug/ml after 1hr | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID1056844 | Antibacterial activity against TEM-1/CTX-M-15 expressing Enterobacter cloacae isolate 62 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID559519 | Antibacterial activity against Streptococcus intermedius assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID396029 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID405091 | Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID523500 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID69755 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-22045 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID573208 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB C116T mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID571895 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID584567 | Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID768033 | Antibacterial activity against Bacillus cereus ATCC 11778 by double-dilution technique | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. |
| AID1716633 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 2048 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID573510 | Antibacterial activity against Citrobacter freundii isolate Cf1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID559522 | Antibacterial activity against Streptococcus salivarius assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID562812 | Antimicrobial activity against Escherichia coli DH5[alpha] | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID1716865 | Antibacterial activity against Pseudomonas aeruginosa 101885 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1374181 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated at 37 degC for 20 hrs by agar dilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID523514 | Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID405431 | fAUC (0 to 24 hrs)/MIC ratio in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID498360 | Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52145R assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. |
| AID1580081 | Induction of outer membrane permeabilization in Pseudomonas aeruginosa PAO1 assessed as increase in accumulation of NPN by measuring fluorescence intensity at 14 ug/ml measured immediately by NPN dye uptake assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. |
| AID1666883 | Inhibition of swarming motility of Pseudomonas aeruginosa HONKR at 10 ug incubated for 18 to 24 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID495509 | Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID446123 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID573541 | Antibacterial activity against Klebsiella pneumoniae Kp38045 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID326542 | Antimicrobial activity against Mycobacterium abscessus NTU446 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID283537 | Antibacterial activity against Pseudomonas aeruginosa FE57U with inactivated rplY and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1666866 | Inhibition of swarming motility of Pseudomonas aeruginosa clinical isolates incubated for 16 to 20 hrs | 2020 | Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5 | Optimized plant compound with potent anti-biofilm activity across gram-negative species. |
| AID622392 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microbroth dilution method in absence of Mg2+ | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID424859 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID498102 | Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID523517 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1422366 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID559533 | Antibacterial activity against Klebsiella oxytoca assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1580096 | Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 by checkerboard assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. |
| AID508726 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1B2 RCA2 harboring acquired beta-lactamase PER-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID1691821 | Antibacterial activity against Pseudomonas aeruginosa PAO1 planktonic cells assessed as reduction in bacterial growth after 18 hrs by resazurin dye based assay | 2020 | European journal of medicinal chemistry, May-15, Volume: 194 | Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1. |
| AID542585 | Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID446130 | Antibacterial activity against AAC6'-2b expressing Escherichia coli PAZ505H8101 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1716869 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID495515 | Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID1873914 | Antibacterial activity against Pseudomonas aeruginosa LTP-3 incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID1824802 | Antibacterial activity against Pseudomonas aeruginosa 1167 assessed as bacterial growth inhibition by broth microdilution method | 2022 | Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1 | New |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID498136 | Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 2 times MIC up to 48 hrs in absence of cystic fibrosis patient sputum | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1447471 | Antibacterial activity against gentamicin/tobramycin/ciprofloxacin-resistant Escherichia coli isolate CANWARD-2011 97615 harboring AAC3-2A after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID531757 | Antibacterial activity against Pseudomonas aeruginosa 1956 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID534171 | Antimicrobial activity against beta lactamase CTX-M-14 producing Escherichia coli TOP10 harboring plasmid COP2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1716656 | Antibacterial activity against gentamicin, tobramycin-resistant Pseudomonas aeruginosa CANWARD 96846 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1716640 | Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID572141 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID534177 | Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid DU by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID325977 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count at 50 ug/ml by rotating disk reactor method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin. |
| AID535697 | Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID1422365 | Antibacterial activity against Staphylococcus aureus SA-1 expressing NorA pump by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID508741 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID554442 | Ratio of MIC for Pseudomonas aeruginosa 3066 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1422375 | Antibacterial activity against Escherichia coli L8058.1 harboring ANT2'-1A by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID559534 | Antibacterial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID508486 | Antimicrobial activity against Pseudomonas aeruginosa isolate BU-36178 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID560591 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID495512 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID523515 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID486970 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by micro broth dilution method | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | 'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID1447469 | Antibacterial activity against gentamicin-resistant Escherichia coli isolate CAN-ICU 61714 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID69750 | Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20697 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID559593 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of Ceftazidime by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1811206 | Antibiofilm activity against Pseudomonas aeruginosa assessed as reduction in CFU at 0.5 ug/ml | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Divergent synthesis and biological evaluation of 2-(trifluoromethyl)pyridines as virulence-attenuating inverse agonists targeting PqsR. |
| AID460801 | Antibacterial activity against Acinetobacter baumannii 3304 after 16 to 20 hrs by microdilution susceptibility test | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii. |
| AID559526 | Antibacterial activity against Acinetobacter lwoffii assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID324856 | Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID565070 | Antibacterial activity against CTX-M-14 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID238114 | Dissociation constant of the compound | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17 | Validation of automated docking programs for docking and database screening against RNA drug targets. |
| AID498098 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573507 | Antibacterial activity against Klebsiella oxytoca isolate Ko0426 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID285579 | Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID508727 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1D5 SA1 harboring acquired beta-lactamase VIM-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID1318922 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 262-101856 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID1447470 | Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 24 hrs by macrobroth dilution method | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID573504 | Antibacterial activity against Morganella morganii isolate Mm1229 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID498101 | Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573527 | Antibacterial activity against Serratia marcescens isolate Sm265 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID409956 | Inhibition of mouse brain MAOB | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
| AID394705 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID573498 | Antibacterial activity against Klebsiella pneumoniae isolate Kp7564 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID486969 | Antibacterial activity against Escherichia coli after 24 hrs by micro broth dilution method | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | 'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID326537 | Antimicrobial activity against Mycobacterium abscessus R31 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID425069 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID1716717 | Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID508721 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C2 PTOL1 harboring beta-lactamase OXA-17 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID165226 | In vitro inhibitory activity against Pseudomonas aeruginosa PAO-1 | 2004 | Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14 | Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. |
| AID530346 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID559498 | Antibacterial activity against vancomycin- resistant Enterococcus faecium assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1846497 | Antibacterial activity against wild type Pseudomonas aeruginosa K767 assessed as reduction in bacterial growth rate in presence of berberine | |||
| AID1447481 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P259-96918 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID523069 | Activity of Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID525564 | Oral bioavailability in normally fed BALB/c mouse at 10 mg/kg, im | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID523498 | Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID164371 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-22233 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID573514 | Antibacterial activity against Klebsiella pneumoniae isolate Kp149 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID523505 | Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1716626 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 0.25 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 32 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID446126 | Antibacterial activity against AAC6'-2a expressing Pseudomonas aeruginosa F03 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID446125 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1677267 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21 | Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants. |
| AID1846499 | Antibacterial activity against Pseudomonas aeruginosa NC01 cystic fibrosis assessed as reduction in bacterial growth | |||
| AID257553 | Antibacterial activity against Pseudomonas aeruginosa | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID1846519 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C31 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID1716632 | Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 4096 ug/ml) | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID285585 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1824799 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as bacterial growth inhibition by broth microdilution method | 2022 | Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1 | New |
| AID573534 | Antibacterial activity against Citrobacter amalonaticus Ca3927 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID65062 | Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID446136 | Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PA22 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID559415 | Antimicrobial activity against Acinetobacter baumannii 3208 expressing multiple-antibiotic resistance gene AbaR5 by Viek 2 system | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii. |
| AID573202 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring deletion od C534 in nfxB mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1678764 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 using DMSO as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID573545 | Antibacterial activity against Klebsiella pneumoniae Kp3799 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID283534 | Antibacterial activity against Pseudomonas aeruginosa FE57 containing inactivated rplY gene with pARAL25 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID544828 | Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID1716866 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID559507 | Antibacterial activity against Staphylococcus saprophyticus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285596 | Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID525567 | Half life in normally fed BALB/c mouse at 10 mg/kg, im | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID531748 | Antibacterial activity against Pseudomonas aeruginosa EryR harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID523518 | Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID571897 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID428869 | Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID164256 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-21508 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID559535 | Antibacterial activity against Legionella pneumophila assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID534302 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID559098 | Bactericidal activity against yafQ gene-deficient Escherichia coli K-12 BW25113 stationary-phase planktonic cell assessed as log reduction of viable cells after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm. |
| AID533858 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium alvei after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID323690 | Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase. |
| AID525571 | AUClast in normally fed BALB/c mouse at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID559540 | Antibacterial activity against Proteus vulgaris assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID573518 | Antibacterial activity against Klebsiella pneumoniae isolate Kp211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID564696 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as resistance isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID522929 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase N196D/D268N mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1881519 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method | 2021 | RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9 | A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against |
| AID1374178 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 incubated at 37 degC for 20 hrs by agar dilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID2939 | Dissociation constant towards 16S rRNA construct B | 2000 | Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14 | Enhanced binding of aminoglycoside dimers to a "dimerized" A-site 16S rRNA construct. |
| AID542584 | Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID559586 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID573544 | Antibacterial activity against Enterobacter cloacae El3799 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID521594 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 5.7 by bioluminescence assay | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID559511 | Antibacterial activity against Lancefield Streptococcus sp. group F assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID373986 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS3 transconjugant from Citrobacter freundii 64 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID68015 | Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-20364 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID559537 | Antibacterial activity against Morganella morganii assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1809548 | Anti-bioflim activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bioflim formation measured at MBIC50 concentration incubated for 24 hrs by crystal violet staining based assay | 2021 | Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19 | Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as |
| AID1716765 | Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID285610 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID446138 | Antibacterial activity against MexAB, MexCD, MexEF, MexXY, TriABC deleted Pseudomonas aeruginosa PA406 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID278802 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD in the presence of arabinose | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID523509 | Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1629134 | Inhibition of cytosolic eukaryotic translation in rabbit reticulocyte S30 extract measured after 60 mins by coupled transcription/translation-based luciferase reporter gene assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID245239 | In vitro minimum inhibitory concentration against Escherichia coli ATCC 25922; Range is 0.25-1 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID519182 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 0.25 ug/ml of ciprofloxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID571891 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID554386 | Antimicrobial activity against mexXY deficient ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID573512 | Antibacterial activity against Klebsiella pneumoniae isolate Kp4614 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1629122 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 47085 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID428870 | Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID1846522 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa C84 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID396027 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID565229 | Antimicrobial activity against Mycobacterium chelonae ATCC 35752 harboring pZS01 carrying mspA gene by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID1322256 | Antibacterial activity against Escherichia coli ATCC 25922 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID559595 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of Ceftazidime by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID498305 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID572143 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID534175 | Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid BEH by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID245043 | In vitro minimum inhibitory concentration against Staphylococcus aureus MRSA 3359 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID523070 | Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1846517 | Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C25 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method | |||
| AID559499 | Antibacterial activity against Listeria monocytogenes assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID405449 | Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in C57BL/6J mouse assessed as lung bacterial count at 10 mg/kg, ip administered every 6 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID519178 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 1 ug/ml of tobramycin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1629133 | Binding affinity to 16S rRNA A-site in Escherichia coli S30 extract assessed as inhibition of translation measured after 30 mins by coupled transcription/translation-based luciferase reporter gene assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID1422377 | Cytotoxicity against mouse J774 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID245278 | In vitro minimum inhibitory concentration against Enterococcus faecalis 29212; range is 8-32 ug/ml | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID498087 | Antibacterial activity against Pseudomonas aeruginosa PA1022 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID278858 | Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID559504 | Antibacterial activity against Staphylococcus haemolyticus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID530347 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1056845 | Antibacterial activity against TEM-1/SHV-12 expressing Enterobacter cloacae isolate 306 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID532086 | Antimicrobial against Pseudomonas aeruginosa 9256 harboring ybhO allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID519185 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 0.25 ug/ml of ciprofloxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID508729 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C8 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID524005 | Antimicrobial activity against Acinetobacter sp. harboring aacA4 gene assessed as percent resistant isolates | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID521601 | Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 infected in mouse J774A.1 macrophage assessed as log reduction in viable counts at 150 ug/ml after 1hr | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. |
| AID1056838 | Antibacterial activity against CTX-15 expressing Escherichia coli isolate 4024 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID571699 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID559591 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutL mutant gene complemented with wild type DNA oxidative repair system mutY gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1824800 | Antibacterial activity against Pseudomonas aeruginosa 1121 assessed as bacterial growth inhibition by broth microdilution method | 2022 | Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1 | New |
| AID554388 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F29S mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1318926 | Antibacterial activity against Pseudomonas aeruginosa PAO1 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID1716762 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID565228 | Antimicrobial activity against Mycobacterium chelonae ATCC 35752 by resazurine microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID544825 | Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 2000 microamperes of electric current by bioelectric effect assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID559602 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of ciprofloxacin by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID523487 | Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID508724 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E2 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID533856 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mucogenicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID534301 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID1318928 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86067 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID498120 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1318915 | Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID584564 | Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID498362 | Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrR containing isogenic acrR knockout assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. |
| AID559525 | Antibacterial activity against Acinetobacter calcoaceticus assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID564467 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1080 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID1318927 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86053 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID330987 | Antimicrobial activity against Enterococcus faecalis 29212 | 2007 | Nature, May-03, Volume: 447, Issue:7140 | PTC124 targets genetic disorders caused by nonsense mutations. |
| AID1318934 | Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 80621 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID1322252 | Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PA22 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1056840 | Antibacterial activity against CTX-15 expressing Aeromonas caviae isolate 258 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID573528 | Antibacterial activity against Acinetobacter isolate A74510 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID278805 | Antimicrobial activity against Stenotrophomonas maltophilia K279a mutant | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID324852 | Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. |
| AID540237 | Phospholipidosis-positive literature compound observed in rat | |||
| AID126449 | Dissociation constant for binding to mitochondrial 12S rRNA construct M2 was determined | 2002 | Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16 | Decoding region bubble size and aminoglycoside antibiotic binding. |
| AID554389 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F1018L mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID573543 | Antibacterial activity against Morganella morganii Mm1229 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID510962 | Antimicrobial activity against Escherichia coli assessed as nonsusceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. |
| AID1364570 | Bactericidal activity against Acinetobacter baumannii ATCC 19606 after 48 hrs by resazurin dye based microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. |
| AID522930 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H/D268N mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID498303 | Antibacterial activity against Pseudomonas aeruginosa PA1042 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID285604 | Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID525566 | Tmax in normally fed BALB/c mouse at 10 mg/kg, im | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID1678780 | Antibacterial activity against Enterococcus faecalis ATCC 51299 using Cyrene as solvent by broth microdilution method | 2020 | RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1 | Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens. |
| AID567091 | Drug absorption in human assessed as human intestinal absorption rate | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Prediction of drug intestinal absorption by new linear and non-linear QSPR. |
| AID245114 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH03; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID572119 | Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID434367 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID498306 | Antibacterial activity against Pseudomonas aeruginosa PA5043 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1056850 | Antibacterial activity against TEM-1/SHV-12 expressing Klebsiella pneumoniae isolate 303 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID572125 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID622390 | Antibacterial activity against colistin-resistant Inquilinus limosus after 24 hrs by microbroth dilution method | 2011 | Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20 | Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities. |
| AID1629128 | Antimicrobial activity against Escherichia coli ATCC 25922 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID565064 | Antibacterial activity against SHV-12 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID508723 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E1 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID542047 | Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID573502 | Antibacterial activity against Klebsiella pneumoniae isolate Kp38045 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID245119 | Minimum inhibitory concentration against Pseudomonas aeruginosa PAO-1; Range is 0.25-1 | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID285588 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID533566 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID571903 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1318905 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID564457 | Antimicrobial activity against Pseudomonas aeruginosa isolate 878 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. |
| AID283222 | Antimicrobial activity against Escherichia coli XL1-Blue [pBluescript 2 SK(+) | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID330986 | Antimicrobial activity against Enterococcus faecium 49624 | 2007 | Nature, May-03, Volume: 447, Issue:7140 | PTC124 targets genetic disorders caused by nonsense mutations. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID1716761 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID532089 | Antimicrobial against Pseudomonas aeruginosa 312 harboring PBPP allele by broth dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. |
| AID325975 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count by rotating disk reactor method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin. |
| AID1374180 | Antibacterial activity against Klebsiella pneumoniae ATCC 4352 incubated at 37 degC for 20 hrs by agar dilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Design, synthesis and antibacterial evaluation of honokiol derivatives. |
| AID531861 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as planktonic cells assessed as concentration and time required inactivate 1 log bacterial cells | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. |
| AID498128 | Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID544635 | Antimicrobial activity against Pseudomonas aeruginosa Xen 5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. |
| AID525568 | Cmax in normally fed BALB/c mouse at 10 mg/kg, im | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID563520 | Antibacterial activity against Pseudomonas aeruginosa NY215 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. |
| AID1716647 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis CANWARD 81388 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1873912 | Antibacterial activity against Staphylococcus chromogenes incubated for 16 to 20 hrs by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID1716760 | Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID1318919 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID529304 | Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID1580087 | Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 assessed as resistant development at sub-MIC measured after 7 days of passaging by microbroth dilution method relative to control | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. |
| AID164253 | Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20741 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID523489 | Antimicrobial activity against Pseudomonas aeruginosa R20 Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID330984 | Antimicrobial activity against Staphylococcus aureus 29213 | 2007 | Nature, May-03, Volume: 447, Issue:7140 | PTC124 targets genetic disorders caused by nonsense mutations. |
| AID283530 | Antibacterial activity against Pseudomonas aeruginosa FE10 with inactivated nuoG gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1716731 | Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID519184 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 8 ug/ml of amikacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1056837 | Antibacterial activity against TEM-1/SHV-12 expressing Escherichia coli isolate 237 after 18 to 24 hrs by two-fold broth microdilution assay | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria. |
| AID533862 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium wolinskyi after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1846500 | Antibacterial activity against Pseudomonas aeruginosa NC01 cystic fibrosis assessed as tobramycin MIC in presence of berberine | |||
| AID521838 | Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID559516 | Antibacterial activity against Streptococcus anginosus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1716739 | Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay | 2019 | European journal of medicinal chemistry, Jul-15, Volume: 174 | Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. |
| AID405816 | Antimicrobial activity against Escherichia coli DH5alpha harboring recombinant pIMPAR31 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID405821 | Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID584560 | Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID245156 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH18; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID498105 | Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID446129 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1846512 | Antibacterial activity against clinical isolate Pseudomonas aeruginosa C54 assessed as fold reduction in MIC in presence of berberine by broth microdilution method | |||
| AID245159 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH21; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID372842 | Antibacterial activity against Acinetobacter baumannii isolate A expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID278856 | Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. |
| AID68017 | Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-21136 organism | 1986 | Journal of medicinal chemistry, May, Volume: 29, Issue:5 | Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin. |
| AID534174 | Antimicrobial activity against armA positive Enterobacter cloacae BEH producing beta lactamase CTX-M-3 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID561326 | Antimicrobial activity against Klebsiella pneumoniae isolate 135 transconjugant expressing aac(6')-Ib-cr gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. |
| AID1318912 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID554436 | Ratio of MIC for Pseudomonas aeruginosa 2721 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID525560 | Tmax in normally fed BALB/c mouse at 10 mg/kg, iv | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Fasting increases tobramycin oral absorption in mice. |
| AID1447480 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID372843 | Antibacterial activity against Acinetobacter baumannii isolate B expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID559588 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1318920 | Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 259-96918 | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID573200 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB C116T mutant gene selected at 1 ug/ml of azithromycin after 1 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID559503 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1706 (37.28) | 18.7374 |
| 1990's | 734 (16.04) | 18.2507 |
| 2000's | 824 (18.01) | 29.6817 |
| 2010's | 967 (21.13) | 24.3611 |
| 2020's | 345 (7.54) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (93.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 629 (12.83%) | 5.53% |
| Reviews | 199 (4.06%) | 6.00% |
| Case Studies | 468 (9.55%) | 4.05% |
| Observational | 21 (0.43%) | 0.25% |
| Other | 3,585 (73.13%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis [NCT01560962] | 100 participants (Actual) | Interventional | 2012-01-31 | Terminated(stopped due to research staffs unable to continue.) | |||
| Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention [NCT05376670] | 44 participants (Actual) | Observational | 2022-04-20 | Completed | |||
| Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session [NCT03904836] | Phase 1 | 11 participants (Actual) | Interventional | 2019-01-31 | Completed | ||
| Phase 1 Feasibility Trial of Inhaled Tobramycin in Preterm Infants With Bronchopulmonary Dysplasia [NCT04560179] | Phase 1 | 54 participants (Anticipated) | Interventional | 2022-03-22 | Recruiting | ||
| Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® [NCT01288170] | 12 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | |||
| Topical Antibiotics in Chronic Rhinosinusitis [NCT03673956] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2018-09-26 | Completed | ||
| A Multicenter, Human Factors Validation Study in Cystic Fibrosis Patients Aged 6 Years and Older to Evaluate the User Interface of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules [NCT03502070] | Phase 4 | 47 participants (Actual) | Interventional | 2018-06-26 | Completed | ||
| Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial [NCT03715322] | Phase 3 | 350 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vi [NCT01111383] | Phase 3 | 209 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis (CRITIC) A Randomized Pharmacokinetic Comparison of Tobramycin in Cystic Fibrosis [NCT01207245] | Phase 4 | 18 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment [NCT02440828] | Phase 4 | 80 participants (Anticipated) | Interventional | 2015-03-31 | Completed | ||
| Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection [NCT02102152] | 40 participants (Anticipated) | Interventional | 2014-04-30 | Not yet recruiting | |||
| Use of Antibiotic Contained Calcium Sulfate Carrier in Acute Periprosthetic Infections(APPI) of Total Knee Replacements [NCT02107924] | 0 participants (Actual) | Observational | 2014-04-30 | Withdrawn(stopped due to No Funding) | |||
| Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis. [NCT01337219] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2011-04-30 | Recruiting | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis [NCT02035488] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study [NCT02269969] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified [NCT02526004] | 223 participants (Actual) | Interventional | 2013-10-01 | Completed | |||
| An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for [NCT03739528] | Phase 3 | 808 participants (Actual) | Interventional | 2018-09-03 | Completed | ||
| A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects [NCT00388505] | Phase 3 | 517 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa [NCT01044719] | Phase 4 | 240 participants (Anticipated) | Interventional | 2010-01-31 | Not yet recruiting | ||
| The Effectiveness of Antibiotic Cement Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Feasibility Study [NCT01079559] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn | |||
| Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis [NCT00097773] | Phase 2 | 304 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Acute Application Of Intrawound Antibiotic Powder In Open Extremity Fracture Wounds [NCT04872400] | Phase 4 | 120 participants (Anticipated) | Interventional | 2021-06-14 | Active, not recruiting | ||
| A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Successfully Completed Participation in Study CTBM100C2303E1 [NCT01069705] | Phase 3 | 49 participants (Actual) | Interventional | 2010-02-12 | Completed | ||
| A Phase 1 Study in Healthy Volunteers Investigating the Delivery of Tobramycin Using the TobrAir® 6.0 Device Compared With the Delivery of Marketed Tobramycin Nebuliser Solution (TOBI®) by PARI LC® PLUS and PARI TurboBoy® SX and With Delivery of Tobramyci [NCT02207426] | Phase 1 | 12 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study [NCT02497365] | 32 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin Via the Cyclops® in Children With Cystic Fibrosis [NCT03485456] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2019-05-29 | Recruiting | ||
| Pilot for Vancomycin and Tobramycin Powder Use in Acute Open Fractures in the Emergency Department [NCT05849090] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2023-03-27 | Enrolling by invitation | ||
| Efficiency and Safety of Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis: a Non-randomized Controlled Study [NCT05353101] | Phase 1 | 48 participants (Actual) | Interventional | 2020-07-01 | Completed | ||
| The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study [NCT02137161] | Phase 4 | 62 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery [NCT01103401] | 145 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| A Phase 2 Multicenter Feasibility Trial to Evaluate Safety and Efficacy in Patients Treated for Hip or Knee Prosthetic Joint Infection (PJI) With Alternating Irrigation of Vancomycin Hydrochloride (HCl) and Tobramycin Sulfate in Two-Stage Exchange Arthrop [NCT03721328] | Phase 2 | 15 participants (Actual) | Interventional | 2018-10-26 | Completed | ||
| Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants [NCT01349738] | 200 participants (Anticipated) | Observational | 2011-05-31 | Enrolling by invitation | |||
| A Study of the Clinical Benefit of Tobramycin Inhalation Solution [NCT06106789] | 1,600 participants (Anticipated) | Observational | 2021-01-01 | Active, not recruiting | |||
| VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia [NCT02528123] | 187 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | |||
| Efficacy of Antibiotic (Tobramycin) Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients: A Multicenter Double-blind Randomized Controlled Trial [NCT02888730] | Phase 3 | 86 participants (Actual) | Interventional | 2017-02-16 | Terminated(stopped due to No suffisant recruitment) | ||
| A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis [NCT01028027] | Phase 3 | 357 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Prospective Randomised Trial of 'Area Under the Curve' (AUC) Dosing Strategy for Intravenous Tobramycin Versus Standard Trough Dosing for Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis (CF) [NCT02489955] | 0 participants | Interventional | 2015-02-28 | Recruiting | |||
| Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis [NCT00705159] | Phase 4 | 137 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery Patients [NCT03308253] | Phase 4 | 60 participants (Anticipated) | Interventional | 2018-07-16 | Recruiting | ||
| Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): Study Protocol for a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial [NCT06093191] | Phase 4 | 364 participants (Anticipated) | Interventional | 2023-09-25 | Recruiting | ||
| Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI™ Podhaler™) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI™ Podhaler™) and Inh [NCT02113397] | 1 participants (Actual) | Observational | 2014-04-30 | Terminated(stopped due to Insufficient enrollment) | |||
| A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis [NCT00105469] | Phase 3 | 743 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Safety and Efficacy Study of Zylet® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects [NCT00420628] | Phase 4 | 108 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Small-Incision Lenticule Extraction [NCT02540785] | 41 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| A Pilot Study of Digital Breast Tomosynthesis Guided Near-infrared Tomographic Optical Breast Imaging (DBT-TOBI) in Monitoring Response of Breast Cancer to Neoadjuvant Therapy [NCT03822312] | 30 participants (Actual) | Interventional | 2019-02-01 | Active, not recruiting | |||
| Effects of Holy-Comod and Tears Naturale Forte on Ocular Surface and Tear Inflammatory Mediators in Patients After Phaco+IOL [NCT02817191] | 80 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | |||
| Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study [NCT02478710] | Phase 4 | 16 participants (Actual) | Interventional | 2015-06-30 | Terminated | ||
| Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT - A Multicenter Randomized Control Trial [NCT04678154] | Phase 3 | 1,200 participants (Anticipated) | Interventional | 2021-05-07 | Recruiting | ||
| Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis Subjects [NCT00420836] | Phase 1 | 20 participants | Interventional | 2006-04-30 | Completed | ||
| A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic [NCT00885365] | Phase 3 | 324 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects [NCT00634192] | Phase 3 | 50 participants (Anticipated) | Interventional | 2008-02-29 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew). [NCT00918957] | Phase 3 | 62 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy [NCT02918409] | Phase 4 | 51 participants (Actual) | Interventional | 2016-08-26 | Completed | ||
| Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis. [NCT01400750] | Phase 4 | 61 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways [NCT00774072] | Phase 2 | 9 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam for Inhalation Solution (AZLI) Versus Tobramycin Inhalation Solution (TIS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects With Cystic Fibrosis Followe [NCT00757237] | Phase 3 | 274 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis [NCT02717871] | Phase 3 | 35 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection [NCT06016088] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| [NCT00834171] | 50 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Effect of Various Treatment Modalities on Dendritic Vial Ulcer [NCT05313828] | 40 participants (Anticipated) | Observational | 2022-03-18 | Recruiting | |||
| Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Among Lenticule Extraction, Laser in Situ Keratomileusis and Femtosecond Laser-assisted Laser in Situ Keratomileusis [NCT02551796] | 75 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Comparison of Antibiotics for Pseudomonas in Early CF [NCT00823238] | Phase 1 | 21 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis [NCT00391976] | Phase 3 | 123 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension [NCT03975374] | Early Phase 1 | 5,000 participants (Anticipated) | Interventional | 2019-06-15 | Not yet recruiting | ||
| [NCT01938417] | 12 participants (Actual) | Observational | 2006-10-31 | Completed | |||
| Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects [NCT01953367] | Phase 1 | 72 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis [NCT01460836] | 0 participants | Observational | 2010-04-30 | Completed | |||
| A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis [NCT00006280] | Phase 2 | 98 participants | Interventional | 2000-02-29 | Completed | ||
| Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial Activity [NCT01608555] | Phase 4 | 10 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty [NCT05429671] | Phase 3 | 80 participants (Anticipated) | Interventional | 2022-06-20 | Enrolling by invitation | ||
| Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy. [NCT02657473] | Phase 2/Phase 3 | 58 participants (Actual) | Interventional | 2016-08-13 | Completed | ||
| Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial [NCT00992355] | 97 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension [NCT00198523] | Phase 3 | 132 participants | Interventional | 2005-07-31 | Completed | ||
| Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers [NCT00695435] | Phase 1 | 21 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa [NCT01315678] | Phase 3 | 302 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326] | 3,520 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| A Randomized, Double-masked, Parallel Comparison of Ocular Tolerance and IOP Effects of Zylet vs TobraDex Administered Four Times Daily for Four Weeks in Healthy Volunteers [NCT00532961] | Phase 4 | 310 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects [NCT00125346] | Phase 3 | 98 participants (Actual) | Interventional | 2005-09-30 | Terminated(stopped due to per Data Monitoring Committee recommendation) | ||
| A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis [NCT00447577] | Phase 4 | 276 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial [NCT05169229] | Phase 2/Phase 3 | 850 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia [NCT00050401] | Phase 3 | 500 participants | Interventional | 2002-07-31 | Completed | ||
| Prospective Study Investigating Antibiotic Elution From Free Intra-articular Vancomycin and Tobramycin After Cementless Total Knee Arthroplasty [NCT04297631] | Phase 4 | 20 participants (Actual) | Interventional | 2020-02-14 | Completed | ||
| Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634] | 75 participants (Actual) | Interventional | 2004-03-31 | Completed | |||
| A Phase 1, Single-Dose, Open-Label, Two-Way Crossover, Pharmacoscintigraphy Study of Aerosol Delivery Characteristics (Measured by In Vivo Lung Deposition, Nebulization Time, Serum Tobramycin Concentrations, and Pharmacokinetic Parameters) and Safety of T [NCT00399945] | Phase 1 | 12 participants | Interventional | 2006-05-31 | Completed | ||
| [NCT00576251] | Phase 3 | 221 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules [NCT02178540] | Phase 4 | 45 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber [NCT00257790] | Phase 4 | 210 participants | Interventional | 2001-09-30 | Completed | ||
| Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial [NCT01740947] | Phase 4 | 485 participants (Actual) | Interventional | 2013-01-31 | Terminated(stopped due to Superiority was no longer attainable) | ||
| A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® PODHALER® (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs [NCT02449031] | 409 participants (Actual) | Observational [Patient Registry] | 2015-05-05 | Completed | |||
| A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303. [NCT00982930] | Phase 3 | 55 participants (Actual) | Interventional | 2009-08-12 | Completed | ||
| TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin [NCT02677701] | Phase 4 | 119 participants (Actual) | Interventional | 2016-10-21 | Completed | ||
| A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis [NCT01677403] | Phase 4 | 120 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Bromfenac Ophthalmic Solution 0.1% for Postoperative Ocular Pain and Inflammation Related To Pterygium Surgery [NCT04022811] | Phase 4 | 60 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| A Double-Masked, Parallel-Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and TOBRADEX Ophthalmic Suspension [NCT00362895] | Phase 3 | 995 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Prospective Randomized Study Investigating the Characterization of Antibiotics From Antibiotic Impregnated Cement After Total Knee Arthroplasty [NCT03928522] | Phase 4 | 60 participants (Actual) | Interventional | 2019-01-28 | Completed | ||
| [NCT01155999] | Phase 3 | 286 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures [NCT03705962] | Phase 3 | 11 participants (Actual) | Interventional | 2015-07-31 | Terminated(stopped due to Unable to continue study due to funding and personnel restraints) | ||
| Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia [NCT01559753] | Phase 4 | 225 participants (Actual) | Interventional | 1998-01-31 | Completed | ||
| OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial [NCT02054156] | Phase 3 | 221 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Crossover, Cluster Randomised Controlled Trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (SuDDICU) [NCT02389036] | Phase 3 | 20,010 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa I [NCT01641822] | Phase 3 | 107 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation [NCT05076955] | Early Phase 1 | 100 participants (Anticipated) | Interventional | 2021-03-31 | Recruiting | ||
| A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin [NCT02873806] | Phase 4 | 53 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction [NCT02958514] | 20 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| [NCT00004829] | Phase 3 | 200 participants | Interventional | 1995-06-30 | Completed | ||
| Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates? [NCT04964947] | Phase 3 | 600 participants (Anticipated) | Interventional | 2022-01-10 | Recruiting | ||
| An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With Nebulized TIS and Nebulized COLI for the Treatment of Pulmonary Pseudomonas Aeruginosa (P.a) in Patients With Cystic Fibrosis [NCT01844778] | Phase 4 | 60 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments [NCT01230593] | 150 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas [NCT02015663] | Phase 4 | 32 participants (Actual) | Interventional | 2014-01-31 | Terminated | ||
| Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients [NCT01270347] | Phase 3 | 267 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis [NCT03464435] | Phase 4 | 20 participants (Actual) | Interventional | 2016-11-01 | Completed | ||
| Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis [NCT01456780] | Phase 4 | 60 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities [NCT05361941] | 132 participants (Anticipated) | Interventional | 2022-09-06 | Recruiting | |||
| Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients [NCT03341741] | Phase 3 | 26 participants (Actual) | Interventional | 2014-03-11 | Completed | ||
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation [NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated(stopped due to NIAID terminated the study due to low subject enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||